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Summary 
Erythropoietin (Epo) is the key hormone regulating red blood cells homeostasis and is produced 
in the foetal liver and adult kidney. Epo plasma levels physiologically increase in response to 
hypoxia and anaemia, following the activation of the HIF (hypoxia-inducible factor) pathway. In 
pathological conditions, such as chronic kidney disease (CKD) or erythrocytosis, Epo levels 
markedly decrease or increase, respectively, leading to a variety of complications. Despite 
extensive efforts to isolate the peritubular interstitial renal cells responsible for oxygen-sensing 
and Epo production, no kidney-derived cellular model capable of expressing Epo in a hypoxia-
inducible manner is available so far. Thus, only the well-established human hepatoma cell lines 
HepG2 and Hep3B and some neuronal cell lines (such as Kelly and SH-SY5Y) expressing 
oxygen-dependent Epo can be used to investigate Epo gene regulation in vitro.  
The lack of an appropriate renal cell model explains the poor understanding of the cis-acting 
element regulating kidney-specific Epo expression (kidney-inducible element or KIE), as defined 
by transgenic animal experiments. By comprehensive in silico analysis we identified a novel 
distal hypoxia response element (HRE) located upstream of the EPO gene, within the KIE, and 
named it Epo 5’-HRE, in contrast to the well-known 3’-HRE, located downstream of the gene 
and responsible for liver-specific Epo induction. Functional studies showed that the 5’-HRE is 
mainly responsive to HIF-2α isoform. We additionally implemented the innovative CRISPR/Cas 
technology to mutate the endogenous 5’- and 3’-HREs in Hep3B cells in order to evaluate the 
contributions of each element in regulating oxygen-dependent Epo expression. Furthermore, we 
screened a number of candidate factors, either known or novel regulators of the HIF pathway, 
for a potential effect on Epo expression using RNA interference-mediated or overexpression 
approaches in combination with newly developed Epo-reporter assays to study the 5’-HRE.  
In erythrocytosis, a disease characterized by inappropriately high Epo plasma levels, Epo 
synthesis appears dysregulated. Whereas in the majority of congenital secondary erythrocytosis 
patients the cause is unknown, a number of mutations in genes involved in the oxygen-sensing 
pathway, such as HIFs and prolyl-4-hydroxylase domain proteins (PHDs) have been identified. 
As part of a collaboration with the group of Dr. Betty Gardie (Nantes, France) we functionally 
characterized several novel mutations in the PHD2 gene causing familial erythrocytosis and 
could group these mutations into two main categories in terms of their effect on HIF regulation. 
Notably, some of the mutations did not lead to impaired PHD2 activity, at least in our in vitro 
assays. 
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An additional layer of modulation of Epo production is represented by humoral factors, including 
peptides and hormones. We tested selected peptides in Hep3B for a potential role in Epo 
regulation and complemented this approach by performing a large-scale screening of a peptide 
library derived from human haemofiltrates using different HIF-reporter cell lines. Results from the 
first, complete screening are promising and showed the presence of both “inhibitory” and 
“activatory” fractions in terms of HIF functionality. 
In conclusion, this PhD work focused on the hypoxic regulation of the EPO gene on multiple 
levels and described for the first time a novel HRE, possibly representing the hypoxia-inducible 
element responsible for kidney-specific Epo induction. The newly identified Epo 5’-HRE 
represents the basis for subsequent studies to investigate the effect of a number of factors and 
peptides on oxygen-dependent Epo regulation.  
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Zusammenfassung 
Erythropoetin ist das Schlüsselhormon, das die Homeostasis der roten Blutkörperchen reguliert 
und wird in der fetalen Leber und der adulten Niere produziert. Die Epokonzentration im Plasma 
erhöht sich physiologisch in Antwort auf Hypoxie und Anaemie im Anschluss an die Aktivierung 
des Hypoxieinduzierter Faktor (HIF) Signalweg. Unter pathologischen Bedingungen, wie 
chronisches Nierenversagen oder Erythrozytose sinkt oder steigt die Konzentration von Epo 
messbar, was zu verschiedenen Komplikationen führt. Trotz Anstrengungen, die peritubulären 
interstitialen Zellen, die für die Sauerstoffwahrnemung und die Epoproduktion verantwortlich 
sind, zu isolieren, ist bisher kein Zellmodel aus der Niere verfügbar, das fähig ist Epo in einer 
hypoxieabhängigen Art und Weise zu exprimieren. Deshalb können nur die gut etablierten 
Hepatoma Zelllinien HepG2 und Hep3B und einige neuronale Zelllinien wie Kelly und SH-SY5Y, 
die Epo in Abhängigkeit von Hypoxie exprimieren, für die Erforschung der Epogenregulation 
verwendet werden.  
Das Fehlen eines passenden Nierenzellmodells erklärt das geringe Verständnis für das cis 
agierende Element, welches die nierenspezifische Epoexpression reguliert (das 
Niereninduziertes Element, KIE), wie es durch Experimente mit transgenen Tieren definiert 
wurde. Durch eine umfassende Analyse in silico  haben wir ein neuartiges distales Element für 
die Hypoxieantwort untersucht, welches upstream des Epogens innerhalb des KIE liegt, und 
haben es Epo 5'-HRE gennant. Im Unterschiedt zu dem wohl bekannten 3' -HRE, welches 
downstream des Gens liegt und sich für die leberspezifische Epoinduktion verantwortlich zeigt. 
Funktionelle Studien haben gezeigt dass das 5'-HRE hauptsächlich auf die HIF-2α Isoform 
reagiert. Wir implementierten zusätzlich die innovative CRISPR/Cas Technologie, um die 
endogenen 5'- und 3'-HREs in Hep3B zu mutieren und so den jeweiligen Beitrag von den beiden 
Elementen zur Sauerstoff abhängigen Epoexpression zu evaluieren. Ausserdem untersuchten 
wir einige neue und bekannte Faktoren in der HIF-Singnalwegregulation auf einen potentiellen 
Einfluss auf die Epoexpression in dem wir ein auf RNA-Interferenz und Überexpression 
basierendes Epo-Reporterassay verwendeten. 
In Erythrozytose, eine Krankheit, die durch einen abnorm hohen Epoplasmastand charkterisiert 
ist, scheint die Synthese von Epo dereguliert. Obwohl bei der Mehrheit der Patienten mit 
angeborener sekundärer Erythrozytose der Ursprunge unbekannt ist, wurden einige Mutationen 
in Genen, wie den HIFs und Prolyl-4-hydoxylase Domänen Proteinen (PHDs), gefunden, die in 
den Sauerstoffwahrnehmungssignalweg involviert sind. Als Teil einer Kollaboration mit der 
Gruppe von Dr. Betty Gardie (Nantes, Frankreich) haben wir die Funktion von mehreren neuen 
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Mutationen im PHD2 Gen charkterisiert, die familiäre Erythrozytose verursachen, und haben 
diese Mutationen im Bezug auf ihren Effekt auf HIF in zwei Hauptklassen eingeteilt. 
Bermerkenswerterweise führten einige dieser Mutationen zumindest in unserern Versuchen 
nicht zu einer Störung der PHD2 Aktivität. 
Eine zusätzliche Ebene der Regulation der Epoproduktion wird representiert durch humorale 
Faktoren, wie Peptide und Hormone. Wir haben eine Auswahl an Peptiden auf eine mögliche 
Rolle in der Eporegulation in Hep3B getestet und diesen Ansatz mit einer breit angelegten 
Untersuchung einer Sammlung von Peptiden aus menschlichen Hämofiltraten ergänzt, indem 
wir verschiedene HIF-Reporter Zelllinien verwendeten. Die Resultate aus einer ersten Reihe 
dieser Untersuchungen sind vielversprechend und zeigen die Anwesenheit von im Bezug auf die 
Regulation von HIF sowohl inhibierenden als auch aktivierenden Fraktionen.  
Zusammengenommen konzentrierte sich diese Doktorarbeit auf die hypoxische Regulation von 
Epo auf verschiedenen Ebenen und beschreibt zum ersten Mal ein neues HRE, welches 
möglciherweise das Element representiert, welches für die Nierenspezifische Epoinduktion 
verantwortlich ist. Das neu identifizierte Epo 5'-HRE legt die Basis für weitere Studien mit dem 
Ziel den Effekt einer Vielzahl von Faktoren und Peptiden auf die Sauerstoff-abhängige 
Eporegulation zu untersuchen. 
 
 
 
 
 
Introduction 
   
1 
 
1. Introduction 
Erythropoietin (Epo) is often a topic of interest for the world’s media because of its wide use as a 
doping agent in a variety of sport disciplines, especially when endurance is involved. Why is there 
such a big illegal market for recombinant Epo? What are the benefits and the side effects of such 
treatment? Recombinant human Epo (rhEpo) was first approved by the American Food and Drug 
Administration in 1989 as a therapeutic approach to treat patients with anaemia, i.e. when the 
number of red blood cells (RBCs) or the concentration of haemoglobin (Hb) is not sufficient to 
support appropriate oxygen (O2) delivery to tissues. Increasing the haematocrit (Hct, volume of 
RBCs on the total blood volume) to a certain extent increases the oxygen-carrying capacity of the 
blood and has the proven effect of enhancing the athlete’s performance too, at least for a certain 
range of Hct values. The number of athletes that have been tested and found positive for doping 
increased exponentially after the introduction of rhEpo on the market in the early 1990’s and 
nowadays new doping routes, including alternative erythropoiesis-stimulating agents and gene 
transfer approaches, are becoming increasingly popular and difficult to detect for the regulatory 
agencies. One of the most famous cases of doping concerns cycling: during the Tour de France in 
1999 for example most of the athletes on the American national team, including famous Lance 
Armstrong, were found to be positive to performance-enhancing substances, mainly Epo. Less 
known is probably the case of “natural doping” of the Finnish cross-country skier Eero Mäntyranta, 
who suffered from a genetic form of polycythemia, or eythrocytosis, a clinical condition leading to 
excessive number of RBCs. The oxygen-carrying capacity of his blood was increased of up to 
50%, a large advantage that led him to win several world and Olympic medals in the 60’s and 70’s. 
On the other hand, erythrocytosis can have deleterious effects due to the increased viscosity of the 
blood and subsequent increased risk of blood vessel occlusion, or thrombosis, and is definitely 
considered a haematological disease. Therefore, it seems important to maintain Epo levels within a 
specific range but what is the physiological meaning of a factor regulating the number of RBCs? 
RBCs, or erythrocytes, are enucleated cells of the blood containing the O2-binding protein 
haemoglobin and represent the mechanism used by higher vertebrates to deliver oxygen to every 
single cells of the body. The amount of oxygen dissolved in the plasma would in fact not be 
sufficient to meet the metabolic demand of the entire organism. O2 is used by the mitochondrial 
respiration machinery of the cell to produce energy in the form of adenosine triphosphate (ATP) 
molecules and conditions of reduced oxygen tension (or hypoxia) are extremely dangerous for life. 
Hypoxic conditions are not so far from every-day life as one would expect: going to high altitude 
(>2500 m on sea level) is already a challenge for our body and it is interesting to know how whole 
populations, such as Tibetans and Peruvians, have adapted in order to live in conditions of chronic 
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hypoxia. Moreover, hypoxia is a hallmark of several diseases such as chronic kidney disease and 
cancer: accumulating evidences in literature suggest that the hypoxic microenvironment of tumours 
for instance supports the growth of the neoplastic tissue, as well as increases angiogenesis and 
chemoresistance. Organisms have developed mechanisms to sense changes in partial pressure of 
oxygen (pO2), to trigger activation of the hypoxia-inducible factor (HIF) pathway at the cellular level 
and consequently to produce changes at the systemic level in order to guarantee adequate O2 
delivery to peripheral tissues. Such adaptive mechanisms include Epo production which will in turn 
increase the Hct and allow the blood to uptake as much oxygen as possible from the environment. 
Basal production of Epo is also required for the normal turn-over of RBCs. Epo is thus an essential 
hormone for life and understanding its regulation is an important challenge, not only to fight against 
illegal doping in sports but mainly to provide improved treatments for patients with inappropriate 
Epo synthesis. 
1.1 Physiology of Epo production 
Epo is the most important regulator of RBCs homeostasis. In adults, the amount of circulating 
RBCs is fairly constant due to a balance between daily produced and removed RBCs. The bone 
marrow is responsible for erythrocyte production (erythropoiesis), whereas the mononuclear 
phagocyte system of the spleen, liver and lymph nodes removes the   ̴120-days old cells from the 
blood stream (Wenger and Kurtz, 2011). In condition of reduced oxygenation (hypoxia) or Hb 
content (anaemia), the oxygen-carrying capacity of the blood is concomitantly reduced and RBC 
production by the bone marrow can be increased up to 8-fold within a few days. This effect was 
described already in the 19th century by Francois-Gilbert Viault, who observed increased RBC 
count in people travelling at the altitude of 4200 m in the highlands of Peru (Viault, 1890). In 1905 
Paul Carnot and his assistant Clotilde Deflandre proposed for the first time the possibility of a 
hormonal regulation of erythrocyte production and in the middle of the 20th century evidences from 
anaemic animals confirmed the existence of a humoral factor responsible for increased 
erythropoiesis (Krumidieck, 1943). Later on, in 1977, Epo protein was isolated form urine of 
anaemic patients (Miyake et al., 1977). Two groups independently succeeded in cloning the EPO 
gene in 1985 (Jacobs et al., 1985; Lin et al., 1985) and it is now clear that Epo is the essential link 
between reduced O2 tension and increased Hct. The Epo-producing cells of the foetal liver and 
adult kidney are able to sense changes in tissue O2 tension and respond with increasing EPO gene 
transcription. Epo is then secreted into the blood stream, reaches the sites of erythropoiesis in the 
bone marrow and stimulates proliferation and differentiation of the erythrocyte progenitors. 
Erythrocytes contain Hb, the protein responsible for O2 binding and transport in the blood, thus an 
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increase in erythrocyte count restores the O2-carrying capacity of the blood to normal levels (see 
figure 1) (Jelkmann, 2011; Wenger and Kurtz, 2011; Bunn, 2013). 
 
Figure 1 Scheme representing RBCs regulation by Epo. 
The importance of Epo is demonstrated by animal experiments in which Epo or its receptor (EpoR) 
has been knocked out. Epo-/- or EpoR-/- mice showed the same phenotype with foetal death at 
embryonic day 12-13 (E12-13) associated with severe anaemia and the complete lack of definitive 
RBCs (Wu et al., 1995; Lin et al., 1996; Wu et al., 1999). On the other hand, many Epo transgenic 
mouse models have been generated and displayed erythrocytosis as a common phenotype 
(Semenza et al., 1989; Semenza et al., 1990; Loya et al., 1994; Madan et al., 1995; Köchling et al., 
1998). Moreover, Epo amino acid sequence is strongly conserved in mammals, as well as the 
overall structure of the protein (Wen et al., 1993), supporting the relevance of Epo function and 
explaining interspecies cross-reactivity of the hormone. 
Epo plasma concentration in healthy human beings is around 10 pM but this value can increase up 
to 1000-fold in certain environmental conditions, such as severe anaemia or hypoxia. The inverse 
relationship between Epo plasma levels and O2 partial pressure/Hct/Hb concentration has been 
demonstrated in human beings exposed to high altitude hypoxia, as well as in several animal 
experiments using different ways to induce hypoxia or anaemia (figures 2A and 2B). Following a 
drop in alveolar and subsequently in arterial O2 tension, plasma Epo levels start to rise after 60-90 
minutes from the beginning of the hypoxic stimulus and continue to rise with a slope depending on 
the severity of the stimulus. The maximal peak is reached at 12-24 h in rodents (Abbrecht and 
Littell, 1972; Jelkmann, 1982) and around 48 h in humans (Abbrecht and Littell, 1972). Epo plasma 
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levels then decrease but remain higher than the baseline value if the hypoxic stimulus persists 
(figure 2C). 
 
Figure 2 A. Time course of Epo serum plasma levels measured by radioimmunoassay (RIA) in 
human beings exposed to high altitude (hypobaric hypoxia) (Eckardt et al., 1989). B. Relationship 
between Hct and Epo plasma levels in anaemic rats (Hir et al., 1991). C. Time course of Epo 
plasma concentration in rats exposed to normobaric hypoxia (O2 tension: 60 mmHg) (Wenger and 
Kurtz, 2011). 
Since the Hct starts to rise long after the peak in Epo plasma levels (Abbrecht and Littell, 1972), it 
is reasonable to assume that an intrinsic feedback mechanism represses EPO transcription in Epo-
producing cells before the effect of restoring the O2-carrying capacity of the blood is actually 
achieved. Desensitization of Epo-producing cells to chronic hypoxia has been proposed as the 
underlying mechanism (see below). 
Hypoxia is not the only stimulus capable of increasing Epo production: as mentioned above, all the 
conditions in which the O2-carrying capacity of the blood is decreased lead to reduced tissue O2 
tension. This is sensed by the Epo-producing cells that respond with increased EPO transcription. 
Anaemia is defined as a reduction of the Hb content of the blood and can be due to blood loss or a 
variety of pathological conditions, such as chronic inflammation and tumour diseases (see below). 
With the exception of renal anaemia, where the main Epo-producing organ is affected, this 
condition is linked with increased Epo levels (Hir et al., 1991; Bunn, 2013). On the other hand, 
patients affected by primary polycythemia, a disease causing inappropriately increased 
erythropoiesis, display sub-normal Epo concentrations (figure 3) (Fernandez-Luna et al., 1998; 
Bunn, 2013). Differences in Hb affinity for oxygen affect O2 release to the tissues and thus have an 
influence on Epo concentration as well: increased Hb affinity for O2 leads to a rise in Epo plasma 
levels and vice versa (Lachermann, 1985). Of note, the curve of Epo level changes according to 
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Hct or Hb concentration has a different shape compared to the hypoxic curve: a fall in Hb 
concentration/Hct up to 70% of the normal value does not induce big changes in Epo levels, while 
after this threshold Epo plasma concentration increases exponentially (see figure 2B) (Cotes, 
1982). This could be explained by the characteristic O2-Hb dissociation curve, which allows 
sufficient oxygen delivery to peripheral tissues even with significant reduction of O2-binding 
molecules (see below) (Boron and Boulpaep, 2005).  
 
Figure 3 Plasma Epo levels measured in patients affected by different types and degrees of 
anaemia. Uremia = final stage of kidney failure (renal anaemia), PVC = polycythemia vera or 
primary erythrocytosis, 2° = secondary erythrocytosis (due to increased Epo levels, see below) 
(Bunn, 2013).  
1.1.1 Sites of Epo production and Epo-expressing cellular models 
Experiments with animals in which different organs have been surgically removed demonstrated 
the prominent role of the kidney in Epo production (Jacobson et al., 1957; Zanjani et al., 1981), 
confirmed by the fact that kidney diseases lead to anaemia due to impaired Epo synthesis (Wenger 
and Kurtz, 2011). In mammals, the kidney accounts for   ̴90% of total Epo production during 
adulthood, while the liver is considered the main source during foetal life (Caro et al., 1983; 
Clemons et al., 1986). The liver maintains its ability to produce Epo in response to hypoxia also 
after birth and represents the major site of extrarenal Epo secretion (Suzuki et al., 2013). 
Evidences in mice embryos suggest that Epo is synthetized by a sub-population of neural cells and 
neural crest cells in early-stage embryos (E8.5-11.5), before the liver starts supporting 
erythropoiesis in late-stage embryonic life (Suzuki et al., 2013). Epo has been detected in other 
organs, such as brain, lung, heart, bone marrow, spleen, hair follicles, the reproductive tract and 
osteoblasts, where it likely acts locally by regulating cellular viability (see below). The only 
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structural differences described for Epo protein produced by different organs concern the 
glycosylation pattern of the hormone (Masuda et al., 1994; Lönnberg et al., 2013). 
The switch from liver to kidney occurs shortly after birth, in a species-dependent fashion. Studies in 
the ovine foetus revealed that both organs contribute significantly to Epo foetal levels and that a 
gradual change occurs from mainly hepatic to mainly renal Epo synthesis in late gestation (Moritz 
et al., 1997). The switch is found around postnatal day 10 in rats (Clemons et al., 1986), whereas it 
starts during the last trimester of gestation and ends several months after birth in humans (Dame 
and Juul, 2000). Differences in organ development are most likely the reason for the switch: in 
many species the kidney is not fully mature at birth and the oxygen-sensing capacity depends on 
intact and complete structure of the organ.    
Liver 
The fact that human Epo cDNA was first cloned from human foetal liver indicates the relevance of 
this organ for Epo production (Jacobs et al., 1985). The mammalian foetus is able to respond to a 
hypoxic stimulus by increasing Epo levels in the serum and amniotic fluid, as measured in sheep 
and rat foetuses (Clemons et al., 1986; Dame and Juul, 2000). The embryonic hypoxia-Epo axis is 
functional in human as well, since serum immunoreactive levels can be measured in blood 
samples from the umbilical cord starting at 18 weeks of gestation (Maxwell et al., 1994; Moritz et 
al., 1997). In spite of this, Epo levels in the foetus remain significantly lower than in adult mammals 
(Maxwell et al., 1994). The hepatic contribution to total Epo plasma levels in adulthood is 
considered to be around 10-20%, even though the extent seems to depend on the severity of the 
stimulus, suggesting that the liver is less sensitive to hypoxia compared to the kidney (Tan et al., 
1991; Tan et al., 1992). Different O2-sensing ability of the two organs is a potential explanation for 
the switch to the kidney after birth and is proven by the fact that the liver cannot compensate for a 
failure in renal Epo production. Another important difference between hepatic and renal Epo-
producing cells concerns the mechanism of increased Epo synthesis in hypoxia: in the liver Epo 
mRNA seems to be up- and down-regulated in certain hepatocytes (Koury et al., 1991) while in the 
kidney a higher number of Epo-producing cells is recruited in case of hypoxia or anaemia (see 
below).  
The cells responsible for O2 sensing and Epo production in the liver are the hepatocytes 
themselves, as demonstrated at first by in situ hybridization using Epo antisense probe in liver of 
anaemic mice (Koury et al., 1991). Koury and colleagues also reported an increase in the number 
of Epo-positive hepatocytes around the central vein in mice carrying a human Epo transgene 
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construct. Many experiments with other transgenic mice carrying different Epo locus-driven 
constructs confirmed the ability of hepatocytes to express Epo (see below). Hepatic stellate cells, 
also known as Ito cells, can produce Epo too, as shown by a transgenic Epo-reporter mouse 
(Maxwell et al., 1994). Moreover, freshly isolated hepatocytes (Eckardt et al., 1993)  and Ito cells 
(Maxwell et al., 1997) from normoxic animals are able to express Epo upon hypoxic exposure. 
Interestingly, Ito cells share some similarities with the renal Epo-producing cells, such as the 
expression of the fibroblast marker 5’-ectonucleotidase (Schmid et al., 1994). 
Since attempts to isolate renal Epo-producing cells have failed so far, liver-derived cellular models 
have been historically used to study EPO gene regulation. The hepatocellular carcinoma cell lines 
Hep3B and HepG2 were shown to express Epo in an oxygen-dependent way already in 1987 by 
Goldberg et al.  (Goldberg et al., 1987) and have been since then the most widely used in vitro 
models (Dame et al., 2004; Warnecke et al., 2004; Dame et al., 2006). In spite of this, Hep3B and 
HepG2 lack the typical feedback regulation of Epo mRNA under chronic hypoxia (see result 
section), as expected for the renal Epo-producing cells, and do not represent an appropriate model 
to study Epo regulation in the kidney. Another issue is the loss of hypoxia-induced Epo expression 
in these cell lines with increasing time in culture: cloning of the cell population is often required in 
order to maintain high Epo mRNA induction upon hypoxic exposure. 
Kidney 
As mentioned above, the kidney is known to be the most relevant Epo-producing organ. This 
observation fits with the kidney being the major oxygen-sensing organ in the body, together with 
the aortic and carotid body. The latter are located close to the lung circulation and are able to 
sense pO2 and pH in arterial, freshly oxygenated blood. Since the tissue is highly perfused, the 
main function of the chemoreceptor cells in the aortic and carotid body is to regulate ventilation 
according to the pO2/pH sensed in arterial blood by communicating with the respiration control 
centre of the brain stem. The location of the chemoreceptors does not allow them to sense 
changes in pO2 arising from changes in the actual oxygen content of the blood, a function that is 
executed by the kidney (Boron and Boulpaep, 2005).  
The kidney can be divided into an external part (cortex) and an internal part (medulla) and its 
primary function is to produce and excrete urine. The whole process of filtering the blood, 
reabsorbing and excreting electrolytes and substances according to the body needs is carried out 
by the epithelial cells of the tubular system. The nephron is the functional unit of the kidney and the 
urine produced in the lumen of each nephron converges in the pelvis and is excreted through the 
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ureters. This process is regulated in an extremely fine manner according to the blood volume, 
pressure and electrolytes/substances content. The vasculature is also peculiar in the kidney: the 
vasa recta in particular run parallel to the renal tubules within the medulla and, like the tubules, 
loop back up at various depths towards the cortico-medullary junction. As a result of the delicate 
anatomy of blood vessels, a countercurrent exchange of O2 along the cortico-medullary axis takes 
place, leading to a unique gradient of O2 towards the inner part of the organ, as well as to relatively 
low tissue O2 tension. According to staining of rat kidneys with the hypoxic probe pimonidazole, the 
oxygen tension in the medulla is around 10-15 mmHg (Rosenberger et al., 2009), lower than what 
is found in other kidney regions where the range is 20-70 mmHg (Muller et al., 1998; O’Connor, 
2006). It must be kept in mind that measuring kidney pO2 directly is not easy, since insertion of 
electrodes (see below) can disrupt the architecture of the organ or result in broken electrodes: 
direct in vivo measurements are available only for the superficial cortex and show a high degree of 
variability (Evans et al., 2008). Moreover, the renal oxygen gradient is independent of changes in 
organ perfusion, since the more blood enters the kidney the more O2 will be consumed by the 
tubular system, mainly for reabsorption, leading to a stable relationship between oxygen supply 
(blood perfusion) and consumption (see figure 4B) (Leong et al., 2007; Wenger and Hoogewijs, 
2010). A relatively constant fraction of oxygen is consumed in the cortex, where filtration and a 
large part of reabsorption/secretion takes place, and renal Epo-producing cells (REPCs) are 
located at the border between cortex and medulla (see figure 4A), the perfect location to sense 
small changes in tissue O2 tension arising from changes in the O2 content of the blood.  
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Figure 4 A. Schematic representation of the kidney tubular system and the countercurrent O2 
exchange leading to a stable cortico-medullary oxygen gradient (blue to white background). In 
hypoxia, the gradient is shifted to the outer cortex and the number of REPCs (brown cells) 
increases (adapted from (Wenger and Hoogewijs, 2010)). B. Changes in renal blood flow (RBF) 
were induced in rabbit kidneys by infusion of different stimuli in the renal artery (ANGII, Angiotensin 
II: decrease in RBF; Saline: no effect; Ach, Acetylcholine: increase in RBF). Cortical and medullary 
pO2 remains relatively constant (Leong et al., 2007).   
Since Epo is not stored in the cells that produce it, attempts to identify REPCs by 
immunohistochemistry did not provide reliable results. In situ hybridization represents instead a 
more suitable technique to study which renal cell types are responsible for Epo expression. In 
anaemic or hypoxic kidneys from different species (mice, rats, sheep and monkey), Epo mRNA is 
localized in interstitial, peritubular cells of the cortex and outer medulla (Koury et al., 1988; 
Lacombe et al., 1988; Eckardt et al., 1993; Darby et al., 1995; Fisher et al., 1996). The same 
expression pattern has been found in human near-term or postnatal kidneys from patients with 
conditions predisposing to severe hypoxia and/or induced polycythemia (Liapis et al., 1995). Epo-
producing cells represent less than 10% of the total interstitial cell population of the kidney in 
severely anaemic animals and REPC number correlates directly with the amount of renal Epo 
mRNA and inversely with the Hct (Koury et al., 1989; Eckardt et al., 1993). Epo seems thus to be 
expressed in an all-or-none fashion and it is likely that an increasing number of Epo-producing 
cells is recruited depending on the severity of hypoxia or anaemia (see figure 4A). It is also 
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possible that the Epo expression pattern observed in these experiments is a consequence of the 
sensitivity of the technique, which would recognize positive cells only if they produce a “threshold” 
amount of Epo mRNA. Other studies made use of transgenic mice expressing human EPO locus-
controlled green fluorescent protein (GFP) to localize REPCs and confirmed the results obtained 
by in situ hybridization. The group of Yamamoto in particular made use of transgenic mice 
generated with a bacterial artificial chromosome (BAC) containing 180 kb of the murine Epo gene 
flanking regions, which should encompass all the possible regulatory elements and allow accurate 
identification of REPCs (Obara et al., 2008; Suzuki et al., 2011). Even though the localization of 
REPCs is usually considered interstitial, it must be mentioned that the location of these cells has 
been a matter of debate for a long time. A number of reports in literature showed Epo mRNA 
expression in other cell types, in particular in the cortical proximal tubule, glomerulus and 
mesangium (Jelkmann et al., 1983; Kurtz et al., 1983; Mori et al., 1985; Loya et al., 1994; Fisher et 
al., 1996; Shanks et al., 1996). The stimuli and techniques used in these studies are usually 
different from the reports showing REPCs as interstitial cells: cobalt chloride (CoCl2) or hypobaric 
hypoxia was used to mimic hypoxia in wild type (wt) mice or transgenic mice carrying LacZ reporter 
gene under the control of Epo locus were generated (Loya et al., 1994). In the last case, the 
flanking regulatory regions encompassing the transgene do not include the kidney-inducible 
element (see below). Nevertheless, tubular cells undergoing neoplastic transformation can acquire 
the ability to produce Epo, as demonstrated by Epo constitutive expression in different cell lines 
and human tumours originating from renal epithelium (Da Silva et al., 1990). A very recent report 
tried to solve the debate on REPC localization by using highly sensitive in situ hybridization 
techniques in normoxic and anaemic rats. Interestingly, in basal conditions Epo mRNA was 
detected mainly in tubular cells of the cortical collecting duct, whereas upon anaemia Epo 
expression became detectable in peritubular cells and only a slight increase could be observed in 
the tubular epithelium. These data suggest the possibility for Epo to be expressed by the renal 
tubule in normoxia but interstitial cells seem to be mainly responsible for the hypoxia-dependent 
increase in Epo concentration (Nagai et al., 2014).  
Despite considerable research effort, the identity of renal Epo-producing cells remains not fully 
understood. Given the interstitial localization and the expression of markers such as the 5’-
ectonucleotidase (CD73) and platelet-derived growth factor receptor β polypeptide (PDGF-β), 
REPCs were initially thought to be fibroblasts (Bachmann et al., 1993; Maxwell et al., 1993). An 
additional layer of complexity is caused by the observation that Epo-producing cells express 
markers of the neuronal lineage as well, including the microtubule-associated protein 2 (MAP2) 
and the neurofilament light polypeptide (NFL), and to display dendritic-like processes. No staining 
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for blood vessels (platelet endothelial cell adhesion molecule 1 or cluster of differentiation 31, 
PECAM/CD31) or macrophages (macrophage antigen 1, Mac1, and major histocompatibility 
complex II, MHCII) co-localized with REPCs (see figure 5) (Obara et al., 2008). The hypothesis of 
neuronal origin of REPCs is additionally supported by the fact that most of the interstitial fibroblasts 
in the kidney are derived from myelin protein 0 (P0)-positive neural crest cells and around 10% of 
P0 lineage-derived renal cells co-localize with Epo expression in transgenic mice (Asada et al., 
2011). Moreover, a recent study identified neural crest cells as the source of Epo during embryonic 
development (Suzuki et al., 2013). Interestingly, renin-producing cells from the kidney 
juxtaglomerular apparatus have been shown to turn into Epo-producing cells when the von Hippel-
Lindau protein (pVHL, see below) is knocked out, followed by HIF-2α stabilization. The study 
shows for the first time the possibility for this specific cell type to acquire REPC characteristics 
(Kurt et al., 2013). Even though from a different embryonic origin, renin-producing cell number also 
increases under low salt diet conditions, suggesting a parallelism between REPCs and renin-
producing cells.  
 
Figure 5 D/E. Epo-producing cells from an Epo locus-driven GFP transgenic mouse are indicated 
by arrows (interstitial localization). When co-stained with cell lineage markers (red), REPCs (green) 
were negative for CD31 (F) and Mac1 (G), but positive for MAP2 (H) and NFL (I) (Obara et al., 
2008).  
Attempts to isolate REPCs to obtain an in vitro kidney-derived model for hypoxic Epo regulation 
have been so far unsuccessful. Only one report in literature shows Epo production by E4, a mixed 
mesenchymal cell population derived from adult mouse kidney. E4 cells were able to up-regulate 
Epo mRNA and protein when exposed to anoxia or hypoxia and immunofluorescence experiments 
showed co-localization of Epo and the fibroblast marker CD73 in roughly 50% of the cells. Apart 
from the paper describing the cells, no independent study confirmed E4 as a renal cell model for 
Epo hypoxic regulation (Plotkin and Goligorsky, 2006). An Epo locus-driven GFP BAC was used to 
tag and isolate REPCs from anaemic mice: GFP-positive cells represented 0.2% of the total kidney 
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tissue and 67% of them co-expressed CD73 (Pan et al., 2011). However, isolated GFP-positive 
REPCs could not be kept in culture. Epo-producing cells are often considered fibroblasts in a 
“resting state” that lose the ability to produce Epo when induced to proliferate, as in case of in vitro 
culturing. Recently, a link between the loss of Epo production and differentiation of REPCs to 
myofibroblasts was proposed (Souma et al., 2013). In this study, a mouse model of renal fibrosis 
was used and the authors could show that most of the myofibroblasts governing fibrosis were 
derived from REPCs, which lost Epo expression after differentiation. Interestingly, the phenotype 
was rescued upon removal of the inflammatory stress. Conversion of REPCs to non Epo-producing 
fibroblasts would also explain anaemia in patients with CKD. 
Other sites of Epo production and non-haematopoietic effects of Epo 
As mentioned above, other cell types are capable of producing Epo, apparently in a similar hypoxic 
response like in liver and kidney. The functional relevance of these small amounts of Epo is 
probably a paracrine/autocrine protection from acute tissue injury. Epo receptor is indeed 
expressed by a number of tissues, such as brain (Tan et al., 1991; Dame et al., 2000), 
cardiomyocytes (Tramontano et al., 2003; Wright et al., 2004), megakaryocytes (Fraser et al., 
1988), endothelial cells (Anagnostou et al., 1994; Yamaji et al., 1996), testis (Yamazaki et al., 
2004) and cancer cells. In the case of tumours, the local production of Epo has been proposed to 
act directly on EpoR of the same neoplastic tissue and to promote proliferation, invasion and 
chemoresistance (a few of the most recent examples include (Wu et al., 2012; Rózsás et al., 2013; 
Todaro et al., 2013; Liang et al., 2014)).  
The brain is one of the most studied alternative Epo-producing tissues: expression of Epo and its 
receptor has been shown in neurons, astrocytes and endothelial cells throughout development 
(Tan et al., 1991; Dame et al., 2000) and conditional knockout of EpoR in brain impairs neural cell 
proliferation and post-stroke neurogenesis (Tsai et al., 2006). Astrocytes in particular are capable 
of oxygen-regulated Epo expression in vitro (Masuda et al., 1994) and in vivo (Tan et al., 1991). In 
the retina, Epo and EpoR have been found to be expressed by the optical nerve, retinal ganglion 
cells, photoreceptors, retinal pigmental and vascular cells, suggesting a role for the hormone in this 
tissue (Juul et al., 1998; Hu et al., 2011; Caprara et al., 2014). Also, during development and 
pathological conditions such as diabetic retinopathy Epo retinal levels are significantly increased 
(Xie et al., 2007; García-Ramírez et al., 2008). Again, a protective role for Epo on retinal neuron 
has been proposed by many groups (reviewed by (Grimm et al., 2006)). Interestingly, the brain 
stem, that is responsible for respiration control, seems to express EpoR, as the chemoreceptors of 
the carotid body, which have also been shown to be a site of Epo production. This suggests the 
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possibility of a coordinated physiological adaptation to hypoxia in which Epo would interact directly 
with the respiration control centres (Soliz et al., 2005; Lam et al., 2009; Soliz et al., 2009). Epo 
expression in the brain is supported by the fact that neuronal cell models are capable of expressing 
oxygen-dependent Epo in culture. The neuroblastoma cell lines Kelly and SH-SY5Y in particular 
are used as in vitro model for hypoxic Epo expression (see results) (Stolze et al., 2002). 
Evidence exists for a protective role for Epo after tissue damage in the heart as well. Several 
groups reported beneficial effect of recombinant Epo in animal models of ischemia/reperfusion and 
myocardial infarction (Parsa et al., 2004; Fiordaliso et al., 2005; Nishiya et al., 2006). The 
mechanism underlying Epo cytoprotective effect is probably link to the pro-survival and anti-
apoptotic JAK/STAT pathway activated upon interaction of Epo with its receptor (see below). 
Another proposed explanation is the effect of Epo on endothelial cells and angiogenesis, also 
thought to be beneficial for tumour cells invasiveness (Wu et al., 2012; Liang et al., 2014). High 
doses of rhEpo have been shown to stimulate endothelial cell proliferation in vitro (Anagnostou et 
al., 1990) and systemic hypoxia can mobilize CD34+ endothelial progenitor cells in an Epo-EpoR-
dependent manner in vivo (Bahlmann et al., 2003; Heeschen et al., 2003). On the other hand, 
angiogenesis in skeletal muscle seems independent from endogenous Epo (Hagström et al., 
2010). The two main Epo-producing organs, the liver and the kidney, have also been shown to 
express EpoR and to be protected by Epo administration in a series of tissue injury model (Cassis 
et al., 2011; de Souza et al., 2012; Xiao et al., 2012; Fu et al., 2013).  
The physiological relevance of the above described Epo non-haematopoietic effects is still 
debated. Epo/EpoR KO mice do show cardiac defects, abnormal vascular development and 
increased apoptosis in the brain besides failure in definitive erythropoiesis (Wu et al., 1999). When 
EpoR was specifically re-introduced in the erythroid lineage, mice survived and showed no 
apparent developmental defect (Suzuki et al., 2002). Additionally, a few reports in literature support 
the lack of functionality of the Epo-EpoR axis in tissues other than the hematopoietic compartment 
due to much lower expression of EpoR or to unresponsiveness of the intracellular signalling 
pathway when rhEpo was administered in vitro (Sinclair et al., 2010; Elliott et al., 2012). 
1.1.2 Erythropoietic effect of Epo 
Epo structure and binding to EpoR 
Once Epo is secreted from REPCs into the blood stream, it has to reach the sites of 
haematopoiesis in the foetal liver and adult bone marrow in order to activate RBC production. Epo 
protein is a   ̴30.4 kDa, heavily glycosylated hormone. Evidences suggest the appearance of Epo 
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already in fish, such as zebrafish and trout (Chu et al., 2008), but most of the knowledge we have 
comes from studies in mammals that show strong interspecies conservation in terms of amino acid 
sequence and structure (Wen et al., 1993). Epo precursor protein contains a canonical leader 
sequence and is cleaved in the endoplasmic reticulum, glycosylated in the Golgi and finally 
released as a 166 residues polypeptide (Jacobs et al., 1985; Lin et al., 1985). Epo folds as a 
globular protein composed by 4 α-helices connected by loops and stabilized by two disulphide 
bridges (Cheetham et al., 1998; Syed et al., 1998). One of the disulphide bridges is critical for the 
activity of the protein and links the amino-terminus with the carboxy-terminus of the polypeptide 
generating a long loop, probably important for binding to EpoR (Boissel et al., 1993). Glycosylation 
of the human protein consists of three N-linked polysaccharide groups and one O-linked group, 
accounting for roughly 40% of total Epo weight (Sasaki et al., 1988). The polysaccharide groups 
are needed to increase Epo plasma half-life but are probably dispensable for biological activity: 
removal of terminal sialic acids increases Epo activity in vitro but shortens the half-life of the 
polypeptide from 7-8 h to a few minutes in vivo (Goldwasser et al., 1974). The different types of 
commercially available rhEpo (Epoetin alpha, beta, delta, omega and zeta) differ indeed in the 
glycosylation residues composition. 
Epo binds to the high affinity EpoR present on the surface of target cells, mainly erythrocytes 
precursors. EpoR is a 70-80 kDa protein containing post-translational glycosylations and 
phosphorylations (Sawyer and Hankins, 1993). It belongs to the cytokine receptor superfamily and 
consists of homodimers of single transmembrane monomer associated to the Janus kinase family 
member 2 (JAK2) (Ihle, 1995). Upon Epo binding, the two subunits of EpoR homodimer are 
brought in close proximity and so are the JAK2 domains: this conformational change initiates the 
transduction cascade by enabling cross-phosphorylation of JAK2 and phosphorylation of the 
cytosolic tail of EpoR subunits. The newly generated SH2 docking sites recruit several proteins, 
including the signal transducer and activator of transcription (STAT)-5, which upon phosphorylation 
homodimerizes, translocates to the nucleus and activates a series of target genes leading to anti-
apoptotic, pro-survival and pro-erythrocyte differentiation effects (Watowich et al., 1994). Other 
intracellular signalling pathway activated by Epo-EpoR interaction include the phosphatidylinositol 
3 kinase (PI3K)/Akt, the extracellular-regulated kinases 1/2 (ERK1/2) and p38 pathways 
(Richmond et al., 2005). JAK2 dephosphorylation and receptor internalization then terminate EpoR 
signalling. The essential role of JAK2 in erythropoiesis is proven by experiments with Jak2-/- mice, 
which are anaemic and die at embryonic day 12.5 due to lack of definitive erythropoiesis 
(Neubauer et al., 1998) . 
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Primitive and definitive erythropoiesis 
Erythropoiesis (from Greek “erythro” = red and “poiesis” = to make) is the process by which RBCs 
are produced. Self-renewing properties of haematopoietic stem cells provide a continuous 
replenishment of differentiated erythrocytes (Orkin, 2000). A first wave of erythrocyte synthesis 
originates in the “blood islands” within the yolk sack and is known as primitive erythropoiesis. This 
early foetal life population consists of large, nucleated cells and their production takes place 
between embryonic day 7 and 9 in mice (Palis et al., 1999). The role of Epo in primitive 
erythropoiesis is still not well defined but recent studies in EpoR-null embryos revealed the 
importance of Epo-EpoR signalling pathway for primitive erythrocyte maturation (Malik et al., 
2013). The finding of Epo expression in neural crest cells by Suzuki et al. also supports the idea of 
Epo acting already on erythropoiesis at this early stage (Suzuki et al., 2013). 
Definitive erythropoiesis occurs instead in the foetal liver and postnatal bone marrow, where the 
whole haematopoiesis, the production of blood cells, takes place starting from a common 
pluripotent stem cell. Figure 6 illustrates the different cell lineages arising from the self-renewing 
stem cell, including the erythropoietic lineage (highlighted on the left). Stem cell progeny is divided 
into committed stem cells, which continue with differentiation, and pluripotent stem cells, which 
maintain the self-renewing pool. Cell division of the committed progenitor originates the myeloid 
lineage on one hand, to which RBCs belong together with platelets, granulocytes, mast cells, 
monocytes and dendritic cells, and the lymphoid lineage on the other hand, including B-, T- and 
NK-cells (Stirewalt and Radich, 2003).  
 
Figure 6 Right panel: schematic representation of the haematopoietic process with the various 
blood cell lineages deriving from the common stem cell. The erythroid differentiation line is 
highlighted in red. Left panel: physiological definitive erythropoiesis within and without 
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erythroblastic island (EI). Macrophages within the EI support eytrhoblasts by promoting cell 
proliferation, assisting iron uptake and enucleation and keeping cells in close proximity in order to 
allow autoregulatory inetractions. Dashed arrows indicate the possibility for erythroblasts to 
repeatedly attach and detach from the EI. Regulation of Epo production by RBC amount in the 
blood is shown (adapted from (Stirewalt and Radich, 2003; Socolovsky, 2013)). 
The most immature compartment of definitive erythroid progenitors consist of the burst-forming 
unit-erythroid (BFU-E). When kept in culture, human BFU-E take 14 days to form colonies of 
mature erythrocytes in semisolid media. The next step is represented by the colony-forming unit-
erythroid (CFU-E), that take only 7 days to give mature erythrocytes in vitro, suggesting a more 
committed phenotype compared to BFU-E (Palis et al., 1999). Epo is essential for CFU-E survival 
and required for colonies formation in culture conditions (Koury and Bondurant, 1990; Wickrema et 
al., 1992). In vivo, CFU-E progenitor cells proliferate and differentiate into progressive erythroblast 
stages during which chromatin is condensed (nuclear pyknosis), cell size is decreased, 
haemoglobin is accumulated (iron-dependent phase) and RNA content is diminished (Koury et al., 
1989; Liu et al., 2011). The final, fundamental step in RBC maturation is enucleation: the newly 
formed erythrocytes, also called reticulocytes, lose the nucleus and all the residual cytoplasmatic 
organelles (especially mitochondria), reduce cell volume and plasma membrane surface and are 
then released into the blood stream (Palis et al., 1999; Ji et al., 2011). The typical shape of mature 
RBCs is a biconcave disc. Erythroblasts are able to generate mature RBCs in vitro without the 
need of accessory cell types but this is probably not valid for the haematopoietic tissues, where 
specific niches called erythroblastic islands (EI) can be found. An EI consists of one or more 
central macrophages to which differentiating erythrobalsts attach in concentric rings. EIs are 
thought to have crucial support functions to the whole process of RBC maturation, mainly by 
promoting cell proliferation, iron-uptake and cell-cell interaction by secreting paracrine factor and 
keeping cells in close proximity. The enucleation step is also facilitated by the presence of EIs 
(Manwani and Bieker, 2008; Mohandas and Chasis, 2010). 
Erythrocyte function and haemoglobin 
It has been calculated that an average adult with approximately 5 L of blood renews more than 
1011 reticulocytes per day (  ̴1% of total) in order to keep a roughly constant number of RBCs (Lang 
et al., 2012; Palis, 2014). Mature erythrocytes feature unique cytoskeletal characteristics that allow 
them to repeatedly and passively deform when passing though narrow capillaries. Plasma 
membrane is for example attached to an elastic network of spectrin and actin cytoskeleton through 
a series or protein, including glycophorin C and ankyrin band 3. Mutations in the genes encoding 
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for such proteins lead to severe haemolytic disorders (characterized by erythrocyte lysis, reviewed 
by (Mohandas and Gallagher, 2008)).  
As mentioned above, oxygen solubility in plasma is not sufficient to transport an adequate amount 
of gas to the whole organism. The most important protein involved in O2 transport in the blood is 
haemoglobin, which is also the most abundant protein in RBCs. One molecule of adult Hb contains 
2 α and 2 β chains, each consisting of a globin polypeptide and a heme group, the binding site of 
molecular oxygen. The porphyrin ring of the heme group chelates a metal atom, iron in the ferrous 
state (Fe2+) in the case of Hb. The interaction between O2 and iron leads to conformational 
changes in the protein tri-dimensional structure that facilitates the binding of additional oxygen 
molecules to the other binding sites of Hb. This cooperative effect between the 4 binding sites is 
responsible for the typical S-shape of the Hb-O2 dissociation curve (figure 7) and allows easier 
load and unload of the protein according to pO2. Several factors can cause allosteric changes in 
Hb conformation and consequently a shift of the curve towards right or left, i.e. decreased or 
increased affinity for oxygen. Acidic pH, increased carbon dioxide partial pressure (pCO2) and 
higher temperature shift the curve to the right, while basic pH, decreased pCO2 and lower 
temperature contribute to the leftward shift of the curve. Physiologically, these effects are strongly 
relevant because they allow easier O2 dissociation (and thus increased O2 availability) in 
metabolically active tissues, such as skeletal muscles where pH is low and pCO2 and temperature 
are high. On the other hand easier O2 binding in metabolically inactive tissue, such as the lungs, is 
ensured. The affinity of Hb for oxygen is also sensitive to the concentration of 2,3-
diphosphoglycerate (2,3-DPG), a metabolite of glycolysis that binds in 1:1 ratio to Hb molecules. 
Binding of 2,3-DPG to Hb destabilizes the interaction of the protein with oxygen. A physiologically 
relevant situation such as hypoxia leads to a switch to glycolytic metabolism, thereby increasing 
2,3-DPG content and facilitating O2 release to the tissues (Boron and Boulpaep, 2005; Mairbäurl 
and Weber, 2011).    
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Figure 7 Oxygen-haemoglobin dissociation curve: pO2 in arterial blood is around 100 mmHg and 
the saturation of Hb in physiological conditions is   ̴97.5%, pO2 in mixed venous blood is around 40 
mmHg and Hb saturation is   ̴75%. The factors increasing or decreasing the affinity of the protein 
are shown.  
It is important to mention that different forms of Hb are expressed in embryonic and foetal life, due 
to the different way by which oxygen is delivered to the mammalian embryo/foetus. Maternal blood 
is the main source of O2 and increased Hb affinity is required for the embryo in order to get enough 
oxygenation. Additional globin chains build the embryonic and foetal forms of Hb and include α-like 
chains (ζ) and β-like chains (γ, δ and ε), encoded by different genes in the same chromosomal loci 
(chromosome 16 for α-like and 11 for β-like chains in the human genome). At birth, the newborn 
blood contains both adult and foetal Hb but the latter gradually decreases till 1-2% of the total (Wild 
and Bain, 2004). Obviously, mutations in Hb-coding gens lead to various forms of anaemia, among 
which sickle cell anaemia is one of the most clinically relevant. A single amino acid replacement 
(V6E) renders the de-oxygenated form of sickle Hb much less soluble: the result is precipitation of 
the protein inside RBCs and formation of long fibres, giving the typical sickle-like appearance. 
Besides being less efficient in carrying oxygen, sickle cells are also more prone to haemolysis 
(Mairbäurl and Weber, 2011).  
RBCs are fundamental not only for oxygen transport in the blood but for CO2 carriage as well. Most 
of the CO2 (90% of total) is in fact transported inside erythrocytes in different forms: a small fraction 
is dissolved (4%), about 22% reacts with Hb forming carbamino groups and the other 64% is 
converted to bicarbonate (HCO3
-) via carbonic anhydrases in the cytosol of RBCs. HCO3
- is then 
transported out of the cells via the chloride-bicarbonate exchanger AE-1 (anion exchanger 1) 
(Boron and Boulpaep, 2005). 
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The average life of erythrocytes in the blood is of 100-120 days. As RBCs age, the size and 
cytoplasm volume get smaller, while Hb concentration remains stable, resulting in increased 
density. Macrophages of the phagocyte system in the spleen, liver and lymph nodes are able to 
recognize senescent erythrocytes thanks to a series of changes in the composition of the plasma 
membrane. During senescence, modified Hb binds to band 3 leading to modification of the protein, 
IgG binding and dissociation of the cytoskeleton from the lipid bilayer. Moreover, vesicles exposing 
senescence markers and phosphatidylserine are fused to the plasma membrane, making the “old” 
RBC a target for scavenger receptors expressed by macrophages (Arese et al., 2005; Bosman et 
al., 2005; Lang et al., 2010). An additional mechanism reducing the amount of damaged RBCs is 
eryptosis or suicidal death of erythrocytes, which may occur in case of cell injury prior to 
senescence. Eryptosis is a kind of programmed cell death, similar to apoptosis in nucleated cells, 
and involves calcium influx into the erythrocyte. In contrast to haemolysis, there is no rupture of the 
cell membrane and no release of the intracellular content but rather blebbing and exposure of 
removal signal, such as phosphatidylserine (Lang et al., 2010; Lang et al., 2011). Interestingly, Epo 
has been shown to inhibit suicidal death of RBCs (Myssina et al., 2003). The physiological 
significance of eryptosis could be removal of defective erythrocytes and prevention of haemolysis, 
a necrosis-like process leading to disruption of the cell membrane and release of Hb in the blood 
stream. Hb is filtered in the kidney and big amounts of circulating protein can have serious 
consequences, such as renal tubule occlusion. 
 
1.2 Hypoxia 
Oxygen is essential for survival of nearly all plants, animals and single-cell organisms, thus its 
concentration in tissues must be maintained within a certain range in order to avoid conditions of 
hypoxia (not enough O2) or hyperoxia (too much O2), both harmful for aerobic cells. Evolution led 
to generation of organisms (plants) that are able to convert solar energy, CO2 and H2O into energy-
containing glucose molecules through the process of photosynthesis, with the production of O2 
molecules as a side product. The increased oxygen levels in the atmosphere was followed by the 
evolution of multicellular organisms (Metazoa) metabolizing glucose in an oxygen-dependent way 
in order to extract energy, via the so-called aerobic respiration taking place in special cellular 
organelles, the mitochondria. This process is extremely efficient, with a virtual yield of 30 ATP 
molecules per glucose molecule metabolized through glycolysis and citric acid cycle. Anaerobic 
glycolysis alone leads to the production of 2 ATP molecules/glucose mole while β-oxidation of fatty 
acids gives around 14 ATPs/glucose mole consumed (Alberts et al., 2002; Semenza, 2014). 
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Sensing and maintaining O2 homeostasis is not only a task of tissues directly involved in O2 uptake 
and delivery, such as the aortic and carotid body, the vascular and respiratory system, but of all the 
nucleated cells of our body that are able to respond to hypoxia by activating the ubiquitous von 
Hippel-Lindau protein/prolyl-4-hydroxylase domain/hypoxia-inducible factor (pVHL/PHD/HIF) 
pathway, explained in details below.  
What is the real partial pressure of oxygen cells are exposed to inside our body? And what does 
hypoxia mean from this point of view? Considering hypoxia every O2 concentration values below 
21% or every pO2 below 160 mmHg (the fraction of O2 in the air at sea level) would be a mistake 
since most of the cells of the organism are actually exposed to much lower oxygen tension, as 
summarized in table 1 (Carreau et al., 2011). Already from external air to air in the alveoli, there is 
a significant drop in oxygen tension of 50 mmHg and this value further decreases when 
considering arterial, freshly oxygenated blood. Different tissues have specific pO2 depending on a 
number of factors, such as blood perfusion, vascular anatomy and O2 consumption of the organ. 
As mentioned above, the kidney features a unique, wide oxygen gradient with values ranging from 
10-20 mmHg in the medulla to 50-70 mmHg in the cortex. Hypoxia is thus a “functional” definition: 
hypoxic cells are exposed to an oxygen tension that is lower than the physiological one for a given 
tissue and that triggers the activation of hypoxia-responsive pathways. The lowest oxygen partial 
pressure at which mitochondria can still perform aerobic respiration is thought to be around 0.15-
0.3 kPa (1-2 mmHg), the so-called Pasteur point (Sandberg and Naylor, 2011). It is interesting to 
notice that in vitro cell cultures are usually performed in 95% air (+ 5% CO2), thus providing 
19.95% O2 (  ̴ 151.7 mmHg), a concentration that probably results in hyperoxia compared to 
physiological conditions inside the human body.   
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Compartment/Tissue pO2 (mmHg) 
Air 160 
Inspired air (tracheus) 150 
Air in the alveoli 110 
Arterial blood 100 
Venous blood 40 
Brain 33.8 ± 2.6 
Lung 42.8 
Liver 40.6 ± 5.4 
Kidney cortex 72.0 ± 20 
Kidney medulla 10 - 20 
Muscle 29.2 ± 1.8 
 
Table 1 Mean oxygen tension values in the microenvironment of different human tissues (adapted 
from (Carreau et al., 2011)). 
The most direct way to measure oxygen levels in tissues is represented by polarographic sensors. 
This method is based on the classical Clark’s electrodes, consisting of a noble material (e.g. silver, 
gold or platinum) which reduces oxygen thanks to a negative polarizing voltage. The measurement 
takes into account the difference between a reference electrode (anode) and a measuring one 
(cathode) and it is directly proportional to the amount of oxygen reduced by the cathode. The tip of 
the electrode is very thin (3-5 μm) and electrically insulated by a gas-permeable but liquid-
impermeable membrane. Inserting the electrodes into the analysed tissue has been so far 
considered as the standard procedure (Clark et al., 1958; Clark et al., 1958; Norton and Rand, 
1974). Optic fibre-based sensors represent another option and are based on O2-dependent 
changes in the lifetime of the pulse of a fluorescent dye placed at the tip of the sensor. The 
advantage compared to the Clark’s electrodes is that oxygen is not consumed by this reaction, so 
that measurements can be recorded continuously (Vanderkooi et al., 1987; Griffiths and Robinson, 
1999). Additionally, a few groups have used mass spectrometry in order to quantify molecular 
oxygen in tissue samples (Ndubuizu and LaManna, 2007). Given the invasiveness of the described 
methods, different techniques to visualize hypoxic regions are used in the clinics, for example for 
tumour imaging. Pimonidazole and other nitroimidazole compounds are the gold standard 
“exogenous” hypoxic markers, since they require immunohistochemical methods to be developed. 
Pimonidazole is selectively reduced in hypoxic conditions to form hydroxylamine that irreversibly 
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binds to proteins or DNA in the cells. The signal dramatically increases below 10 mmHg of oxygen 
and the probe can also be injected into the patient prior to biopsy of the tumour (Nunn et al., 1995). 
Non-invasive methods include PET (positron emission tomography), NIRS (near-infrared 
spectroscopy) and MRS (magnetic resonance spectroscopy), which do not measure directly 
oxygen tension but rather target hypoxic areas by imaging oxygenation of the blood or O2 
consumption in the tissue (reviewed by (Carreau et al., 2011)).    
The mammalian response or adaptation to hypoxia can be considered at the systemic and at the 
cellular level. The systemic response occurs when the entire organism is exposed to low pO2, as in 
the case of high altitude, and includes a series of changes involving mainly the respiratory and 
vascular systems. The cellular response studies the activation of oxygen-sensitive pathways within 
the cell, with the stabilization of the transcription factors of the HIF family as central mechanism, 
and can be localized to a specific tissue/group of cells. The two levels are certainly connected; in 
particular the activation of the cellular pVHL/PHD/HIF pathway underlies adaptation to systemic 
chronic hypoxia. 
1.2.1 Systemic response to hypoxia: adaptation to high altitude    
When describing adaptation to high altitude, we refer to the so-called hypobaric hypoxia, which 
occurs when the pO2 is lower due to the lower total pressure of the air gases mix. The higher we 
go, the lower total air pressure and, subsequently, the lower pO2. Air pressure is considered to fall 
by around half every 5500 m (Boron and Boulpaep, 2005). Usually, an altitude of 1500-2500 m is 
known as “moderate”, while an altitude of > 2500 m is considered as “high”, since the pO2 falls low 
enough to cause a systemic adaptive response in human beings, sometimes leading to acute 
mountain sickness (AMS) (Hill et al., 2011).  
As mentioned above, the aortic and carotid bodies are responsible for sensing pO2 in arterial, 
freshly oxygenated blood. These highly vascularized organs contain chemoreceptor cells (Type I or 
glomus cells) able to sense changes in oxygen tension, as well as in blood pH, which is in direct 
relation with pCO2. Of note, peripheral chemoreceptors cannot sense changes in oxygen delivery 
arising, for instance, from anaemia. In case of hypoxia, acidosis and hypercapnia (increased 
pCO2), the K
+ channels in the membrane of glomus cells are inhibited, voltage-sensitive Ca2
+ 
channels open, intracellular Ca2
+ increases and neurotransmitters are released. The threshold after 
which the transmitter release is significantly increased is around 60 mmHg of pO2 in arterial blood, 
which corresponds to roughly 40% of reduction compared to physiological conditions (Lahiria et al., 
2006). The mechanisms behind K+ channel inhibition by hypoxia in glomus cells are not fully 
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understood. Involvement of protein kinase C (PKC), NADPH oxidase (NOX) and reactive oxygen 
species (ROS) has been demonstrated in vitro but this pathway is not driving the complete 
response in vivo, since NOX inhibition is not sufficient to suppress the hypoxia-mediated effect 
(O'Kelly et al., 2001; Buttigieg et al., 2012). The nerve fibres of peripheral chemoreceptors project 
in the cardiorespiratory centre of the medulla, leading to an acute and reversible increase in 
ventilation in order to reduce pCO2 and maximize the uptake of O2. Interestingly, this acute 
increase in ventilation is followed by a ventilatory decline, probably when CO2 levels fall too low, 
and by a slow increase in ventilation if the hypoxic stimulus persists (Boron and Boulpaep, 2005; 
Sandberg and Naylor, 2011). This slow increase occurs during the acclimatization phase, usually 
during the next few days to weeks at high altitude, and is mediated by central chemoreceptors 
sensing a decrease in the pH of the cerebral-spinal fluid. The kidney also accounts for 
acclimatization by decreasing acid secretion to counteract respiratory alkalosis due to the initial 
hyperventilation (Boron and Boulpaep, 2005). 
Changes in the respiration pattern are paralleled by changes in cardiac output and heart rate: the 
two parameters acutely increase in order to deliver more oxygen to peripheral tissues. The reason 
for this effect is the increase in sympathetic activity during hyperventilation, due both to activation 
of the lung stretch receptors and of the central chemoreceptors responding to decreased pCO2. 
Acclimatized subjects and natives of high altitude display normal cardiac output and heart rate 
values, suggesting that adaptation has occurred (Sandberg and Naylor, 2011). Additionally, 
hypoxia has a direct effect on smooth muscle cells regulating blood vessel resistance. Local 
hypoxia in the alveoli inhibits K+ channels, in a similar way as in the glomus cells, resulting in Ca2
+ 
release from the intracellular storages and extracellular space and, ultimately, in myocyte 
contraction. Hypoxic pulmonary vasoconstriction is thought to be a residual mechanism from birth, 
when the foetal circulation transforms into the newborn one. Increased resistance in lung capillary 
can cause pulmonary hypertension and consequently right ventricular hypertrophy (Hooper and 
Mellor, 2011). In around 5% of low landers going to high altitude over a short period of time, 
pulmonary hypertension leads to pulmonary oedema, one the hallmarks of severe AMS. The 
incidence of this condition increases with the degree of altitude (Basnyat et al., 2000). On the other 
hand, cerebral blood flow is increased, probably to ensure sufficient oxygen delivery to a 
demanding organ like the brain. The effect seems to follow carotid and cerebral vessel vasodilation 
and can cause headache in non-acclimatized subjects (Wolff, 2000). The molecular mechanisms 
underlying changes in vascular tone are not completely understood but the central and peripheral 
chemoreceptors play certainly a fundamental role in the process of adaptation. 
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Stimulation of the carotid body by hypoxia additionally leads to natriuresis and diuresis, with an 
acute effect of reducing plasma volume (Honig, 1989). Another reason for decreased plasma 
volume could be dehydration due to evaporative loss during profound respiration in the first 
hours/days in hypoxia. However, the most important haematological change is the increase in red 
cell mass as a consequence of Epo production, which occurs via the classical HIF pathway 
activation in renal Epo-producing cells (see below). It has been calculated that, when corrected for 
loss of body weight, there is a mean increase of 67.5% in RBC mass with a final increase in 
plasma volume of 22.8% after a few days/weeks at high altitude (Hooper and Mellor, 2011). 
Increased incidence of thrombosis in individuals ascending to high altitude can be explained by 
both pulmonary vasoconstriction and increased blood viscosity due to higher count of RBCs 
(Gupta and Ashraf, 2012). 
AMS is a clinical condition occurring upon hypoxic exposure of non-acclimatized individuals going 
to high altitude, with an incidence of   ̴10% for those going from sea level to 2500 m and of 30% to 
40% when ascending to 3500 m or more (Mairer et al., 2009). It develops within 1 to 5 days during 
the ascent and the main symptoms include fatigue, dyspnoea (shortness of breath), sleep 
disturbance, headache, dizziness and nausea. The hyperventilatory response explains the 
dyspnoea and sense of fatigue and causes during the night alternative periods of respiratory 
stimulation by hypoxia followed by apneas or hypopneas due to inhibition by hyperventilation-
induced hypocapnia (Weil, 2004). Headache is probably the most common symptom of acute high 
altitude illness and is thought to derive from vasodilation of cerebral vessels and brain swelling. 
Cases of cerebral oedema have been reported and represent the most dangerous, life-threatening 
situation (Wilson et al., 2009). As mentioned above, pulmonary oedema can also occur. The best 
treatment for AMS consists in descending to lower altitude or in giving oxygen to the patient in 
order to remove the primary cause of the symptoms, hypoxia. Pre-acclimatization, slow ascent and 
fluid intake are all protective factors against AMS, while drugs such as antihypertensive, analgesic 
and beta-blockers are used to treat severe symptoms (Netzer et al., 2013). The term CMS (chronic 
mountain sickness) refers instead to the overproduction of RBCs observed in some individuals 
exposed to prolonged periods of high altitude. Polycythemia is thus the primary cause of this 
clinical condition, characterized by increased risk of thrombosis and right ventricular hypertrophy 
due to increased blood viscosity and pulmonary vasoconstriction (Boron and Boulpaep, 2005). 
Given all the consequences that exposure to hypobaric hypoxia can have, how do populations like 
Tibetans and Andeans constantly live at 3000-5000 m of altitude? It is interesting to notice that the 
two populations took two different ways to adapt to the extreme environmental conditions found at 
high altitude, both successfully. Starting from ventilation, Tibetans seem to have kept the 
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hyperventilatory response typical of low landers going to high altitude, as demonstrated by their 
increase in resting ventilation, while Andeans show sea level-like or even lower ventilation rates 
(Beall et al., 1997). Hb concentration is surprisingly lower in Tibetans compared to Andeans living 
at the same altitude and is accompanied by lower Epo levels and O2 saturation of the blood, 
making Tibetan people profoundly hypoxic (see figure 8) (Beall et al., 1998). People living in the 
Andes often display pulmonary hypertension, whereas Tibetans do not show any sign of lung 
capillary vasoconstriction. Also, the response to pregnancy is different in the two representative 
populations: Andeans increase ventilation in order to increase oxygen delivery to the foetus, while 
Tibetans rather increase the blood flow by production of the vasodilatatory mediator nitric oxide 
(NO) (Beall, 2007). Weight at birth of newborns is usually lower than at sea level for both 
populations, as for low-landers exposed to hypoxia (Soria et al., 2013). In conclusion, Andeans are 
considered to display features of classical adaptation to hypoxia and are able to cope with them for 
their entire life, while Tibetans show a different way of adapting with surprisingly low oxygen 
saturation levels. Genome-wide association studies have been performed in order to identify 
genetic traits responsible for such adaptation and their heritability: genes belonging to the HIF 
pathway, as well as genes involved in O2 transport showed up in such studies but the functional 
link between specific polymorphisms and different response to hypoxia is often unclarified 
(Cheviron and Brumfield, 2012). 
 
Figure 8 Resting ventilation rate, Hb concentration and oxygen saturation of the blood of Tibetan 
and Andean samples living at   ̴4000 m of altitude (adapted from (Beall, 2007)). 
A few recent studies do characterize non-synonymous coding region substitution in EGLN1, the 
gene encoding for PHD2. The haplotype D4E/C127S was markedly enriched in the Tibetan 
population analysed compared to low-landers and the resulting mutant PHD2 protein displayed 
reduced interaction with p23, a heat shock protein (HPS) 90 co-chaperone that facilitates HIF-α 
hydroxylation by PHD2 (Song et al., 2014). The result is decreased PHD2 protein activity and 
increased HIF pathway activation, somehow counterintuitive if considered that Tibetans display 
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rather low values of Hb and Hct. Nevertheless, certain genetic traits in the HIF2A locus are also 
enriched in the Tibetan population and may account for compensatory mechanisms (Bigham and 
Lee, 2014). Increased HIF-1α activation could even be beneficial at high altitude, since this subunit 
is responsible for increased respiration and nitric oxide production (Melillo et al., 1995; Kline et al., 
2002). On the other hand, Lorenzo et al. showed that the same missense mutations increase 
PHD2-mediated de-stabilization of HIF-2α in hypoxic Hep3B cells and that the mutant protein 
displays lower affinity constant (Km) value for O2. Moreover, proliferation of the erythropoietic 
progenitors derived from Tibetans carrying the D4E/C127S haplotype was impaired under hypoxic 
culture conditions (Lorenzo et al., 2014). Collectively, these data suggest a complicated and still 
unclear relation between the genetic traits found to be associated to high altitude population and 
the phenotypic consequence on systemic adaptation to hypoxia. 
1.2.2 Cellular response to hypoxia: the pVHL/PHD/HIF pathway 
The response of nucleated mammalian cells to hypoxia is mediated by the stabilization of the 
ubiquitously expressed transcription factor HIF, which activates a number of genes involved in 
anaerobic glycolysis, angiogenesis, erythropoiesis, iron uptake and cell proliferation control. The 
HIF pathway has a central role in the systemic response described above, mainly in adaptation to 
chronic hypoxia rather than in the acute phase. Heterozygous mutant Hif1a mice show in fact 
normal acute ventilatory response but impaired chronic ventilatory adaptation (Kline et al., 2002). 
Hypoxia-inducible factors were discovered in the early 90’s, when Semenza and co-workers 
isolated a factor binding the downstream enhancer of the EPO gene in hypoxic nuclei of Hep3B 
cells (Semenza and Wang, 1992). Later on, characterization of the purified factor demonstrated the 
heterodimeric nature of the HIF complexes, which consist of a hypoxia-inducible,  ̴120 kDa α 
subunit and a constitutive 91-94 kDa β subunit (Wang and Semenza, 1995). Other groups 
managed to isolate the same factors in different cell lines exposed to hypoxia (Maxwell et al., 
1993). Three HIF-α subunits have been identified so far, encoded by different genes and 
conserved in Metazoa, but absent in bacteria, yeast and plants (Taabazuing et al., 2014). The 
basic structure of HIF-1α, -2α and -3α proteins is similar and is depicted in figure 9. A basic helix-
loop-helix (bHLH) domain is present at the N-terminus and capable of DNA binding, 2 Per-Arnt-Sim 
homology (PAS) domains are responsible for protein-protein interaction with the β subunit, the 
oxygen-dependent degradation domain (ODDD) is involved in HIF stability regulation and the N- 
and C-terminus activation domains (NAD and CAD) confer transcriptional activity. The inhibitory 
domain (ID) is required for normoxic repression of the CAD (Lisy and Peet, 2008). HIF-1α and -2α 
can form transcriptionally active dimers with HIFβ or ARNT (aryl hydrocarbon receptor nuclear 
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translocator), while HIF-3α shows no or weak transcriptional activity and is considered as a 
negative regulator of the other two isoforms. The human HIF3A locus is subjected to alternative 
splicing and can originate different variants. Among these are a hypoxia-induced isoform, termed 
inhibitory PAS domain protein (IPAS), capable of dimerizing with HIF-1β and inhibit transcription of 
target genes, and a transcriptionally weak isoform, termed neonatal and embryonic PAS (NEPAS), 
also able to form heterodimers with HIF-1β (Makino et al., 2001; Yamashita et al., 2008). 
Therefore, HIF-3α could play a role in modulating the hypoxic response mediated by HIF-1α and -
2α. Importantly, HIF-β displays a similar structure but lacks the ODDD and is thus not regulated 
according to oxygen tension (Semenza et al., 1997). 
 
Figure 9 Structural domains of HIF-α, IPAS and HIF-β monomers (Lisy and Peet, 2008). 
The ODDD is crucial for the oxygen-dependent regulation of HIFs, which occurs at the protein 
stability level rather than at the transcriptional level, allowing a very fast response in case of 
hypoxia. The ODDD contains two proline residues (Pro402 and Pro564 for human HIF-1α, Pro405 
and Pro531 for human HIF-2α) that are hydroxylated in the presence of O2 by the PHD enzymes. 
PHD-1, -2 and -3 belong to the superfamily of non-heme iron/2-oxoglutarate-dependent 
hydroxylases (Bruick and McKnight, 2001; Epstein et al., 2001). In normoxic conditions, PHDs 
catalyse a reaction in which O2 and 2-oxoglutarate are converted to CO2 and succinate, with the 
concomitant hydroxylation of the proline residues in the HIF-α subunits (Kallio et al., 1999). 
Hydroxylated HIF-α is recognized by an E3 ubiquitin-protein ligase, pVHL, and targeted for 
proteasomal degradation (Ohh et al., 2000). Of note, oxygen availability represents the limiting 
factor for the reaction, making PHDs the actual oxygen sensors of mammalian cells. Also, due to 
their high O2 Michaelis constant (Km) value, and thus low O2 affinity, PHDs have optimal oxygen-
sensing properties under all physiologically relevant oxygen concentrations (Stiehl et al., 2006). In 
hypoxia, the hydroxylation reaction cannot take place and HIF-α subunits are stabilized, 
translocate into the nucleus and dimerize with HIF-β, forming the transcriptionally active complex 
(Schofield and Ratcliffe, 2004). The heterodimer recruits co-factors such as p300/CBP in order to 
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regulate transcription of target genes (Arany et al., 1996). Another member of the hydroxylase 
enzyme family is the factor inhibiting HIF (FIH), which hydroxylates an asparagine residue within 
the CAD (Asn803 in human HIF-1α and Asn851 in human HIF-2α), blocking the interaction 
between HIF-α and p300 (Lando et al., 2002). Figure 10 summarizes the oxygen-dependent 
regulation of the HIF pathway: PHD-2 and -3 are HIF target genes themselves and their expression 
is increased in hypoxia, providing an intrinsic feedback mechanism (Ang et al., 2002; McDonough 
et al., 2006). 
 
Figure 10 Simplified overview of the pVHL/PHD/HIF pathway, its regulation by oxygen tension and 
cross-talk with mitochondria metabolism  (adapted from (Wenger and Hoogewijs, 2010)). 
While HIF-1α expression can be found in all the nucleated cells of metazoan species, HIF-2α 
expression seems to be restricted to specific cell types, such as renal interstitial cells, hepatocytes, 
epithelial cells of the duodenum, cardiomyocytes and astrocytes in rodents exposed to systemic 
hypoxia (Patel and Simon, 2008). Global knockout for both Hif1a and Epas1 (the genes encoding 
for HIF-1α and HIF-2α, respectively) showed lethal phenotype during embryonic life, suggesting a 
fundamental role of both factors in development. Hif1a-/- mice died at E11 due to cardiovascular 
malformation and open neural tube defects (Iyer et al., 1998; Kotch et al., 1999). Different 
phenotypes have been reported for global Epas1 knockout: bradycardia due to insufficient 
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catecholamine production (Tian et al., 1998), impaired remodelling of the primary vascular network 
(Peng et al., 2000), multiple organ pathology, metabolic abnormalities and impaired homeostasis of 
ROS (Scortegagna et al., 2003) and anaemia with impaired Epo production in one particular viable 
strain (see below) (Scortegagna et al., 2005). Arnt-/- mice showed aberrant placental architecture 
and vasculature (Adelman et al., 2000), while knockdown and transgenic models for Hif3a revealed 
a role for this isoform in heart and lung development (Yamashita et al., 2008; Huang et al., 2013). 
How do HIF complexes exert their function as master regulators of the hypoxic response? As 
transcription factors, they bind to the so-called hypoxia-response element (HRE), present in the 
promoters and regulatory regions of hypoxia-regulated genes. Analysis of validated HIF target 
genes has identified the sequence 5′-RCGTG-3′ (R = A or G) as the core HIF-binding site (HBS) 
(Wenger et al., 2005). In many HREs, the HBS is followed after 0-8 nucleotides by the sequence 
5’-CACA-3’, the “CACA repeat” (Semenza, 2013). Single mutagenesis of the HBS or of the CACA 
sequence within the 3’ EPO HRE (see below) abrogated hypoxic induction of the gene, indicating 
that the two elements are equally important for the functionality of the HRE (Semenza and Wang, 
1992). To date, no factor binding to the CACA repeat has been identified. Recent studies have 
made use of pan-genomic techniques, such as chromatin immunoprecipitation-sequencing (ChIP-
seq), in order to screen the entire genome for HBS (Xia and Kung, 2009; Tanimoto et al., 2010; 
Schödel et al., 2011; Mimura et al., 2012; Schödel et al., 2012). The number of identified HBS is in 
the order of 500 for any particular cell line. Even though the results vary according to the 
stringency of the HBS/HRE definition, it is interesting to note that for example HIF-1α binding sites 
are usually closer to the transcriptional start site of target genes compared to HIF-2α binding sites, 
which often lie at promoter-distant regions (possibly enhancers). Additionally, the distribution of 
HBS in the genome seems to be cell-line specific, with few overlap between the cell lines tested 
(Schödel et al., 2013). Different approaches, such as genomic-wide transcript analysis in HIFs 
knockout/knockdown cell lines, lead to the identification of many more genes (in the order or 
hundreds or even thousands) that are directly or indirectly regulated by hypoxia (Elvidge et al., 
2006; Warnecke et al., 2008; Xia et al., 2009). Again, no marked overlap can be seen between the 
tested cell lines. HIF-1α or -2α specificity does not depend on the DNA sequence of the binding 
site: no obvious difference in the core HRE composition could be observed. Isoform specificity 
rather lies in recruitment of different co-factors and in tissue-specific expression pattern (Wenger et 
al., 2005). A recent report in literature suggested that the transcription factors STAT3C (signal 
transducer and activator of transcription 3) and USF2 (upstream stimulatory factor 2) are recruited 
in vitro on promoters/enhancers of HIF-1α and -2α target genes, respectively, thus playing a role in 
HIF isoform specificity (Pawlus et al., 2013). 
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Examples of genes regulated in hypoxia include glycolytic enzymes, such as phosphoglycerate 
kinase 1 (PGK-1) and lactate dehydrogenase A (LDHA), that promote the switch form aerobic 
metabolism to anaerobic glycolysis, in order to produce energy in form of ATP molecules even in 
the absence of O2. The constitutive activation of anaerobic metabolism, which is remarkably less 
efficient than the aerobic one, is known as “Warburg effect” and was first described as a 
mechanism used by tumour cells to survive the hypoxic micro-environment typical of cancers. 
Genes involved in oxygen transport and vascular remodelling are also HIF targets: Epo, transferrin 
(TF), vascular endothelial growth factor (VEGF) and nitric oxide synthases (NOS) are the most 
well-known examples. The list of validated HIF-target genes is long and include up- and down-
regulated pathways that will ultimately promote adaptation of the cells to the stress conditions of 
reduced O2 availability (Wenger et al., 2005; Semenza, 2013). Recent reports revealed the HIF-
dependent regulation of long non-coding RNAs as well, another level of the complex adaptation of 
mammalian cells to hypoxia (Camps et al., 2014; Choudhry et al., 2014). Moreover, one report 
identifies a strikingly new effect of the transcriptional response to hypoxia: the release of pre‐bound 
promoter‐paused RNA polymerase 2 by binding of HIFs (Choudhry et al., 2014). 
 
1.3 Transcriptional regulation of the EPO gene in hypoxia 
1.3.1 Regulatory regions in the EPO locus 
Since the discovery of Hep3B and HepG2 as Epo-expressing in vitro models and the kidney as the 
major source of Epo in vivo, it was clear that EPO gene is regulated by hypoxia (Goldberg et al., 
1987), by hypoxia-mimetics such as CoCl2 (Beru et al., 1986) and by anaemia (Semenza et al., 
1990). This fact was further confirmed by the discovery of HIF-1 as a heterodimer binding to the 3’ 
enhancer of the EPO gene (Semenza et al., 1991). Comparison between the mouse Epo and 
human EPO genes and surrounding sequences revealed homology not only of the coding part, but 
also of the flanking regions, suggesting an important role for such regions in the regulation of the 
gene. In particular, the fragment directly upstream of the transcriptional start site (TSS), the first 
exon, the first intron and the fragment directly downstream of the poly-adenylation site (polyA) are 
the most conserved (Galson et al., 1993). EPO is present in single copy on the long arm of 
chromosome 7 in human and on chromosome 5 in mouse and consists of 5 exons and 4 introns. 
Most of the knowledge we have concerning Epo hypoxic regulation by cis-acting sequences comes 
from in vitro experiments in hepatoma cell lines and from in vivo studies with transgenic mice 
carrying different fragments of the EPO genomic locus. Two peculiarity of Epo regulation are worth 
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to be mentioned: it occurs at the transcriptional level only (and not at the RNA or protein stability 
levels (Gordeuk et al., 2005)) and it is restricted to very specific Epo-producing cell types. The 
molecular basis of Epo tight tissue specificity remains largely unknown.  
Figure 11A summarizes the constructs that have been used to characterize Epo regulatory 
regions. The first transgenic mouse was generated with a 4 kb fragment containing the human 
EPO gene, 0.4 kb upstream of the TSS (encompassing the promoter) and 0.7 kb downstream of 
the polyA. These animals were profoundly polycythemic, due to promiscuous expression of Epo 
and elevated Epo serum levels. Nevertheless, increased Epo mRNA could be detected in liver, but 
not kidney, of anaemic mice, indicating the presence of a liver-inducible element (LIE) within this 
fragment (Semenza et al., 1989). Expansion of the region upstream to the TSS to 6 kb decreased 
Epo ectopic expression, suggesting a sequence between -0.4 and -6 kb is responsible for a 
general repressive effect on EPO transcription (the so-called negative regulatory element or NRE). 
Hypoxia inducibility was maintained in the liver and absent in the kidney (Semenza et al., 1990). 
The same authors further increased the size of the 5’ flanking sequence to 14 kb and could show 
hypoxia inducibility also in the kidney of transgenic mice exposed to bleeding anaemia. They 
concluded that the kidney-inducible element (KIE) must be located between -6 and -14 kb from the 
TSS in the human EPO locus (Semenza et al., 1991). Some of the transgenic lines generated with 
these constructs still showed a polycythemic phenotype which was due to dramatically increased 
Epo levels in the liver. Normal Epo levels and anaemia-induced transgene expression in both liver 
and kidney were obtained by Madan et al. by increasing the size of the 3’ flanking region to 8.5 kb 
from the polyA, speaking for the presence of a negative regulatory liver element (NRLE) between 
0.7 and 8.5 kb downstream of EPO (Madan et al., 1995). To test whether the intron sequences are 
important for EPO regulation, a construct containing 0.4 kb of the upstream region, 0.7 kb of the 
downstream region and a minigene lacking introns II-IV was generated: Epo ectopic expression 
pattern with liver, but not kidney, inducibility was observed, similar to the constructs containing all 
the introns (Madan et al., 1995). Later studies also confirmed the importance of intron I, but not of 
introns II-IV, in hypoxic EPO regulation (Obara et al., 2008). Again, some of the transgenic mouse 
strains displayed high Hct values, which correlated with the copy number of the construct inserted 
into the genome. The presence of open chromatin structures within the putative KIE and LIE, and 
thus their potential role as regulatory regions, was proven by DNaseI hypersensitivity site (HS) 
mapping in nuclei of kidney and liver of anaemic mice (Semenza et al., 1991; Köchling et al., 
1998).   
The next “generation” of vectors used to study Epo regulation consists of reporter genes under the 
control of the mouse Epo locus (figure 11B). LacZ was first used to confirm the presence of a liver-
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specific silencing element within 1.2 kb from the polyA of the Epo gene (Haidar et al., 1996). The 
most important Epo reporter model was generated by inserting the GFP gene into a BAC clone of 
180 kb: 60 kb upstream and 120 kb downstream of the gene. This construct fully recapitulated Epo 
expression pattern/hypoxic inducibility and was used to characterize and isolate REPCs as well 
(see figure 5) (Obara et al., 2008; Pan et al., 2011). Moreover, mutated versions of this model were 
useful to assess the functionality of different transcription factor binding sites, such as the GATAs 
and HIF itself (see below) (Suzuki et al., 2011). The newest construct generated by the group of 
Yamamoto encompasses 22 kb 5’ to the TSS and 163 kb 3’ to the polyA: once again, GFP 
expression pattern follows the physiological one for Epo. This BAC clone was used to study 
embryonic Epo expression in neural crest cells (Suzuki et al., 2013). 
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Figure 11 Schematic representation of the human EPO locus (A) and reporter mouse Epo locus 
(B) constructs used to generate trangenic mice. Transgene expression pattern and references are 
indicated. 
The different, tissue-specific regulatory regions identified with transgenic animals have been 
extensively characterized with the help of in vitro models, starting from the promoter. Reporter 
assays in Hep3B led to the identification of the Epo minimal promoter (EpoProm), a sequence of 
117 bp upstream of the TSS with weak activity (Gupta and Goldwasser, 1996). Moreover, binding 
of the murine factor HAF (hypoxia-associated factor, homologous of the human squamous cell 
carcinoma antigen recognized by T cells (SART)-1) has been found in EpoProm. HAF mRNA is 
ubiquitous in mice and highly abundant in foetal liver, while its expression declines in adult liver, 
mirroring Epo hepatic regulation. HAF knockdown resulted in reduced, but not absent, Epo hypoxic 
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induction in Hep3B cells (Gupta et al., 2000). The EpoProm also contains a putative HRE at -180 
bp position, but reporter assays demonstrated the lack of functionality of this sequence (Blanchard 
et al., 1992). Other important factors binding in the promoter are the GATA factors 2, 3 and 4. 
GATAs are important regulators of haematopoiesis (Shimizu and Yamamoto, 2005) and GATA 
binding sites have been identified in the EpoProm (Imagawa et al., 1997). GATA-2 and -3 seem to 
have an inhibitory effect on EPO transcription, while GATA-4 has the opposite effect, as 
demonstrated by knockdown and overexpression experiments in hepatoma cell lines. ChIP assays 
confirmed the binding of GATAs to EpoProm in vitro and in vivo. Given the increasing expression 
of GATA-2 and -3 and decreasing expression of GATA-4 in the developing liver, these factors have 
been hypothesised to play a role in silencing Epo expression in the adult liver (Dame et al., 2004). 
Additionally, the importance of the GATA binding site was proven by its mutation in GFP reporter 
mice: in the mutated strain, ectopic GFP expression was observed, confirming the inhibitory effect 
of this element on EPO transcription (Obara et al., 2008). The Wilms tumour suppressor (Wt-1) is 
an additional transcription factor that has been shown to bind and activate EpoProm in vitro. Since 
its expression pattern resembles the one of Epo, Wt-1 could be important in maintaining Epo tissue 
specificity (Dame et al., 2006).  
Due to the availability of liver-derived cellular models, the LIE (or 3’ Epo enhancer) has been 
studied in depth over the past few years. An HRE consensus sequence is present within the LIE, 
at   ̴120 bp from the end of the polyA, and consists in the typical HBS sequence followed after 7 bp 
by a CACA repeat (Pugh et al., 1991; Semenza and Wang, 1992). Reporter assays in human cell 
lines showed that this HRE is responsible for hypoxic induction of Epo mRNA by synergizing with 
the minimal EpoProm (Beck et al., 1991; Imagawa et al., 1991; Blanchard et al., 1992). Mutation of 
the HBS in reporter mice abrogated hypoxia-inducible Epo expression in the liver, but not in the 
kidney, confirming the liver-specificity of this element and suggesting the presence of an additional 
HRE regulating renal Epo expression (Suzuki et al., 2011). As mentioned above, despite no factor 
binding to the CACA repeat has been identified so far, this element is necessary, but not sufficient, 
for Epo induction by hypoxia (Semenza and Wang, 1992). A DR-2 site (direct repeat of two steroid 
hormone receptor half sites, separated by 2 bp) is present in the 3’ enhancer and has been shown 
to bind non-oxygen regulated protein complexes. Mutation of the DR-2 markedly inhibited Epo 
expression in hypoxia (Blanchard et al., 1992). Different transcription factors, belonging to the 
steroid hormone receptor family, can bind to the DR-2 and hepatic nuclear factor-4α (HNF-4α) has 
been identified as one of them in vitro (Galson et al., 1995). HNF-4α is expressed in hepatocytes 
and renal cortex and is replaced on the DR-2 site by the retinoic acid receptor (RXRα) in 
embryonic mouse liver, suggesting the possibility that different members of the steroid hormone 
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receptor family can bind the DR-2 repeat in the LIE (Makita et al., 2001). As for the other HIF-target 
genes, the general activator of transcription p300/CBP is recruited upon hypoxia to the 3’ enhancer 
of EPO (Arany et al., 1996). Besides the oxygen-regulated HIF complex, another, constitutive 
transcription factor complex has been identified bound to the LIE: proteins such as activating 
transcription factor 1 (ATF-1) and cAMP responsive element binding protein (CREB) are part of the 
latter (Semenza and Wang, 1992). The final model for EPO transcriptional regulation is depicted in 
figure 12. In hypoxia, the HRE is bound by the stabilized HIF-2 complex, HNF-4α interacts with the 
HIF-α subunit and both HIF-α and -β interact with p300/CBP, forming an active complex that 
enhances EPO transcription up to 100 folds. Only one report in literature showed the presence of a 
putative HRE sequence at -9.2 kb from the TSS, within the KIE. This sequence is homologous to 
the 3’ enhancer HRE and is located in a DNaseI HS in nuclei of kidney of anaemic mice. No 
functional characterization of this sequence has been reported so far (Köchling et al., 1998). 
             
Figure 12 Scheme depicting the human EPO genomic locus, with the most important regulatory 
DNA sequences and transcription factors. The presence of an HRE within the KIE (5’ HRE) is still 
debated. Numbers indicate the distance in kb from the TSS (-: upstream, +: downstream). 
Epigenetic regulation participates in Epo expression in the form of CpG methylation. DNA 
methylation is known to occur on position 5 of cytosine in the CG dinucleotide and to inhibit 
transcription via recruitment of chromatin-remodelling complexes that keep the DNA locus close 
(Alberts et al., 2002). EPO promoter and 5’ untranslated region (5’UTR) are indeed located in a 
CpG island and methylation of this region inversely correlates with Epo expression in vitro (Yin and 
Blanchard, 2000). Moreover, methylation of the HBS in the 3’ enhancer seems to prevent HIF 
binding to the DNA and also inversely correlates with Epo expression in cell lines and tissues 
(Wenger et al., 1998; Stolze et al., 2002). These reports show the requirement of a methylation-
free HBS in order to have HIF binding to the 3’ enhancer and Epo induction in hypoxic conditions. 
Interestingly, treatment of different cancer cell lines with the DNA methylation inhibitor 5-aza-2′-
deoxycytidine rescued Epo hypoxic expression in neuroblastoma cells but had no effect on Hep3B 
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cells, where the EPO locus is already de-methylated and open to transcription (Steinmann et al., 
2001). DNA methylation can thus be an important factor contributing to EPO gene silencing in 
tissues other than kidney and liver. 
1.3.2 HIF/PHD isoforms regulating Epo 
EPO is often used as a paradigm for hypoxia-induced gene transcription and is indeed regulated 
by the canonical pVHL/PHD/HIF pathway. VHL is known to be a tumour suppressor gene and a 
number of mutations can cause familial erythrocytosis as well, supporting its role as an important 
regulator of Epo (Bader and Hsu, 2012). Which PHD/HIF isoforms specifically control Epo 
expression? The answer to this question comes from in vitro knockdown experiments, conditional 
knockout mice generation and genetic diseases where mutations in the PHD/HIF genes lead to 
impaired Epo expression. Among the genes encoding for PHD-1, -2 and -3 (Egl9 homolog (EGLN)-
2, -1 and -3, respectively), inducible knockout models for PHD-2 showed increased Epo levels, 
polycythemia and angiogenesis, accompanied by cardiomyopathy and premature death 
(Minamishima et al., 2008; Takeda et al., 2008). Consistently, global knockout for PHD-2, but not 
PHD-1 or -3, resulted in embryonic lethality at E12-14 due to placental and cardiac defects 
(Takeda et al., 2006). Additional evidence for a major role of PHD-2 in regulating Epo expression is 
given by the identification of mutations in EGLN1, but not EGLN2 or 3, in families affected by 
congenital erythrocytosis (Percy et al., 2006; Percy et al., 2007; Ladroue et al., 2008). The first 
proof of Epo as a HIF-2α-specific target gene came from in situ hybridization studies in ischemic 
rat kidneys showing expression of HIF-2α in peritubular fibroblasts, the putative REPCs 
(Rosenberger et al., 2002). In vitro confirmation of HIF-2α prominent role was given by Warnecke 
at al., who made use of the RNA interference (RNAi) approach to knockdown the two isoforms: 
only HIF-2α knockdown significantly decreased Epo hypoxic induction (Warnecke et al., 2004). As 
mentioned above, one mouse model of global Epas1 knockout turned out to be viable and showed 
decreased renal Epo levels and anaemia (Scortegagna et al., 2005). Liver-specific VHL knockout 
resulted in polycythemia in mice and this phenotype could be rescued by concomitant deletion of 
Arnt or Epas1 but not Hif1a (Bigham et al., 2010). Furthermore, experiments with hepatic and renal 
single Epas1-/- mice confirmed the role of HIF-2α, rather than HIF-1α, in regulating Epo expression 
in both organs (Rankin et al., 2007; Kapitsinou et al., 2010). In order to avoid embryonic lethality, 
acute ablation of Epas1 after birth was performed and led to anaemia in adult mice (McMullin, 
2009). Evidences for HIF-2 specificity of EPO regulation in humans are derived from mutations 
identified in EPAS1 causing hereditary erythrocytosis (a few of the most recent examples: 
(McMullin et al., 2005; Clodagh et al., 2013; Bento et al., 2014; Moulard et al., 2014)), whereas no 
mutations in HIF1A or HIF3A have been reported so far. In order to produce functional RBCs, iron 
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uptake and release from the body storage is increased during erythropoiesis: iron metabolism is 
indeed linked to oxygen-sensing via HIF-2α (Mastrogiannaki et al., 2009). DMT-1 (divalent metal 
transporter 1) and DcytB (duodenal cytochrome b) are examples of HIF-2-dependent genes 
involved in iron uptake (Haase, 2010) and the 5’UTR of HIF-2α mRNA itself contains iron-
responsive elements (Zimmer et al., 2010). The cross-talk between iron metabolism and HIF-2 
additionally supports the primary role of HIF-2α in Epo regulation. Moreover, genome-wide 
association studies performed comparing lowlanders to highlanders identified polymorphisms in 
EGLN1 and EPAS1 in association with RBC mass, confirming that these two genes are indeed 
involved in Epo expression control (Bigham et al., 2010; van Patot and Gassmann, 2010). Taken 
together, these data point in the direction of pVHL/PHD-2/HIF-2α as the main axis regulating Epo 
expression in hypoxia. It must be mentioned that experiments performed both in vitro and in vivo 
demonstrated binding of HIF-1α and HIF-2α on Epo 3’ HRE, suggesting the possibility of binding 
(but not functionality) of both isoforms or of different HIF-α-specificity according to the tissue/cell 
line tested (Stolze et al., 2002; Yeo et al., 2008). A model targeting REPCs in vivo is still missing 
and would be required to dissect the role of different PHD/HIF isoforms at the physiological site of 
Epo production. 
1.3.3 Epo negative feedback regulation 
As shown in figure 2C, Epo plasma concentration decreases during chronic hypoxia before the Hct 
values actually reach normal levels and restore the O2-carrying capacity of the blood (Jelkmann, 
1982). This drop is due to a decrease in renal Epo mRNA and protein abundance and is 
independent of changes in extracellular Epo levels (Rosa et al., 1978; Gordeuk et al., 2005). 
Therefore, an intrinsic feedback loop in the pVHL/PHD/HIF pathway in REPCs has been proposed, 
but not yet proven, as the underlying mechanism. PHD-2 and -3 are indeed HIF-target genes and 
could be involved in decreasing Epo expression after a certain time of hypoxic exposure (Ang et 
al., 2002; McDonough et al., 2006). Another important issue is the high degree of plasticity of the 
HIF pathway: even small changes in PHD/HIF levels or activity can lead to big changes in the 
downstream effects. If HIF-α isoform’s abundance is increased, for example, the system would be 
saturated because PHDs are not fully active even in normoxic conditions and stabilization of HIF 
complexes would occur. It is then easy to imagine that regulators of PHDs/HIFs levels or activity 
can be involved in the feedback mechanism (Kaelin, 2007; Lee and Percy, 2011). Many peptides 
and proteins have been identified as PHD interactors and some of them do regulate the stability or 
activity of the enzymes (Furlow et al., 2009). Moreover, intermediated of the Krebs cycle, such as 
succinate or fumarate, reactive oxygen substances, like ascorbate, transition metals, NO and ROS 
can all regulate PHDs activity (see figure 10) (Wenger and Hoogewijs, 2010; Wenger and Kurtz, 
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2011). In conclusion, no clear mechanism has been proven so far to be responsible for the drop in 
Epo levels in chronic hypoxia and a kidney-derived, Epo-expressing cell model would be useful to 
investigate further in this direction. 
 
1.4 Pathophysiology of Epo 
Two main and opposite clinical conditions arise from impaired Epo synthesis: when Epo is 
overproduced, erythrocytosis or polycythemia can occur, whereas insufficient Epo production 
results in anaemia. Besides these two diseases, described in details below, medical procedures 
interfering with the main Epo-producing organ, the kidney, can result as well in impaired 
erythropoiesis. Kidney allotransplantation represents such a case and was used to treat anaemia 
before the introduction of rhEpo. In patients undergoing kidney transplantation, Epo levels usually 
increase within the first few days, probably due to blood loss during the operation (Eckhardt et al., 
1990) and in 10% of the cases polycythemia can occur (Davis, 1987). Interestingly, not only the 
transplanted, but also the native kidney plays a role in increasing Epo levels after transplantation 
(Martino et al., 1994). This fact supports the hypothesis according to which even damaged kidneys 
retain their ability to produce Epo but are somehow not able to couple Epo synthesis and O2-
sensing when the organ is not functioning correctly. Kidney functionality seems indeed to be a 
prerequisite to physiological Epo production: when the kidney is able to exert its excretory function, 
oxygen-sensing and Epo synthesis appear to be normal. In particular, correct function of the 
proximal tubule (the main oxygen-consuming segment of the nephron) seems to be the most 
relevant in order to maintain the O2 gradient and thus the oxygen-sensing capacity of the kidney 
(Wenger and Kurtz, 2011). 
1.4.1 Erythrocytosis 
Erythrocytosis is a synonymous of polycythemia and refers to inappropriately increased RBC 
mass. Table 2 summarizes the classification and aetiology of the disease: erythrocytosis can be 
classified into primary, when defects intrinsic in the haematopoietic progenitors lead to excessive 
RBC formation, and secondary, when impaired Epo production is the cause for increased Hb 
content of the blood. In addition, both primary and secondary erythrocytosis can be acquired or 
congenital (i.e. due to inherited mutations, also called familial). Hereditary pattern of the congenital 
disease can be both autosomal recessive and autosomal dominant, depending on the mutation. 
Diagnostic criteria are the following: Hb concentration > 18.5 g/dL in men and 16.5 g/dL in women 
(McMullin, 2009). An absolute or true erythrocytosis is present only when the red cell mass is 
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greater than 125% of that predicted for sex and body mass (Clodagh et al., 2013). A group of 
individuals for whom the cause of erythrocytosis is still not clear exists and is referred to as 
idiopathic erythrocytosis. 
Primary erythrocytosis Secondary erythrocytosis 
Acquired Acquired 
Polycythemia vera, clonal expansion 
of erythroid progenitors in the bone 
marrow 
Central hypoxia (chornic lung disease, 
cardiovascular diseases, high altitude) 
Local hypoxia (end-stage renal disease, post-
renal transplant erythrocytosis) 
Pathological erythropoietin production 
(tumour-related) 
Iatrogenic (erythropoietin, Epo-stimulating 
agents, androgens) 
Congenital Congenital 
EpoR mutations High oxygen-affinity haemoglobins 
Bisphosphoglycerate mutase deficiency 
Oxygen-sensing pathway gene mutations 
(VHL, EGLN1, EPAS1) 
 
Table 2: classification and aetiology of erythrocytosis (adapted from (Gordeuk et al., 2005; 
McMullin et al., 2005)). 
The most common form of the disease, with around 1.6 cases/100`000/year in Europe, is called 
polycythemia vera and represents a primary, acquired condition usually arising from expansion of 
mutated clones within the bone marrow (Moulard et al., 2014). Primary congenital erythrocytosis is 
rarer and most of the cases are caused by mutations in EpoR resulting in constitutive activation of 
the pathway and subsequently in inappropriate proliferation of RBC precursors (Bento et al., 2014).  
Any condition that increases Epo production causes instead acquired secondary erythrocytosis. 
The most common examples include pathological Epo synthesis by kidney, liver and brain 
tumours, iatrogenic stimulation (due to Epo-stimulating drugs), central and local hypoxia of 
different aetiology, such as cardiovascular diseases, exposure to high altitude, chronic lung 
disease, carbon monoxide poisoning and kidney transplantation (Clodagh et al., 2013). 
Secondary congenital erythrocytosis is due to inherited mutations in genes involved in oxygen 
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sensing and transport. Increased O2 affinity of mutated Hb causes polycythemia because it 
prevents oxygen dissociation in peripheral tissues, leading to tissue hypoxia and compensatory 
erythropoiesis (Percy et al., 2009). As mentioned above, 2,3-DPG is one of the most important 
regulator of Hb affinity and loss-of-function mutations in the enzyme responsible for 2,3-DPG 
synthesis, bisphosphoglycerate mutase, have been reported in families affected by 
erythrocytosis (Rosa et al., 1978; Hoyer et al., 2004). It is not surprising that mutations in genes 
encoding for the pVHL/PHD2/HIF-2α axis have a great impact on EPO transcriptional control and 
a number of mutations have been indeed associated with secondary familial erythrocytosis 
(Bento et al., 2014). From a molecular point of view, these naturally occurring mutations are 
extremely useful to study the conformational change and impact on functionality of the mutated 
proteins; a few examples are given in the next paragraph. It must be mentioned that not all the 
mutations identified result in increased Epo levels: some patients with gain-of-function mutations 
clearly leading to increased activity of the HIF pathway display Epo concentrations within the 
normal range but increased Hct, suggesting additional primary changes in haematopoietic 
precursors (Perrotta et al., 2013). 
The main symptom experienced by polycythemic patients is increased viscosity of the blood due 
to high RBC mass, which can cause fatigue, chest and abdominal pain, myalgia, headache and 
blurred vision. The most clinically relevant consequence is definitely the increased risk of 
thrombosis (formation of blood clot and possibly vessel occlusion). Therapy is different according 
to the patient’s symptoms and the degree of erythrocytosis but it usually involves venesection (or 
phlebotomy, surgical opening of a vein to remove excessive RBC mass) and administration of 
anti-coagulant drugs, such as aspirin. Novel therapies in clinical trials for congenital 
erythrocytosis aim to target the specific altered pathway (Clodagh et al., 2013). 
Mutations in the VHL/ENGL1/EPAS1 axis associated with secondary congenital erythrocytosis 
Homozygous R200W mutation in VHL is known to cause an autosomal recessive form of 
poylcythemia, initially detected in the Russian region of Chuvash (thus termed “Chuvash 
polycythemia”) (Ang et al., 2002). This mutation results in impaired binding of pVHL to 
hydroxylated HIF-α subunits and increased activation of the oxygen-sensing pathway. Epo and 
other HIF-target gene levels are in fact elevated but, surprisingly, no malignancy is associated 
with Chuvash patients as for other VHL mutations causing multiple cancer syndromes or VHL 
disease (Haddad et al., 2013). Moreover, increased sensitivity of erythroid progenitors to Epo 
has also been demonstrated in these patients, suggesting that Chuvash polycythemia shares 
features of both primary and secondary erythrocytosis (Gordeuk et al., 2005). VHL is considered 
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a tumour suppressor gene and its loss-of-function is detected in > 90% of clear cell renal cell 
carcinomas (ccRCC), the most frequent from of kidney cancer (Frew and Moch, 2015). It is 
remarkable that only a few mutations in VHL gene have been causally associated to both 
erythrocytosis and VHL disease (two examples are Y157C and L188V) (Lorenzo et al., 2013). A 
very recent report further explores the genotype-phenotype correlations of a unique family 
carrying heterozygous R200W mutation in combination with an additional mutation in the same 
gene, R161Q. In this case, heterozygosis of the R200W mutation was not sufficient to cause 
erythrocytosis, as the mutant protein displayed similar but not equal activity in de-stabilizing HIF-
2α as the wt protein. Interestingly, an additive effect of R200W and R161Q leads to high risk of 
developing kidney tumour in this family (Couvé et al., 2014). Taken together, these evidences 
suggest that differences in the mutated copy number carried by the patient and impact on mutant 
protein activity strongly influence the correlated phenotype and that a gradient of pVHL 
dysfunction in oxygen sensing seem to occur. 
37 patients carrying 24 different mutations in the EGLN1 gene have been identified so far. The 
first PHD2 mutation associated with familial erythrocytosis was the amino acid substitution 
P317R (Percy et al., 2006). Crystallographic studies showed that the proline residue 317 is 
conserved and localized within the catalytic domain of the enzyme, in close proximity to the iron-
chelating residues 313 and 315 (McDonough et al., 2006). PHD2-P317R displayed indeed 
diminished hydroxylation capacity compared to the wt protein in vitro (Percy et al., 2006). A 
heterozygous mouse model carrying a mutation that mimics the human P371R substitution in 
heterozygosis was generated (Phd2P294R/+) and showed a degree of erythrocytosis 
comparable to the one of animals carrying a single wt allele of Phd2 (Phd2+/-). This study 
indicates that the effect of P317R mutation occurs through haploinsufficiency of the wt form of 
the protein (Arsenault et al., 2013). Besides the P371R, a number of germline missense 
mutations have been identified, often within PHD2 catalytic domain (P200Q, N203K, K204E, 
D254H, G285R, W334R, K291I, P304L, R371H, H374R and K423E) (Bento et al., 2014). The 
functional consequence of these mutations on protein structure and activity is not always clear. 
Frame-shift and nonsense mutations also have an impact on PHD2 functionality and have been 
associated to congenital polycythemia (Bento et al., 2014). Among the missense mutations, 
H374R was also linked to recurrent paraganglioma, a neuroendocrine neoplasm that can 
develop at different body sites, suggesting that EGLN1 can act as a tumour suppressor gene 
(Ladroue et al., 2008). Interestingly, one germline mutation in EGLN2 gene, encoding for PHD1, 
was recently identified in a patients suffering of pheocromocytoma and polycythemia and led to 
decreased protein stability with consequent activation of the HIF pathway (Yang et al., 2014).  
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While the mutations identified in EGLN1 result in loss-of-function of the protein, mutations in 
EPAS1 usually translate into gain-of-function of HIF-2α and increased Epo production. In total, 
22 patients have been reported to have heterozygous EPAS1 mutations. Interestingly, the 
majority of them (I533V, P534L, M535T/V/I, G537W/R, D539E and F540L) are located in exon 
12, in close proximity to Pro531, one of the hydroxylated residues on human HIF-2α (Lee and 
Percy, 2011). The effect could then be reduced recognition and hydroxylation by PHD enzymes 
(Furlow et al., 2009). Mouse models mimicking the human G537W mutation were generated, 
both in homozygosis and heterozygosis: the phenotype was dose-dependent erythrocytosis and 
pulmonary hypertension with a high degree of penetrance (Tan et al., 2013). Another well-
characterized HIF2A mutation is the D539E, for which clearly impaired binding with PHD2 and 
pVHL was demonstrated in vitro (van Wijk et al., 2010).  As for EGLN1, some of the described 
EPAS1 mutations associate with pheocromocytoma, a neuroendocrine neoplasm of the adrenal 
gland, and paraganglioma, tumours that also show impairment of the pVHL/PHDs/HIFs pathway 
(Kaelin, 2007). The Pacak–Zhuang syndrome is a clinical condition characterized by multiple 
paragangliomas, pheocromocytoma and polycythemia and is due to gain-of-function mutations in 
HIF2A gene, leading to increased stabilization of the protein. Interestingly, these somatic 
mutations have been identified mainly in female patients (Zhuang et al., 2012; Pacak et al., 
2013). Only one report  describes the case of a male patient with Pacak–Zhuang syndrome 
(Toyoda et al., 2014), suggesting that sex-related differences, for instance in sexual hormone 
levels in the blood, could have an influence on the Epo-producing pathway (see below). 
1.4.2 Anaemia 
Anaemia is the most common haematological disorder and is defined as a reduction in the Hb 
content of the blood. Since Hb concentration varies according to age, gender and genetic 
background, there are no clear-cut diagnostic criteria, but Hb levels < 13 g/dL in men and < 12 
g/dL in women represent the rule of thumb. Aetiology of anaemia is diverse and the disease can be 
divided at least in two categories: the number of produced erythrocytes is not adequate or the 
RBCs are sufficient in count but not functional, as in the case of sickle-cell anaemia (described 
above). Among the causes of anaemia are nutritional deficiency (iron and vitamin B12), acute or 
chronic blood loss, haemoglobinopathy (due to mutations in the Hb-coding genes making oxygen 
transport not efficient), bone marrow failure and renal failure. The main symptom is thus insufficient 
oxygen delivery to the peripheral tissues and subsequent pallor, fatigue and dyspnoea (Hand, 
2001).  
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Impaired Epo synthesis clearly leads to insufficient erythropoiesis and is the major drive of 
anaemia in patients with chronic kidney disease (CKD). CKD are a group of pathological conditions 
of different aetiology leading to progressive damage of the kidney, measured by decreasing 
glomerular filtration rate (GFR), and consequent renal failure. The last stage of CKD is referred to 
as end stage renal disease (ESRD) and patients in this condition need replacement therapy 
(dialysis, hemofiltration or transplantation) in order to survive. The number of affected people 
doubled over the past decade and the costs of replacement therapies are extremely high, making 
CKD a global challenge for health care. The prevalence of CKD in 2014 is estimated to be around 
10% of the adult population in USA, more than 20 million people (data from the American Centers 
for Disease Control and Prevention). A complex mixture of genetic and environmental factors is at 
the basis of CKD. Hypertension, diabetes, hyperlipidaemia, age, obesity and smoking are common 
risk factors linking cardiovascular to renal diseases: the main function of the kidney is in fact to 
“clear” the blood from substances that are toxic or in excess and increasing the blood pressure or 
the amount of such substances can result in damage of the nephron system. A number of other 
pathological conditions, such as severe infections and auto-immune diseases, also cause the initial 
inflammatory insult in the kidney which can progress to CKD. A vicious cycle of inflammation and 
fibrosis begins at the glomerular or tubulo-interstitial sites and functionality of the organ is 
compromised. Decreased GFR and proteinuria (presence of proteins in the urine) are the direct 
consequences of renal failure (El Nahas and Bello, 2005). Anaemia can be considered as a 
complication of CKD and is thought to arise from damage to the architecture of the organ and the 
cellular sources of Epo. Besides the fact that Epo levels are blunted and do not rise appropriately 
to the degree of anaemia (Caro et al., 1979), CKD patients still retain the capacity to produce renal 
Epo when exposed to hypoxia (Chandra et al., 1988) or PHD inhibitors (Bernhardt et al., 2010) and 
the Hct-Epo feedback loop seems to be functional (Walle et al., 1987). Moreover, anaemic patients 
need decreased dosage of rhEpo when living at high altitude, in other words they respond better to 
the treatment, possibly due to increased endogenous Epo production (Brookhart et al., 2008). The 
role of hypoxia is still debated: according to the “chronic hypoxia hypothesis”, progressive renal 
injury leads to decreased blood flow and, together with anaemia, to tubulo-interstitial hypoxia, 
which further supports fibrosis and kidney damage. Reports in literature showed that renal hypoxia 
indeed precede and can be a cause of tissue fibrosis (Fine and Norman, 2008). On the other hand, 
the kidney is less functional, thus oxygen consumption is decreased and REPCs would experience 
higher O2 tension which does not allow them to reach the hypoxic threshold necessary for Epo 
production. As mentioned above, probably intact organ structure and function are needed to keep 
the oxygen gradient along the cortico-medullary axis and thus for REPCs to sense decreased O2-
carrying capacity of the blood and synthetize Epo. Even though hepatic Epo expression can be 
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increased in CKD animal models (Tan et al., 1991; Kapitsinou et al., 2010), this is not enough to 
normalize Hct levels and the situation in humans is still unclear. The inflammatory component of 
CKD certainly plays a role in decreased Epo levels: inflammatory cytokines are known to inhibit 
Epo production (see below) and a recent report showed that, in a CKD mouse model, REPCs can 
undergo trans-differentiation into myofibroblasts losing the ability to synthetize Epo (Asada et al., 
2011). 
The most effective treatment for anaemic patients is represented by administration of rhEpo, with 
approximately 95% of treated patients responding to the therapy. Anaemia arising from renal 
failure, chronic inflammatory disease and cancer is usually treated with parenteral injection of 
rhEpo and its glycosylation-modified derivates (Bunn, 2013). Recombinant Epo replaced blood 
transfusion therapy in the early 90’s with significant increase in efficacy and safety of the treatment, 
as shown in figure 13. 
 
 
Figure 13 Response of a patient with renal failure and under dialysis to blood transfusions and 
rhEpo treatment. The second treatment regimen led to sustained increase in Hct and reticulocyte 
count. The dose of rhEpo was lowered to prevent the Hct from rising too high. The blue box shows 
values of serum iron, total iron binding capacity (TIBC), saturation and ferritin. Note that the severe 
iron overload is resolved with rhEpo treatment, indicating functional erythropoiesis has occurred 
(Eschbach et al., 1987).   
Possible side effects of rhEpo therapy are thrombosis, due to excessive RBC number (Singh et al., 
2006; Phrommintikul et al., 2007), or tumour growth promotion, since Epo is a pro-survival factor 
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for cancer cells expressing EpoR (Henke et al., 2003). However, recent studies did not confirm the 
latter case (Bohlius et al., 2006; Bennett et al., 2010). There seem instead to be a link between 
excessively high Hb levels and risk of cardiovascular complications (Besarab et al., 1998; Haase, 
2013; McCullough et al., 2013): indeed repetitive administration of rhEpo usually lead to high 
Hb/Hct levels, far above the physiological range necessary to treat anaemia. Additional 
complications of this treatment regimen are the high cost of therapy, which virtually continues for 
the entire life of the chronic anaemic patient, and the need for parenteral administration. A large 
number of companies are currently working on novel erythropoiesis-stimulating agents, including 
PHD inhibitors, with promising results in rodents and humans (Yan et al., 2010; Flamme et al., 
2014). Besides increased compliance of the patients, pre-clinical data showed that PHD inhibitors 
are capable of reversibly increasing Hb/Hct to more physiological levels compared to rhEpo, 
without significantly affecting the other HIF target genes tested in the study (Wang et al., 2012; 
Hong et al., 2013; Flamme et al., 2014).  
 
1.5 Regulation of Epo by humoral factors 
Some evidences in literature suggest the possibility for Epo to be regulated through putative 
humoral factors, independently of tissue hypoxia in the kidney. Despite the fact that some single 
peptides have been shown to directly regulate Epo in vitro or in vivo, the precise mechanism of 
Epo humoral regulation remains clear. It is reasonable to assume that other factors are involved in 
Epo normoxic/hypoxic transcription, in the negative feedback upon chronic hypoxia and in 
pathological conditions. REPCs de-differentiation into myofibroblasts could be the reason for 
anaemia in CKD patients but this hypothesis is not yet proven and regulatory peptides could 
significantly contribute to Epo impairment in these patients.  
The most common hypothesis suggests Epo as a blood volume (BV)-regulating hormone since it is 
the main factor influencing the number of RBCs, which accounts for approximately 45% of BV. 
Manoeuvres affecting central venous pressure (mimicking increased BV filling in the right atrium), 
such as head-down tilt, led to decreased Epo plasma levels (Gunga et al., 1996), while in 
conditions of blood fluid loss (decreased BV) Epo levels in the plasma have been shown to 
increase in dogs and humans (Ehmke et al., 1995; Revelli et al., 2013). Moreover, one report 
showed that intravenous infusion of plasma albumin and physiological solution in healthy humans, 
thus mimicking an acute increase in BV, led to 14.3% lower Epo plasma levels. Epo concentration 
remained decreased for 5 h after the injection (Szyguła et al., 1995). All these experiments were 
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performed at sea level or in water immersion, implying that atmospheric hypoxia cannot be the 
cause of the changes observed in Epo concentration. Even more interesting, the hypophysis 
seems to play a role in Epo regulation: hypoxia stimulation of the brain stem (but not of the kidney) 
in rats led to increased Epo plasma levels and this effect is gone when the animals were 
nephrectomized or hypophysectomized, suggesting that the brain stem is able to sense O2 and 
regulate Epo production in the kidney (von Wussow et al., 2005). Finally, one report described a 
direct link between ADH/AVP (anti-diuretic hormone/arginine vasopressin) and Epo in rats. Epo 
plasma levels doubled when rats were treated with ADH in normoxic conditions and blockade of 
the V1a receptor completely abolished this effect without changes in renal blood flow (Engel and 
Pagel, 1995). 
A second research line focuses on the role of inflammatory mediators on Epo regulation. 
Inflammation is known to cause anaemia, called anaemia of infection or anaemia of chronic 
disease, due to several factors: decreased proliferation rate of erythroid progenitors, dysregulation 
of iron homeostasis and decreased Epo expression. Clinical observation of a blunted erythropoietic 
response came from patients with autoimmune disease, such as rheumatoid arthritis and 
inflammatory bowel disease, with acute and chronic infections, including acquired 
immunodeficiency syndrome (AIDS), and with cancer (Jelkmann, 1998; Weiss and Goodnough, 
2005). BFU-E and CFU-E proliferation is impaired in patients with anaemia of infection, possibly 
because of the growth-inhibitory and pro-apoptotic effect of inflammatory cytokines, among which 
interferon γ seems to be the most important mediator (Means, 2003). Iron homeostasis 
dysregulation is a hallmark of inflammatory chronic diseases and is caused by increased uptake 
and retention of iron by the mononuclear phagocyte system, making iron less available for 
erythropoiesis. The underlying mechanisms are not fully understood, but up-regulation of iron-
related protein such as DMT-1 and ferritin in macrophages has been shown in animal models of 
inflammation. Again, inflammatory cytokines are the soluble mediators of the effect (Ludwiczek et 
al., 2003). Epo plasma levels in patients suffering from anaemia of inflammation are not adequate 
to the degree of anaemia in most of the cases, meaning that Epo concentration is too low for the 
Hb concentration/Hct observed (Ward et al., 1971; Miller et al., 1990; Camacho et al., 1991). 
Impaired renal Epo production has been demonstrated in rodents treated with inflammatory stimuli 
including lipopolysaccharide (LPS) and interleukin-1β (IL-1β), both in normoxia and hypoxia 
(Jelkmann et al., 1992; Frede et al., 1997). More evidences come from in vitro experiments with 
HepG2 and Hep3B, where LPS, IL-1α, IL-1β and tumour necrosis factor α (TNF-α) showed dose-
dependent inhibition of Epo hypoxic induction (Jelkmann et al., 1990). Treatment of macrophages, 
the cellular source of cytokines, with the anti-inflammatory drug dexamethasone was able to 
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reverse the effect (Leng et al., 1996). All the above mentioned reports refer to Epo mRNA levels, 
implying again a regulation at the transcriptional level. 
Furthermore, it should be mentioned that factors stabilizing HIFs can have an effect on Epo as 
well. Several proteins and peptides have been reported to stabilize HIF-α under normoxic 
conditions but their relevance for Epo regulation is unknown (Wenger et al., 2005). Among the 
“Epo normoxic regulators”, sexual hormones are the most well studied and have been proposed to 
be the cause of gender-related differences in Hct. Indeed, healthy adult women display 12% lower 
Hb concentration in venous blood than age and race matched men (Murphy, 2014), but 
erythropoietin plasma levels do not seem to vary between sexes (Jelkmann and Wiedemann, 
1989). Sexual hormones administration to human subjects does affect Hb concentration in the 
blood; in particular estrogen treatment lowers the Hct, while androgen treatment increases it. The 
steroid hormone effect on erythropoietic progenitors in the bone marrow is known and partially 
accounts for sex-related differences in RBC mass (Murphy, 2014). Nevertheless, a series of 
evidences speak for an effect of steroid hormones on renal EPO transcription as well. Estrogen 
treatment of Hep3B culture decreased Epo-reporter assay activity and protein levels (Mukundan et 
al., 2004) and estrogen administration to hypoxic rats attenuated Epo synthesis (Mukundan et al., 
2002). On the other hand, androgen therapy in human subjects increased Epo plasma and urine 
levels (Alexanian, 1969), suggesting again a direct effect of sex hormones on transcription of the 
EPO gene. Moreover, aneprhic or ESRD patients do not show gender-related differences in Hct 
values (Neff et al., 1981) and do not respond with increased Epo production to androgen treatment 
(Teruel et al., 1996). Collectively, these observations point in the direction of a direct effect of sex 
hormones on Epo production in the kidney, at the transcriptional level if considering the in vitro 
experiments. 
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2. Aims of the thesis 
Erythropoietin (Epo) is the main humoral factor regulating red blood cells homeostasis and is 
transcriptionally regulated in a very thigh manner by a variety of mechanisms. Although it is often 
used as a paradigm for hypoxia-induced genes, several aspects of Epo regulation remain 
unclear. In this PhD work, we were interested in using the currently available Epo-expressing 
cell models in order to study EPO transcriptional regulation at different levels.  
I. The chromosomal position and function of the element responsible for renal Epo 
inducibility (the kidney-inducible element, KIE), as well as the maintenance of the 
extremely high tissue specificity of Epo expression represent the main focus of the 
thesis. To this aim, we generated a series of reporter constructs containing different EPO 
flanking regions and tested their activity in Epo-expressing and non Epo-expressing cell 
lines. This approach was combined with transient or stable knockdown/overexpression of 
various candidates playing a role in the hypoxia-signalling cascade in order to dissect 
their role in Epo hypoxic regulation. Finally, the cluster regularly interspace short 
palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) technique was 
introduced as innovative approach to study the remote Epo enhancer elements in cell 
culture. 
II. Novel mutations in Egl9 homolog 1 (EGLN1) gene associated with secondary congenital 
erythrocytosis were identified by the group of Dr. Betty Gardie (Nantes, France). As part 
of a collaborative effort the functional effect of these mutations on the activity of the 
encoded protein (prolyl-4-hydroxylase domain 2, PHD2) was characterised. 
III. In order to identify putative humoral factors regulating the von Hippel-Lindau 
protein/prolyl-4-hydroxylase domain/hypoxia-inducible factor (pVHL/PHD/HIF) pathway, 
and potentially EPO transcription as well, a number of selected peptides were tested for 
their effect on Epo mRNA levels. Moreover, a library of bioactive peptides isolated from 
haemofiltrates of patients with chronic renal failure generated in the lab of Prof. W.G. 
Forssmann (Hannover, Germany) was screened for the effect on HIF-dependent reporter 
cell lines. 
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Erythropoietin (Epo) is the main humoral regulator of erythropoiesis. During development Epo 
production switches in a species-specific manner from the liver to the kidneys which account 
for   ̴90% of total Epo synthesis in the adult. Renal Epo is produced by peritubular interstitial cells 
with fibroblastic and neuronal features, located in the juxtamedullary cortex (Maxwell et al., 
1993; Obara et al., 2008; Wenger and Hoogewijs, 2010; Souma et al., 2013). These cells 
respond to a decrease in tissue oxygen partial pressure by hypoxia-inducible transcription factor-
2 (HIF-2)-dependent induction of Epo synthesis (Kapitsinou et al., 2010). DNA sequences 
required for oxygen-dependent regulation of the EPO gene are different in liver and kidney. 
Under physiologic conditions, EPO gene expression is controlled by elements located within 0.4 
kb of the 5' and 0.7 kb of the 3'-flanking region in the liver, while an essential regulatory element 
for renal Epo expression resides between -14 and -6 kb in the distal 5'-region (Semenza et al., 
1990; Köchling et al., 1998). The liver-inducible element consists of a proximal downstream 
enhancer which synergizes with the minimal promoter region to achieve up to 100-fold 
transcriptional induction (Blanchard et al., 1992). Detailed analysis of this conserved 50 bp 3'-
enhancer revealed a tripartite cis-regulatory structure with a consensus HIF binding site (HBS, 
ACGTG) and a CACA repeat downstream of the HBS (Semenza and Wang, 1992). The latter 
element is necessary, but not sufficient for hypoxia inducibility of the 3'-enhancer. However, so 
far no protein binding to this element has been defined. While the Epo 3'-enhancer is well 
characterized and has been confirmed to be both essential and sufficient for liver-specific Epo 
expression in mice beyond embryonic day 14.5 (Suzuki et al., 2011), the kidney-inducible 
element (KIE) remains unexplored. In the present study we functionally analyzed a distal 
upstream hypoxia response element (HRE) which confers oxygen regulated Epo transcription 
and presumably represents the hitherto uncharacterized KIE. 
We used the ENCODE data integrated in the UCSC Genome Browser (http://genome.ucsc.edu/) 
to identify a distal conserved putative HBS in the Epo 5'-region, located within a DNase I 
hypersensitivity site (DSS) observed in 9 different non-Epo producing cell lines and strongly 
conserved in multiple vertebrate species (figure 1A). This distant locus, 9248 bp upstream of the 
Epo transcription start site, contains a putative HBS and is flanked by the most frequently 
neighboring residues observed around the consensus HBS (Schödel et al., 2011) and a CACA 
repeat 8 bp upstream, very similar to the established 3'-HRE. The striking overlap of this region 
with a previously reported anemia-inducible DSS in liver and kidney of anemic Epo transgenic 
mice (Köchling et al., 1998) prompted us to perform a detailed functional analysis. Two Epo-
expressing (Hep3B and Kelly, figure 1B) and two non-expressing (HeLa and HK-2) human cell 
lines were transfected with firefly luciferase reporter gene constructs under the control of the 
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exogenous SV40 promoter and a 100 bp fragment encompassing the novel candidate 5'-HRE, 
containing either wild-type or mutant HBS and CACA elements. The isolated distal 5'-HRE 
conferred robust hypoxic reporter gene induction in all cell lines tested (figure 1C), which was 
abrogated upon mutation of either the HBS or the CACA sequence (figure 1D).  
We next combined the endogenous Epo minimal promoter (117 bp) with the distal 5'-HRE of 
either 100 bp, 300 bp (covering the entire conserved DSS region), or 3 kb length as indicated in 
Figure 2A. All three constructs, but not the Epo minimal promoter alone, increased reporter gene 
activity in hypoxic Hep3B cells (figure 2B). No further induction was observed by inclusion of the 
3'-HRE (126 bp), suggesting that at least under our experimental conditions the 5'-HRE and the 
3'-HRE do not cooperate. Because the 3 kb containing fragment did not further increase the 
hypoxic response it was excluded from later analyses.  
To analyze HIFα isoform transcriptional selectivity, reporter gene constructs were co-transfected 
with constitutively active (double proline mutant) HIF-1α or HIF-2α overexpressing plasmids. 
Reporter assays using the plasminogen activator inhibitor 1 (PAI-1) and carbonic anhydrase IX 
(CAIX) promoters as well as pH3SVL served as controls for HIFα overexpression. HIF-2α 
enhanced transactivation of the Epo promoter substantially better than HIF-1α (figure 2C), in line 
with the previously reported dominant role of HIF-2α in hypoxia-inducible Epo transcription in 
vitro (Warnecke et al., 2004). Interestingly, no HIFα isoform specificity was observed in reporter 
genes driven by the heterologous SV40 promoter (figure 2D), indicating a crucial role of the 
endogenous Epo minimal promoter in HIFα isoform selectivity. Reporter gene assays were 
repeated in small interfering (si)RNA-mediated HIFα-deficient Hep3B cells, as described before 
(Wollenick et al., 2012). Both HIF-1α and HIF-2α siRNA reduced 5'-HRE dependent luciferase 
activity in hypoxic Hep3B cells (figure 2E). Rather unexpectedly, both Epo 5' and 3'-HRE 
dependent luciferase activity was more affected by depletion of HIF-1α than HIF-2α. This might 
be partially explained by less efficient knockdown of HIF-2α, as reflected by the PAI-1 and 
pH3SVL reporter activity and HIF-2α mRNA expression levels (figure 2E and F). Alternatively, 
knockdown of HIF-1α might decrease hypoxic prolyl hydroxylase domain protein 3 (PHD3) 
induction, which has been shown to preferentially target HIF-2α (Appelhoff et al., 2004). Notably, 
hypoxia-inducible Epo mRNA expression was not entirely HIF-2 dependent in hypoxic Hep3B 
cells (figure 2F). 
To analyze HIFα DNA binding to the endogenous sites, chromatin immunoprecipitation (ChIP) 
assays were performed using either anti-HIF-1α (5 μg, Ab2185; Abcam) or anti-HIF-2α (5 μg, 
Ab199; Abcam) antibodies in hypoxically treated Hep3B cells, as described before (Wollenick et 
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al,. 2012). The PAI-1 and Epo 3'-HRE were employed as positive controls, and regions 1 kb 
upstream and downstream of the 5'-HRE served as negative controls. ChIP analysis revealed 
hypoxia-inducible HIF-2α, but not HIF-1α enrichment at the 5'-HRE or at any other of the tested 
5' loci (figure 2G, left panel). In contrast, both HIF-1α and HIF-2α bound to the Epo 3'-HRE and 
the known PAI-1 HRE (figure 2G, right panel).  
Collectively, our results demonstrate the identification of a functional HIF-2α dependent distal 5'-
HRE regulating Epo transcription. The lack of a renal cell culture system capable of hypoxia-
inducible Epo expression precluded further validation of the kidney-specificity of this 5'-HRE. 
Additional distal elements contributing to kidney-specific Epo expression are likely to exist, 
because a BAC covering more than 180 kb flanking Epo regulatory regions is required to fully 
recapitulate endogenous Epo expression in transgenic mice (Obara et al., 2008; Yamazaki et al., 
2013). Our study is the first to functionally analyze the enigmatic KIE and provides the basis for 
further investigations on the cooperation between other putative distal and proximal regions in 
regulating kidney-specific inducible Epo expression. 
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Figure 1 
 
Figure 1 Location of a functional distal HRE in the Epo 5' regulatory region. A. UCSC Genome 
Browser output (hg19) of the Epo genomic and 5' upstream region. Shown are the ENCODE 
DSS clusters and mammalian PhastCons conservation tracks with a closer view of the region in 
28 vertebrates extracted using the 46-MULTIZ whole-genome multiple alignment algorithm. B. 
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Epo mRNA levels in human Hep3B and Kelly cells were measured by RT-qPCR and normalized 
to ribosomal protein L28 mRNA levels. C. Both cell types (3x105 cells) were co-transfected with 
the indicated SV40-driven firefly luciferase reporter gene plasmids (500 ng) and a Renilla 
luciferase control plasmid (5 ng, Promega) in a six-well format by polyethylenimine (PEI). 24 h 
post-transfection, cells were incubated for another 24 h under normoxic or hypoxic conditions 
(0.2% O2). Luciferase activities of triplicate wells were determined using the Dual Luciferase 
Reporter Assay System according to the manufacturer's protocol (Promega). All results are 
displayed as ratios of firefly to Renilla relative light units (R.L.U.). D. Cells were co-transfected 
with pGL3p Epo 5'-HRE wild-type (w), pGL3p Epo HBS mutated (m) (ACGTG to AAAAG), 
pGL3p Epo CACA mutated (CACA to AAAA) or pGL3p Epo HBSm, CACAm and a Renilla 
luciferase control plasmid, and reporter gene experiments performed as in (D). B-D. All data are 
expressed as mean ± SEM of 3 independent experiments and statistical analyses were 
performed with one-way ANOVA and Tukey correction for multiple comparisons (***p < 0.001, 
n.s. = not significant). 
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Figure 2   
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Figure 2 HIF-2α dependent hypoxic regulation of the Epo distal enhancer element. A. Scheme 
depicting the constructs used. The numbers are relative to the transcriptional start site (TSS). 
KIE, kidney-inducible element; NRE, negative regulatory element; LIE, liver-inducible element; 
NRLE, negative regulatory liver element. B. Dual luciferase analyses using the Epo minimal 
promoter (117 bp) and several indicated extensions of the distal 5'-HRE alone or in combination 
with the 3'-HRE. All reporter gene experiments were performed as in Figure 1. C. The indicated 
vectors were co-transfected with HIF-α or empty expression vectors into Hep3B cells. CAIX and 
PAI-1 promoter constructs were used as controls for HIF-1α and HIF-2α specificity, respectively. 
pH3SVL is controlled by a concatamerized non-HIFα isoform specific HRE and an SV40 
promoter. D. Comparison between SV40-driven and Epo promoter-driven luciferase expression, 
following HIFα overexpression in Hep3B cells. E. Effect of siRNA-mediated HIFα knockdown on 
the indicated vectors in Hep3B cells. F. HIF-1α, HIF-2α, Epo, PAI-1 and CAIX mRNA levels were 
measured by RT-qPCR and normalized to ribosomal protein L28 mRNA levels. G. Scheme 
depicting the different primer regions used for ChIP experiments. ChIP of normoxic or hypoxic 
(0.2% O2, 24 h) Hep3B cells using antibodies directed against HIF-1α or HIF-2α. The amount of 
co-precipitated chromatin derived from the human Epo 5' regulatory region, its upstream and 
downstream regions, and the Epo 3'-HRE was determined by qPCR. The PAI-1 promoter was 
used as additional positive control. Mean values ± SEM of 3 (B-F) or 4 (G) independent 
experiments are shown and statistical analyses were performed with one-way ANOVA and 
Tukey correction for multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Abstract 
Background Congenital secondary erythrocytoses are due to deregulation of hypoxia inducible 
factor resulting in overproduction of erythropoietin. The most common germline mutation 
identified in the hypoxia signaling pathway is the Arginine 200-Tryptophan mutant of the von 
Hippel-Lindau tumor suppressor gene, resulting in Chuvash polycythemia. This mutant displays 
a weak deficiency in hypoxia inducible factor α regulation and does not promote tumorigenesis. 
Other von Hippel-Lindau mutants with more deleterious effects are responsible for von Hippel-
Lindau disease, which is characterized by the development of multiple tumors. Recently, a few 
mutations in gene for the prolyl hydroxylase domain 2 protein (PHD2) have been reported in 
cases of congenital erythrocytosis not associated with tumor formation with the exception of one 
patient with a recurrent extra-adrenal paraganglioma. 
Design and Methods Five PHD2 variants, four of which were novel, were identified in patients 
with erythrocytosis. These PHD2 variants were functionally analyzed and compared with the 
PHD2 mutant previously identified in a patient with polycythemia and paraganglioma. The 
capacity of PHD2 to regulate the activity, stability and hydroxylation of hypoxia inducible factor α 
was assessed using hypoxia-inducible reporter gene, one-hybrid and in vitro hydroxylation 
assays, respectively. 
Results This functional comparative study showed that two categories of PHD2 mutants could 
be distinguished: one category with a weak deficiency in hypoxia inducible factor α regulation 
and a second one with a deleterious effect; the mutant implicated in tumor occurrence belongs 
to the second category. 
Conclusions As observed with germline von Hippel-Lindau mutations, there are functional 
differences between the PHD2 mutants with regards to hypoxia inducible factor regulation. 
PHD2 mutation carriers do, therefore, need careful medical follow-up, since some mutations 
must be considered as potential candidates for tumor predisposition. 
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Introduction 
Secondary erythrocytosis is due to external factors such as increased production of 
erythropoietin, the origin of which is variable and may result from germline mutations in genes 
encoding factors involved in the oxygen-sensing pathway. The primary cellular component 
implicated in oxygen homeostasis is the hypoxia-inducible transcription factor (HIF). HIF 
operates as a heterodimer composed of a constitutively expressed beta subunit, also known as 
aryl hydrocarbon receptor nuclear translocator, and an alpha subunit (1α, 2α or 3α) that is tightly 
regulated by oxygen via post-translational modification. The prolyl-4-hydroxylase domain (PHD) 
enzymes hydroxylate proline residues located in the oxygen-dependent degradation (ODD) 
domain of HIF-α. This hydroxylation allows the binding of the von Hippel-Lindau protein (pVHL), 
the substrate recognition subunit of an E3 ubiquitin ligase complex that induces ubiquitination 
and subsequent degradation of HIF-α by the proteasome (Pouyssegur  et al., 2006; Kaelin Jr, 
2008). In the absence of oxygen, HIF-α is stabilized, heterodimerizes with HIF-1β and induces 
expression of hundreds of genes involved in cell survival, angiogenesis, erythropoiesis and cell 
proliferation (Wenger et al., 2005; Pouyssegur et al., 2006). There is some restricted target gene 
specificity depending on the HIF-α subunit of the HIF-α/β heterodimeric transcription factor. For 
example, renal and hepatic erythropoietin is regulated by the HIF-2α subunit in vivo 
(Rosenberger et al., 2002; Warnecke et al., 2004; Rankin et al., 2007; Wenger and Hoogewijs, 
2010). Germline mutations in genes involved in the HIF pathway have been reported in 
association with syndromes that predispose patients to both neoplasms and/or congenital 
secondary erythrocytosis (Richard et al., 2004). The most frequent mutations involve the VHL 
tumor suppressor gene. Heterozygous germline mutations in this gene are responsible for von 
Hippel-Lindau (VHL) disease, an autosomal dominant condition predisposing to multiple tumors 
including central nervous system and retinal hemangioblastomas, clear-cell renal cell carcinoma, 
pheochromocytomas and pancreatic endocrine tumors (Richard et al., 2004). Established 
correlations between genotype and phenotype predict the risk of 
paraganglioma/pheochromocytoma, with VHL deletions or truncating mutations being associated 
with a low risk (VHL type 1) and VHL missense mutations being associated with a high risk (VHL 
type 2) (Maher et al., 1996; Nordstrom-O'Brien et al., 2010). 
In addition, a homozygous 598C>T (R200W) VHL germline mutation has been shown to account 
for Chuvash congenital polycythemia, an autosomal recessive disease, endemic in the Chuvash 
Autonomous Republic of the Russian Federation (Ang et al., 2002). Homozygous carriers of the 
R200W-VHL germline mutation do not develop tumors but instead have Chuvash congenital 
polycythemia due to high levels of erythropoietin (Ang et al., 2002). The lack of tumor 
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development in this disorder is due to a weak defect of the mutation in terms of its HIF-α 
regulation (leading to delayed ubiquitination) because of its localization outside pVHL functional 
domains (Ang et al., 2002). Other homozygous and compound heterozygous polycythemia-
associated VHL mutations have also been reported (Nordstrom-O'Brien et al., 2010). Functional 
studies of some of these mutants have shown a weak to undetectable defect of HIF-1α 
regulation (unpublished data).  
Recently, a similar phenotype of high erythropoietin-associated polycythemia without associated 
tumors has been reported in carriers of heterozygous germline mutations in the PHD2 and HIF-
2A genes (Percy et al., 2006; Percy et al., 2007; Al-Sheikh et al., 2008; Gale et al., 2008; Martini 
et al., 2008; Percy et al., 2008; Percy et al., 2008; van Wijk et al., 2010), with the exception of 
one patient carrying a H374R-PHD2 mutation (Ladroue et al., 2008). This particular patient 
simultaneously developed congenital secondary erythrocytosis and recurrent paraganglioma, a 
tumor originating from neural crest cells similar to pheochromocytoma but with an extra-adrenal 
localization (Ladroue et al., 2008). The analysis of the tumor showed a loss of heterozygosity 
including the wild-type PHD2 allele, suggesting a potential tumor suppressor role of PHD2. 
PHD2 and VHL act in concert to regulate HIF-α. Based on the observation that VHL mutation 
carriers display different phenotypes depending on the relative capacity of the VHL mutants to 
regulate HIF, we sought to define the genotype-phenotype relationship regarding the capacity of 
PHD2 mutants to differentially regulate HIF-α. Here we report a functional study comparing five 
PHD2 variants associated with isolated congenital secondary erythrocytosis with the mutation 
identified in a patient with recurrent paraganglioma. 
 
Design and Methods 
Patients and mutation screening 
Thirty-four patients who did not fulfill World Health Organization diagnostic criteria for 
polycythemia vera were investigated. The local ethics committee of Kremlin Bicetre Hospital 
approved the study and all patients provided written informed consent. Blood samples were 
collected from all patients and germline DNA was extracted and analyzed by direct sequencing 
(Ladroue et al., 2008). DNA from the blood of healthy donors of Caucasian origin was used as a 
control.  
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Assay of hypoxia inducible factor transcriptional activity  
In order to assay HIF transcriptional activity, dual luciferase assays were performed in Hek293T 
cells as described previously (Ladroue et al., 2008). A pGL3promoter vector expressing 
luciferase under the control of hypoxia response elements (Dayan et al., 2006) was used. Cells 
were exposed to hypoxic conditions (1% O2) for 4 h before extraction. 
Assay of hypoxia inducible factor stability 
HeLa cells were transiently co-transfected with increasing amounts (50-200 ng) of an expression 
vector encoding the HIF-2α ODD domain (amino acids 404-569), fused to yeast Gal4 DNA-
binding domain and Herpes simplex VP16-derived transactivation domain, together with the 
Gal4-response element driven firefly luciferase reporter, pGRE5xE1b (125 ng), and a Renilla 
luciferase control plasmid (4 ng) (Köditz et al., 2007). Twenty-four h post-transfection, cells were 
cultured under either normoxic (20% O2) or hypoxic (1% O2) conditions for an additional 16 h, 
and firefly luciferase activity was determined and normalized to Renilla luciferase activity. 
Hydroxylation assay 
PHD2 and HIF-ODD proteins (plasmid pcDNA3-HA-Gal4-HIF-1α-ODD was a generous gift from 
WG Kaelin Jr, Dana-Farber Cancer Institute, Boston, USA) (Ohh et al., 2000) were produced in 
wheat germ extract in vitro using the TnT transcription-translation kit (Promega). The 
hydroxylation reaction was carried out by mixing PHD2 and HIF-1α ODD (amino acids 536-652) 
proteins in a reaction buffer containing co-factors (Fe2+, ascorbic acid and 2-oxoglutarate) as 
described previously (Huang, Zhao et al. 2002). The samples were incubated at 30°C, collected 
at different time points, and immunoblotted with anti-HA (Tebu) and anti-HIF-1α (Pro 564)-OH 
(Cell-Signaling Technology) antibodies. 
 
Results 
We sequenced the PHD2 gene on germline DNA from a series of Caucasian patients with 
unexplained polycythemia associated with normal or elevated serum erythropoietin levels (figure 
1A). Four novel heterozygous sequence variants were identified in the PHD2 gene [c.G471C, 
p.Gln157His (Q157H); c.C599A, p.Pro200Gln (P200Q); c.G760C, p.Asp254His (D254H); 
c.C1192T, p.Arg398X (R398X)] as well as the already described c.G1112A, p.Arg371His 
(R371H) mutation (Percy et al., 2007) (Figures 1A and B). Genetic testing was performed on 
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available parents and relatives of the PHD2 mutation carriers, but no mutation was found except 
in the mother of the PHD2-R398X carrier who presented characteristics of polycythemia (figure 
1A). She harbors the PHD2 mutation but with a mosaic status as demonstrated by the reduced 
height of the peak on the sequence chromatogram (figure 1B). The low proportion of the 
mutated allele was confirmed by a quantitative allele-specific oligonucleotide method (data not 
shown). 
Concerning the other families, only a few relatives were available for further genetic and clinical 
investigations but there was no history of familial polycythemia. Briefly, the brother, the sister 
and the son of patient #2295 and the father of patient #2403 agreed to genetic testing and were 
not carriers of PHD2 mutation. Other parents had died previously, of known causes in two 
cases: esophageal cancer for the mother of patient #2403 and colon cancer for the mother of 
patient #2412. Finally, patient #0424 was an adopted child, without children. 
The frequencies of the different variants were evaluated in a control population (figure 1C). Only 
the Q157H variant was found and was, therefore, classified as a polymorphism. Analysis of 
amino acid conservation supports this conclusion, as the Q157 amino acid is not conserved 
either between species or within the PHD protein family (PHD1 and 3) (online supplementary 
table S1). In contrast, amino acids P200 and R371 are highly conserved and the D254 amino 
acid is fully conserved, similar to H374 described in our previous study (Ladroue et al., 2008). As 
far as concerns the location of the amino acids in the protein, D254, like H374, is part of the 
PHD2 catalytic site (McDonough et al., 2006). The P200 amino acid is located within the nuclear 
localization signal (NLS) implicated in the shuttling of PHD2 between the cytoplasm and the 
nucleus which plays a crucial role in HIF regulation (Steinhoff et al., 2009). We tested the 
shuttling of the P200Q mutation by immunofluorescence but we did not observe any impact of 
the mutation on the capacity of PHD2 to shuttle (data not shown). 
We next studied the PHD2 mutants using a one-hybrid reporter assay based on the capacity of 
PHD2 to induce HIF-α protein instability. Cells were co-transfected with expression vectors 
containing the different PHD2 mutants (50 to 200 ng), the oxygen-dependent degradation 
domain of HIF-2α (HIF-2α-ODD) fused to yeast Gal4 DNA-binding domain and Herpes simplex 
VP16-derived transactivation domain, together with a reporter vector expressing luciferase under 
the control of a Gal4-response element. In this assay, luciferase expression reflects the stability 
of HIF-2α ODD. A trend similar to that in the previous test was obtained: there was no detectable 
effect of the P200Q and R371H substitutions on PHD2 activity (which was comparable to that of 
the wild-type PHD2) and there was total abolition of the D254H mutant activity (comparable to 
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that of the truncated PHD2 variant R398X, figure 2B). Identical results were obtained using a 
HIF-1α ODD stability reporter (data not shown). The experiment was repeated with the P200Q-
PHD2 mutant in oxygen-regulated erythropoietin- expressing cells (including the human 
hepatoma cell line Hep3B and renal erythropoietin-producing cells, a new cell model isolated 
from the tumor-free tissue of a patient with renal carcinoma) but no significant difference was 
observed (data not shown).  
We next performed a sensitive in vitro assay in order to test the ability of the PHD2 mutants to 
hydroxylate HIF-1α in a time-dependent manner. In this assay, in vitro-translated PHD2 proteins 
were mixed with HIF-1α ODD in the presence of co-factors necessary for the hydroxylation 
reaction. The capacity of the different PHD2 mutants to hydroxylate HIF-1α was measured by 
immunoblotting using an antibody specific for the hydroxylated HIF-1α ODD (HIF-OH, Figure 
3A). The H374R and D254H substitutions totally impaired HIF-1α hydroxylation (figure 3A). By 
contrast the R371H mutant behaved like the wild-type PHD2 and the P200Q mutant, although 
capable of hydroxylating HIF-1α (figure 3A), showed a reproducible and consistent delay (figure 
3B). 
 
Discussion 
Taken together, these results show that PHD2 mutations can be divided into several different 
classes in terms of their effects on HIF regulation. Genotype/phenotype correlations cannot be 
established for PHD2 mutations because they are rare events that have been reported in only 
ten families to date (including those in the present study), in contrast to the 945 families 
described with a VHL mutation (Nordstrom-O'Brien et al., 2010). In addition, the parents of the 
PHD2 mutation carriers reported in the literature were either dead or not available for further 
genetic and clinical investigations (including one parent who died of esophageal cancer (Percy 
et al., 2006)). In our study, only one parent was genetically tested and diagnosed as a mosaic 
carrier which prevents any conclusion regarding the developed phenotype. Nonetheless, 
regarding the close functional relation between VHL and PHD2 in the regulation of HIF and the 
implication of the HIF pathway in the genesis of pheochromocytoma (Eisenhofer et al., 2004; 
Dahia et al., 2005; Pollard et al., 2006; Favier et al., 2009), we can hypothesize similarities 
between the various types of mutants and raise the question of a possible risk of development of 
paraganglioma/pheochromocytoma in PHD2 mutation carriers. Subjects with one category of 
mutation (P200Q and R371H) display features similar to those with the VHL-R200W mutation 
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responsible for Chuvash polycythemia without any increased risk of neoplasia (Ang et al., 2002). 
Like the VHL-R200W mutant, which is located outside functional domains, the PHD2-P200Q and 
R371H mutations are not located in the catalytic domain of the enzyme and have a moderate 
impact on HIFα regulation. In addition, the VHL-R200W mutant only induces delayed 
ubiquitination of HIFα which may be comparable to the delayed hydroxylation of HIFα observed 
with the PHD2-P200Q mutant. Interestingly, Pro200 is only one residue N-terminal to Cys201 
which has been shown to chelate zinc and cadmium ions, providing evidence for the existence 
of a second metal binding site on PHD2 (Mecinović et al., 2008; Mecinović et al., 2009). This 
Cys201 affects PHD2 hydroxylation activity and appears to be implicated in redox signaling in 
vitro (Nytko et al., 2011). The very close location to the functionally important Cys201 residue 
could be the cause of the delayed hydroxylation of HIF-1α by the PHD2-P200Q mutant. 
Intriguingly, concerning the confirmed R371H mutant, the previously reported loss-of-function 
effect of this mutant (Percy et al., 2007) could not be confirmed by any of the three tests of our 
study. The R371H mutation segregates with erythrocytosis in two different families (described 
herein and by Percy et al. (Percy et al., 2007)) and is unequivocally involved in this pathology. 
We currently cannot explain why, in our hands, the R371H mutation failed to abolish PHD2 
catalytic activity. The PHD2 expression vectors were re-sequenced and their functions confirmed 
by immunoblotting. Parallel experiments with other PHD2 mutants confirmed the validity of our 
assays. For this category of mutants which have a moderate impact on HIFα regulation, we 
cannot rule out potential indirect regulation on the oxygen sensing pathway via PHD2-interacting 
proteins. Indeed, during the past decade a large number of PHD2-interacting proteins have been 
discovered, including both upstream regulators and downstream targets of PHD2, substantially 
increasing the complexity of the PHD/HIF oxygen-sensing regulation pathway (Wenger and 
Hoogewijs, 2010). Moreover, PHD2 has been reported to have hydroxylation-independent gene 
regulatory functions (Chan et al., 2009; Shao et al., 2009; Bordoli et al., 2011). 
Another category, including the PHD2-R398X mutation and three other PHD2 truncated 
mutations described previously (Al-Sheikh et al., 2008), can be compared to the VHL truncation 
mutations (VHL disease type 1) which are not associated with the development of 
pheochromocytomas. Subject with these first two categories could be considered at low risk of 
developing paraganglioma/pheochromocytoma.  
A last category could be compared to the VHL missense mutations involved in VHL disease type 
2, associated with a high risk of paraganglioma/pheochromocytoma. This category includes the 
previously described PHD2-H374R mutation identified in a 43-year-old patient with 
paraganglioma. A loss of the PHD2 wild-type allele was demonstrated in the patient with this 
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tumor, arguing for a tumor suppressor role of PHD2 (Ladroue et al., 2008). No PHD2 mutations 
have been identified in other series of patients affected by pheochromocytomas (73 patients with 
hereditary paraganglioma and pheochomocytoma syndrome, Gimenez-Roqueplo, Hôpital 
Européen Georges Pompidou, Paris, unpublished data) and/or renal carcinoma (Astuti et al., 
2011), but the risk that germline PHD2 mutation carriers have of developing tumors should not 
be underestimated. Indeed, like His374, Asp254 is highly conserved, and located in the catalytic 
site of PHD2 (McDonough et al., 2006). Moreover, the D254H mutation results in a severe loss 
of function. Therefore, although no cases of paraganglioma or pheochromocytoma have yet 
been detected in the D254H-PHD2 mutation carrier, this mutation may be considered as a 
potential candidate for tumor predisposition.  
In conclusion, using three different approaches we demonstrated that distinct PHD2 mutations 
have differential effects on HIF regulation. We suggest that, by analogy to VHL mutations, 
carriers of particular PHD2 mutations may be prone to tumor development. These patients would 
then require screening for tumor prevention and early detection. 
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Figure 1 
 
Figure 1 Identification of PHD2 mutations in patients with polycythemia. A. Table of patients 
diagnosed with erythrocytosis and a PHD2 variation. Ht: hematocrit; Hb: hemoglobin; RC: 
number of red cells; EPO: erythropoietin; m: male; f: female; N: normal; NA: not available; *: 
previously described (Ladroue, Carcenac et al. 2008). B. Sequence chromatogram of PHD2 in 
the area of the mutated nucleotide. Wild-type DNA was used as reference (Ref) (top) and 
compared to germline DNA of the patient (bottom). Only one relative of a patient was available 
for genetic testing (the mother of the PHD2-R398X carrier). She harbors the PHD2 mutation but 
with a mosaic pattern as demonstrated by the reduced height of the peak on the sequence 
chromatogram. C. Frequency of the PHD2 variations in a control population.  
A 
B 
C 
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Figure 2 
  
Figure 2 Functional study of PHD2 mutants using luciferase reporter assays. A. PHD2-
dependent regulation of endogenous HIF in an assay based on a hypoxia response element 
reporter gene. Cells were co-transfected in a 12-well format with various amounts of pcDNA3-
HA-PHD2 expression vectors (to enable the expression of the same amount of PHD2 proteins) 
in addition to pGL3 reporter vectors encoding firefly luciferase under the control of a sensitive 
hypoxia response element and Renilla luciferase as a control of transfection efficiency. Cells 
were placed in hypoxic conditions (1% O2) for 4 h in order to accumulate endogenous HIF-α 
before being collected. Results are given in percentage of firefly luciferase activity normalized to 
Renilla luciferase activity. The amount of HA-PHD2 transfected (PHD2) was quantified by 
immunoblotting using an anti-HA antibody. B. The effect of PHD2 effect on HIF-2α protein 
stability in a one-hybrid reporter assay. Cells were co-transfected in a 6-well format with various 
amounts of pcDNA3-HA-PHD2 expression vectors (200, 100 and 50 ng), a Gal4-VP16-HIF-
2αODD (amino acids 404-569) construct as well as a Gal4 response element-driven firefly 
luciferase reporter and a Renilla luciferase control plasmid. Twenty-four h post-transfection cells 
were incubated for 16 h in normoxic or hypoxic conditions. Results are mean values of three 
independent experiments performed in triplicate.  
A B 
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Figure 3 
 
Figure 3 Functional analysis of PHD2 mutants using an in vitro hydroxylation assay. A. 
Immunoblot estimation of HIF-1α-ODD protein hydroxylation in vitro. PHD2 and HIF-1α-ODD 
proteins were synthesized separately by in vitro transcription-translation reactions. The 
hydroxylation reaction was then processed by mixing HA-PHD2 and HA-HIF-1α-ODD proteins in 
a reaction buffer containing PHD2 enzymatic co-factors. The reaction was carried out at 30°C 
and samples were collected after 0, 10, 30, and 60 min of incubation. For immunoblotting, 10 μL 
aliquots of the hydroxylation reaction assays were separated by SDS-PAGE, blotted, and 
incubated with an anti-HA antibody [to quantify PHD2 and total HIF-ODD (HIF)] and anti-
hydroxylated HIF-1 antibody [to quantify hydroxylated HIF-ODD (HIF-OH)]. B. Quantification of 
hydroxylated HIF-1α. The proportion of hydroxylated HIF-1α was measured and related to total 
HIF-1α. The 100% value corresponds to the quantity of HIF-1α hydroxylated by the PHD2-WT 
protein after 1 h. Means were obtained with three independent experiments. 
A 
B 
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Unpublished data 
Since the HIF transcriptional and stability reporter assays (figure 2A and B) were performed in 
Hek293T and HeLa cells, which do not express Epo, we repeated both experiments with the 
P200Q-PHD2 mutant in an Epo-expressing system (Hep3B cells, see figure 4). However, no 
significant differences could be observed between mutant and wild type PHD2. Further 
experiments are required in order to elucidate the functional meaning of this mutation on the 
PHD/VHL/HIF pathway. In particular, a PHD2-deficient background would be necessary in order 
to avoid interference of the endogenous protein with the assays. Additionally, repeating the 
experiments in a kidney-derived, more physiological cell model would be helpful to understand 
the real effect of the P200Q mutation on PHD2 functionality. However, such renal cell model is 
currently not available (see next chapter). 
 
Figure 4 
 
Figure 4 HIF transcriptional (A) and stability (B) assays were performed in Hep3B cells 
transfected with the wt and P200Q mutant PHD2-expressing vectors, as in figure 2. The stability 
assay was performed with both HIF-1α and HIF-2α ODD and with increasing amount of the 
PHD2-expressing constructs (50, 100 and 200 ng). Results are mean values of 3 independent 
experiments performed in triplicates and shown as ratio of firefly to Renilla relative luciferase 
units (R.L.U.). 
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Introduction 
In order to study erythropoietin (Epo) hypoxia-regulated expression in vitro, we first characterize 
a series of cellular models for their ability to produce Epo in response to reduced oxygen tension 
or hypoxia-like stimuli (hypoxia mimetic compounds). Historically, the hepatocellular carcinoma-
derived human cell lines HepG2 and Hep3B have been used as models for Epo oxygen-
dependent expression (Goldberg et al., 1987; Warnecke et al., 2004). Recently, a novel renal 
cell model capable of hypoxia-induced Epo production was reported and showed for the first 
time several features typical of the renal Epo-producing cells (REPCs) in vivo (Frede et al., 
2011). REPCs were isolated form the tumour-free tissue of a patient with renal carcinoma and 
have been shown to express 5’-ectonucleotidase (CD73), microtubule-associated protein 2 
(MAP2) and neurofilament light polypeptide (NFL), known markers overlapping with Epo 
expression in kidney cells. Moreover, REPCs displayed dendritic-like processes and the typical 
negative feedback regulation of Epo mRNA during chronic hypoxia, with a peak after 48 h at 1% 
O2. We obtained and extensively characterized this model but, unfortunately, DNA profiling using 
8 different and highly polymorphic short tandem repeat (STR) loci revealed that REPCs were 
cross-contaminated with Hep3B. The same analysis was independently performed by several 
groups that received different batches of REPCs, including our group, all confirming the hepatic 
identity of what were thought to be REPCs. Consequently, the paper describing REPCs by 
Frede et al. (Frede et al., 2011) was retracted from the journal Blood (see below). Besides 
kidney and liver, the brain represents the third organ with relatively abundant Epo expression. 
It’s not surprising that two neuroblastoma cell lines, Kelly and SH-SY5Y, have been shown to 
express Epo mRNA in an oxygen-dependent way (Stolze et al., 2002).  
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Materials and methods 
Cell culture and reagents 
Hep3B, HepG2, REPCs and Hek293T were cultured in DMEM (high glucose, Sigma-Aldrich) 
supplemented with 10% heat-inactivated foetal calf serum (FCS), 50 IU/ml penicillin and 50 
µg/ml streptomycin (Invitrogen). Kelly and SH-SY5Y cells were cultured in RPMI (Sigma-Aldrich) 
supplemented with 10% heat-inactivated FCS, 50 IU/ml penicillin and 50 µg/ml streptomycin 
(Invitrogen). Hypoxia experiments were carried out at the indicated concentration of oxygen and 
5% CO2 in a gas-controlled glove box (InvivO2 400, Ruskinn Technologies). 
Dimethyloxaloylglycine (DMOG, D1070, Frontier Scientific) was dissolved in dimethyl sulfoxide 
(DMSO) and used at the concentration of 1 mM for 8 h. Deferoxamine (DFX, Sigma-Aldrich) was 
dissolved in water and used at a concentration of 100 μM for 16 h. 
RNA extraction and quantitative PCR 
RNA was extracted by using the phenol-chloroform method and cDNA was generated by 
reverse transcription (RT) of 2 µg of total RNA using AffinityScript reverse transcriptase 
(Agilent). Transcript levels were quantified by quantitative (q) PCR using a SybrGreen qPCR 
reagent kit (Sigma-Aldrich) in combination with a MX3000P light cycler (Agilent) and the primers 
listed in table 1. Initial template concentrations were calculated by comparison with serial 
dilutions of a calibrated standard. Ribosomal protein L28 mRNA levels were used to normalize 
the data.  
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon size 
hL28 GCAATTCCTTCCGCTACAAC TGTTCTTGCGGATCATGTGT 198 bp 
hEpo TCACTGTCCCAGACACCAAA CCTCCCCTGTGTACAGCTTC 362 bp 
hCAIX GGGTGTCATCTGGACTGTGTT CTTCTGTGCTGCCTTCTCATC 309 bp 
hHIF-1α CATAAAGTCTGCAACATGGAAGGT ATTTGATGGGTGAGGAATGGGTT 148 bp 
hHIF-2α TTGATGTGGAAACGGATGAA GGAACCTGCTCTTGCTGTTC 196 bp 
hPAI-1 ACTGGAAAGGCAACATGACC GAGGAAGGGTCTGTCCATGA 296 bp 
Table 1 Primers used for qPCR amplification 
HIF-α knockdown cells and lentiviral transduction 
Lentiviral expression vectors encoding shRNA sequences targeting human HIF1A at nucleotides 
1168-1188 (NM_001530.x-1048s1c1), human HIF2A at nucleotides 2055-2075 (NM_001430.x-
1694s1c1) and a non-targeting control sequence in a pLKO.1-puro plasmid were purchased 
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from Sigma. Viral particles were produced in Hek293T cells by co-transfection of the respective 
transfer vector (3 μg) with the packaging plasmids pLP1 (4.2 μg), pLP2 (2 μg) and pVSV-G (2.8 
μg, all from Invitrogen) using PEI transfection as previously described (Stiehl et al., 2012). Cells 
were transduced with lentiviral-pseudotyped particles and cell pools were derived by puromycin 
selection. 
Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using a high salt extraction buffer 
containing 0.4 M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 x protease inhibitory cocktail (Sigma-
Aldrich). Protein concentrations were determined by the bicinchoninic acid assay method and up 
to 80 µg of cellular protein was subjected to immunoblot analyses. Membranes were probed with 
antibodies against HIF-1α (clone 54/HIF-1α, BD Transduction Laboratories), HIF-2α (PAB12124, 
Abnova) and -actin (Sigma-Aldrich). Signals from HRP-coupled secondary antibodies were 
detected with ECL substrate (all Pierce) using a luminescent image analyser (LAS-4000, 
FUJIFILM). -actin was used as loading control. 
 
Results 
Hepatoma cell lines 
HepG2 and Hep3B are known to lose Epo hypoxic inducibility over cell culture passages and 
often require sub-cloning in order to keep high Epo induction folds upon hypoxic exposure. We 
therefore tested different batches of cells available in the lab and chose the ones showing the 
most optimal hypoxia-inducibility in terms of Epo mRNA for further experiments (figure 1). We 
also used DMOG as a hypoxia mimetic and confirmed the expected increase in Epo 
transcription after 8 h of treatment. DMOG is an ester of N-oxalylglycine that penetrates cells 
readily and inhibits all prolyl-4-hydroxylase domains (PHDs) 1–3 and factor-inhibiting HIF (FIH). 
DMOG competes with PHD endogenous substrate, 2-oxoglutarate, and inhibits the hydroxylation 
reaction, resulting in hypoxia-inducible factor (HIF) stabilization (Jaakkola, Mole et al. 2001).  
Renal Epo-producing cells (REPCs) 
Before the STR loci analysis was performed and the paper describing REPCs was retracted, we 
extensively characterized the cell line. Results obtained with this model will be labelled 
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hereinafter with “exREPCs” and will be treated as from an alternative batch of Hep3B cells. 
ExREPCs showed Epo mRNA induction upon exposure to hypoxia, in a time- and oxygen-
dependent manner, as well as to common hypoxia mimetics (figure 2). Importantly, we couldn’t 
recapitulate the feedback regulation in Epo transcription levels upon chronic hypoxia, as 
expected from in vivo and in vitro data (Jelkmann, 1982; Frede et al., 2011). In addition to 
DMOG, we used DFX, an iron-chelator. Iron is required for hydroxylation of HIF subunits by 
PHDs, thus DFX stabilizes HIFs by sequestering iron and inhibiting the hydroxylation reaction 
(Keberle, 1964). 
Moreover, we generated stable HIF-1α and HIF-2α deficient cell lines by using a lentiviral-
mediated knockdown approach to dissect the role of the single HIFα subunits in Epo hypoxic 
induction. As expected (Warnecke et al., 2004; Wenger and Hoogewijs, 2010), knockdown of 
HIF-2α, but not HIF-1α, resulted in significant reduction of Epo mRNA upon hypoxia when 
compared to control cells (figure 3). Efficiency of the knockdown was evaluated at the RNA and 
protein level, as well as by measuring mRNA levels of isoform-specific target genes, CAIX 
(carbonic anhydrase 9) for HIF-1α and PAI-1 (plasminogen activator inhibitor type 1) for HIF-2α. 
Increased HIF-2α protein levels were observed in HIF-1α deficient cells, followed by increased 
PAI-1, but not Epo, mRNA levels (figure 3B and C). This fact is not unexpected and has already 
been shown in different breast cancer cell lines (Fuady et al., 2014). 
Neuroblastoma cell lines 
Two cell lines derived from patients with neuroblastoma, Kelly and SH-SY5Y, were described in 
literature for their ability to produce Epo in an oxygen-dependent way (Stolze et al., 2002). We 
exposed them to hypoxia and measured Epo mRNA induction: Kelly cells displayed high Epo 
expression in hypoxia, whereas SH-SY5Y cells showed much lower levels of Epo mRNA and 
only a slight induction after 24 h of hypoxic exposure (figure 4). 
 
Discussion 
A prerequisite to investigate Epo regulation in vitro is a cell model with robust and reliable Epo 
hypoxic induction. Therefore, we tested several cell lines known to express oxygen-dependent 
Epo by exposing them to different % of O2 or to hypoxia mimetics, such as DMOG and DFX. The 
hepatoma cell lines HepG2 and Hep3B showed the expected induction in Epo mRNA with 
different kinetics: HepG2 displayed higher absolute levels of Epo compared to Hep3B but lower 
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hypoxic induction folds, mainly at early time points (4-8 h). Epo mRNA in Hep3B remained high 
even after prolonged hypoxia (128 h exposure, figure 1A and B). Both hepatoma cell lines also 
responded to DMOG, an inhibitor of PHD enzymes, by increasing Epo expression (figure 1C and 
D). Hep3B were chosen for further experiments, as Epo hypoxic induction was remarkably 
stronger than in HepG2. Despite several batches of HepG2 were tested, Epo mRNA levels did 
not further increase in hypoxia (data not shown).  
Even though we extensively characterized REPCs, this model turned out to be a peculiar sub-
population of Hep3B: we thus used them as an alternative source of hepatoma cells. Indeed, 
exREPCs showed time- and oxygen-dependent induction of Epo mRNA, with stable Epo levels 
after prolonged exposure (up to 6 days). DMOG and DFX were used as hypoxia mimetics and 
were able to increase Epo expression (figure 2). HIF-2α specificity for the EPO gene was also 
confirmed by generation of stable knockdown cell lines for the two HIFα subunits (figure 3). It 
must be mentioned that the genes tested, including Epo, were not totally HIF-1 or HIF-2 specific, 
meaning that non-statistically significant reduction of mRNA levels occurred also in cells silenced 
for the other HIF-α subunit (figure 3B). PAI-1 on the other hand displayed increased mRNA 
levels in HIF-1α silenced cells, consistently with increased HIF-2α protein levels in these cells 
(figure 3B and C). The effect of HIF isoform knockdown is thus not clear-cut and seems to be 
gene-specific. The retraction letter for the paper describing REPCs as a novel, kidney-derived 
cell line (Frede et al., 2011) is reported below. 
The neuroblastoma cell models Kelly and SH-SY5Y showed the ability to increase Epo 
transcription when exposed to hypoxia at different extents. Absolute Epo levels in SH-SY5Y 
were significantly lower than in Kelly, as well as the hypoxic induction folds (figure 4). We thus 
decided to proceed with Kelly cells as a non-hepatic, Epo-producing in vitro model. 
A kidney-derived cell line capable of expressing Epo when exposed to hypoxia is still missing 
and would be the most appropriate model to study renal Epo regulation. Attempts were made to 
isolate primary REPCs but they all failed due to impossibility of keeping the cells in culture or 
loss of Epo expression over a short period of time. Our lab extensively tried to establish the 
mouse kidney-derived E4 line as an Epo in vitro model (Plotkin and Goligorsky, 2006), but the 
few Epo-expressing cells in the mixed population seem to be lost with culture passages even 
after subcloning (Sara Santambrogio, data not shown). It is possible instead to target Epo-
producing cells in vivo and we are currently generating transgenic mice carrying the tamoxifen-
dependent Cre recombinase (CreERT2) under the control of the mouse Epo locus using the 
bacterial artificial chromosome (BAC) technology. Crossing the Epo-Cre animals with mice 
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baring different floxed alleles allows studying the role of the floxed gene of interest in renal Epo 
regulation (see next chapter).  
Unpublished results: Epo-producing cellular models 
 
103 
 
Figure 1 
 
Figure 1 HepG2 (A-C) and Hep3B (B-D) were exposed to 0.2% O2 or to 1 mM DMOG for the 
indicated time points and Epo mRNA levels were measured by RT-qPCR. Data are expressed 
as mean ± SEM or mean alone. 
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Figure 2 
 
Figure 2 ExREPCs were exposed to different O2 concentration (A and B) or hypoxia mimetics 
(C) for the indicated time points and Epo mRNA levels were measured by RT-qPCR. Data are 
expressed as mean ± SEM or mean alone. 
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Figure 3 
 
Figure 3 Stable HIF-1α and HIF-2α knockdown in exREPCs was generated by means of 
lentiviral transduction. Control (shCTR), HIF-1α silenced (shHIF-1α) and HIF-2α silenced (shHIF-
2α) cells were exposed to 0.2% O2 for 24 h and Epo, CAIX, PAI-1 (A), HIF-1α and HIF-2α (B) 
mRNA levels were measured by RT-qPCR. Efficiency of the knockdown is shown as % of 
shCTR cells and was evaluated at the protein level as well as by immunoblotting (C). Data are 
expressed as mean ± SEM. Statistics: student t-test, *p < 0.05, n.s. = not significant. 
 
Figure 4 
 
Figure 4 Kelly (A) and SH-SY5Y (B) were exposed to 0.2% O2 for the indicated time points and 
Epo mRNA levels were measured by RT-qPCR. Data are expressed as mean ± SEM or mean 
alone. 
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Retraction letter 
Frede S, Freitag P, Geuting L, Konietzny R, Fandrey J. Oxygen-regulated expression of the 
erythropoietin gene in the human renal cell line REPC. Blood. 2011;117(18):4905-4914. 
 
The Editors of Blood wish to retract the above-mentioned publication. 
The paper reported on a permanent human renal cell line, which was established from the 
tumor-free renal tissue of an anonymized male patient suffering from a kidney tumor. The cells, 
which were capable of hypoxia-inducible erythropoietin production and therefore termed renal 
erythropoietin producing cells (REPC), showed features of neuronal cells and were negative for 
hepatitis virus B. 
After publication, the authors have freely provided the cells to a number of researchers who 
requested them. One of the collaborators has brought to the authors’ attention that the REPC 
were contaminated with human Hep3B cells. Upon this, the authors have externally tested the 
cells including frozen aliquots of the youngest passage that were left after treating all REPC for 
mycoplasma infection. DNA profiling using 8 different and highly polymorphic short tandem 
repeat (STR) loci revealed that the REPC were cross-contaminated with Hep3B. STR profiles of 
the used cells matched the STR reference profile of the cell line Hep3B as indicated by a search 
of the STR database from the cell banks ATCC (United States), HPACC (United Kingdom), 
JCRB (Japan), RIKEN (Japan), KCLB (Korea) and DSMZ (Germany). Upon this, all groups who 
received cells were immediately informed about the contamination and have been asked to send 
back aliquots of the cells. These were again externally tested, but the contamination was 
confirmed. One collaborating group had identified different cell phenotypes in the REPC cultures 
by immunohistochemistry and tried to isolate single clones from the phenotypically different-
appearing cells. The latest STR profiling of the 2 clones, however, also revealed persisting 
cross-contamination with Hep3B. 
Thus, the authors notified Blood that they can currently neither provide cells that were described 
in the original publication nor reproduce the original results due to the lack of the cells. Because 
the cells should have served as an important new in vitro model or renal cells to study 
erythropoietin production, the authors and the Journal feel obliged to retract the above 
publication to avoid any further confusion about the existence of a permanent human renal 
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erythropoietin-producing cell line. The authors apologize for any inconvenience that the research 
community may have faced with REPC obtained directly from them or from other sources. 
All authors agree to the retraction. 
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Introduction 
In the last years, a number of proteins regulating the von Hippel-Lindau protein/prolyl-4-
hydroxylase domain/hypoxia-inducible factor (pVhl/PHD/HIF) pathway have been identified, 
some of them by our group (Köditz et al., 2007; Balamurugan et al., 2009; Wenger et al., 2009; 
Wenger and Hoogewijs, 2010; Wollenick et al., 2012; Chiang et al., 2013; Pawlus et al., 2013). 
We aimed to evaluate the effect of selected established as well as novel interactors of the 
oxygen-sensing signalling on erythropoietin gene (EPO) transcription in hypoxia. After 
measuring endogenous expression of such factors in Epo-producing cells, we chose to silence 
the genes of interest by small interfering or short hairpin RNAs (si- or shRNAs) in order to 
generate transient or stable deficient cells, respectively, and evaluate the consequences of the 
knockdown on Epo mRNA levels. Moreover, we combined the knockdown approach with 
luciferase reporter assays using constructs containing the Epo 5’ hypoxia-response element 
(HRE, see chapter 3) to investigate a potential effect/binding of the candidate factors on the 
novel regulatory element. When possible, overexpression of the gene of interest was used as a 
parallel strategy. A short overview of the analysed transcription factors and the rationale of our 
choice are provided in the results section. 
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Materials and methods 
Cell culture and reagent 
Hep3B, HepG2, exREPCs, Hek293T and PC-3 were cultured in DMEM (high glucose, Sigma-
Aldrich) supplemented with 10% heat-inactivated foetal calf -serum (FCS), 50 IU/ml penicillin 
and 50 µg/ml streptomycin (Invitrogen). Hypoxia experiments were carried out at the indicated 
concentration of oxygen and 5% CO2 in a gas-controlled glove box (InvivO2 400, Ruskinn 
Technologies). 
RNA extraction and quantitative PCR 
RNA was extracted by using the phenol-chloroform method and cDNA was generated by 
reverse transcription (RT) of 2 µg of total RNA using AffinityScript reverse transcriptase 
(Agilent). Transcript levels were quantified by quantitative (q) PCR using a SybrGreen qPCR 
reagent kit (Sigma-Aldrich) in combination with a MX3000P light cycler (Agilent) and the primers 
listed in table 1. Initial template concentrations were calculated by comparison with serial 
dilutions of a calibrated standard. Ribosomal protein L28 mRNA levels were used to normalize 
the data.  
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon size 
hL28 GCAATTCCTTCCGCTACAAC TGTTCTTGCGGATCATGTGT 198 bp 
hEpo TCACTGTCCCAGACACCAAA CCTCCCCTGTGTACAGCTTC 362 bp 
hETV-4 ACGGACTTCGCCTACGACTCA CCTGGCGACCTCCTCAGGCT 348 bp 
hVIM GAGAACTTTGCCGTTGAAGC TCCAGCAGCTTCCTGTAGGT 170 bp 
hCITED-2 GGAGCAGAAATCGCAAAAAC GACCCATGAACTGGGAGTTG 334 bp 
hCAIX GGGTGTCATCTGGACTGTGTT CTTCTGTGCTGCCTTCTCATC 309 bp 
hHIF-1α CATAAAGTCTGCAACATGGAAGGT ATTTGATGGGTGAGGAATGGGTT 148 bp 
hHIF-2α TTGATGTGGAAACGGATGAA GGAACCTGCTCTTGCTGTTC 196 bp 
hUSF-2 AAAAATTGATGGAACCAGAACACC TCCCGTCTTGCTGTTGTC 151 bp 
hPAI-1 ACTGGAAAGGCAACATGACC GAGGAAGGGTCTGTCCATGA 296 bp 
hVEGFA CTACCTCCACCATGCCAAGT TGGTGATGTTGGACTCCTCA 263 bp 
hATF-4 TCAAACCTCATGGGTTCTCC GTGTCATCCAACGTGGTCAG 226 bp 
hPAG-1 CTGATGAACGTGCCTTCAGA CATTTTGGTTTCCCTGTGCT 215 bp 
hDNMT3A TATTGATGAGCGCACAAGAGAGC GGGTGTTCCAGGGTAACATTGAG 111 bp 
Table 1 Primers used for qPCR amplification 
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Generation of stable knockdown cell lines 
Lentiviral expression vectors encoding the indicated shRNA sequences in a pLKO.1-puro 
plasmid were purchased from Sigma. Viral particles were produced in Hek293T cells by co-
transfection of the respective transfer vector (3 μg) with the packaging plasmids pLP1 (4.2 μg), 
pLP2 (2 μg) and pVSV-G (2.8 μg, all from Invitrogen) using polyethylenimine (PEI) transfection 
as described before (Stiehl et al., 2012). Cells were transduced with lentiviral-pseudotyped 
particles and cell pools were derived by puromycin selection. 
RNA interference 
Hep3B cells were plated at a density of 4×105 cells per single well of a 6-well plate or of 1.5x106 
per 10 cm dish. The day after, cells were transfected in fresh media with 300 pmol of the 
indicated siRNA duplexes (Invitrogen/Dharmacon) using Lipofectamine 2000 according to the 
manufacturer's protocol (Invitrogen). Cells were evenly split onto 24- or 6-well plates 24 h post 
transfection and exposed to 21% or 0.2% oxygen for an additional 24 h before analysis. 
Human Epo ELISA 
Hep3B cells were plated at a density of 4×105 cells per single well of a 6-well plate. The day 
after, medium was replaced with 1.5 mL of DMEM, containing 10% FCS and antibiotics and cells 
were exposed to 21% or 0.2% of oxygen for 8 or 24 h. Medium was collected on ice, centrifuged 
in order to remove cells in excess and stored at -80°C. Medium from an empty well (no cells) 
was used as a control for the experiment. Human Epo ELISA (human erythropoietin Quantikine 
IVD ELISA Kit, DEP000, R&D Systems) was performed according to the manufacturer’s 
instruction.  
Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using a high salt extraction buffer 
containing 0.4 M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 x protease inhibitory cocktail (Sigma-
Aldrich). Nuclear extracts were prepared using a low salt followed by a high salt extraction buffer 
containing 0.15 or 0.4 M NaCl, respectively, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 x protease inhibitory 
cocktail (Sigma-Aldrich). Protein concentrations were determined by the bicinchoninic acid assay 
method and up to 80 µg of cellular protein was subjected to immunoblot analyses. Membranes 
were probed with antibodies against HIF-1α (clone 54/HIF-1α, BD Transduction Laboratories), 
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HIF-2α (PAB12124, Abnova), ETV-4 (20580002, Novus Biologicals), USF-2 (N-18, SC-861; 
Santa Cruz Biotechnology), SP-1 (SC-59, Santa Cruz Biotechnology), ATF-4/CREB-2 (C-20, 
SC-200, Santa Cruz Biotechnology), PAG-1 (MAB0935, Abnova) and -actin (Sigma-Aldrich). 
Signals from HRP-coupled secondary antibodies were detected with ECL substrate (all Pierce) 
using a luminescent image analyser (LAS-4000, FUJIFILM). -actin was used as loading control 
for combined cytoplasmic and nuclear extracts, SP-1 was used as loading control for nuclear 
extracts. 
Chromatin immunoprecipitation (ChIP) 
ChIP experiments were performed as described previously (Wollenick et al., 2012) using 5 µg of 
anti-USF-2 (C-20, SC-862, Santa Cruz Biotechnolgy) or anti-flotillin antibody (H-104, SC-25506, 
Santa Cruz Biotechnology) as a negative control. ChIP samples were analyzed by RT-qPCR 
using the primers listed in table 2, designed to detect occupancy of the specified regions. To 
determine USF-2 occupancy, the change in cycle threshold relative to input DNA was calculated 
and expressed as a percentage. 
DNA region Forward primer (5’-3’) Reverse primer (5’-3’) 
Amplicon 
size 
Epo 5’-HRE GATGGAGCTGTGTCTCCCTG AGTGGCAATGTGGAGGTCTG 206 bp 
Downstream GGTGCTTGGTCAGGAGTTGA GACACGTTCTCGTCCAACCT 79 bp 
Epo 3’-HRE CAGCAGTGCAGCAGGTCCAGGTCC CGAGAGGTCAGACAGGCTGTGTGAG 89 bp 
PAI-1 
-248/-128 
GGCTTTTTGGGTCACCCGGCA ACCCCAATAGCCTTGGCCTGA 117 bp 
Table 2 Primers used for ChIP analysis 
Plasmids and luciferase assays 
The following overexpressing plasmids were used in combination with luciferase reporter vectors 
described in chapter 3: pcDNA3.1hygro2xFLAG-hUSF-1/2 (Invitrogen, (Pawlus et al., 2012)), 
pcDNA3.1nV5-hATF-4 (Invitrogen, (Köditz et al., 2007)) and pcDNA3.1-hGATA-2/-3/-4 
(Invitrogen, kindly provided by Chistof Dame, Charité-Universitätsmedizin Berlin, Germany). For 
reporter assays, 4x105 Hep3B cells were transiently transfected with 500 ng firefly expressing 
plasmid and 500 ng of overexpressing vector in a six-well format by PEI (polyethylenimine). To 
control for differences in transfection efficiency and extract preparation, 5 ng pRL-SV40, pRL-
CMV or pRL-TK Renilla luciferase reporter vectors (Promega) were co-transfected. Cultures 
were evenly split onto 24-well plates 24 h post transfection and exposed to 21% or 0.2% oxygen 
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for an additional 24 h. Luciferase activities of triplicate wells were determined using the Dual 
Luciferase Reporter Assay System according to the manufacturer’s protocol (Promega). 
Reporter activities were expressed as relative firefly/Renilla luciferase activities. All reporter 
gene assays were done at least 3 independent times. pH3SVL, PAI-1 and CAIX reporter 
constructs were previously described (Wanner et al., 2000; Pawlus et al., 2013). 
 
Results 
ETV-4 
The E-twenty six transcription factor ETS translocation variant 4 (ETV-4), also known as 
polyomavirus enhancer activator 3 (PEA3), belongs to the ETS family of transcription factors. 
These factors are  characterized by the ETS domain, capable of binding to DNA sequences with 
a 5′-GGA(A/T)-3′ core, even though factor-specific differences in preferential binding sites have 
been identified (Wei et al., 2010; Oh et al., 2012). ETV-1 and -5 are the closest relatives to ETV-
4, thus belonging to the same sub-family, and overlapping physiological roles have been 
demonstrated at least for ETV-4 and -5. Branching morphogenesis, where primitive epithelial 
buds bifurcate to generate arborized ducts or acinar structures during embryogenesis, is 
certainly a process in which ETVs play a role (Chotteau-Lelievre et al., 2003). ETV-4 and -5 
knockout mice failed to develop kidneys, while inactivation of single genes had no impact on 
nephrogenesis, suggesting that either gene can compensate for the other one in the context of 
kidney organogenesis (Lu et al., 2009). The main signalling pathways involved in kidney 
development include the glial cell derived neurotrophic factor/ret proto-oncogene  (GDNF/Ret) 
and the fibroblast growth factor 10 (FGF-10) axes which, upon activation, lead to ETV-4 and -5 
expression and activation (Costantini, 2010). Additionally, ETV-4 and -5 deficient animals 
showed defects in the reproductive function and both females and males were less fertile than 
control mice or even sterile, suggesting a role for ETVs in the reproductive system (Laing et al., 
2000; Eo et al., 2011). Erythroid parameters, such as RBC count or Epo plasma levels, have not 
been extensively studied in these animals. Well established is instead the oncogenic potential of 
ETVs in different cancer types, where they are often overexpressed and correlate with adverse 
outcome. Factors of the PEA3 family can function as oncogenes in breast cancer, prostate 
cancer and Ewing’s sarcoma, in which chromosomal translocations lead to formation of fusion 
proteins between the Ewing's sarcoma (EWS) gene and ETV-1 or -4. Moreover, the majority of 
prostate tumours display chromosomal translocations involving transmembrane protease serine 
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2 (TMPRSS2) and ETVs (Oh et al., 2012). ETVs can be regulated post-translationally by the E3 
ubiquitin ligase COP-1, which recognises specific amino acid binding motives and targets ETVs 
for degradation. Consistently, COP-1 has been shown to behave as a tumour suppressor gene 
in prostate cancer (Vitari et al., 2011). 
ETV-4 has been recently found to act as a broad co-activator of the HIF signalling. It contributed, 
among others, to PHD2 gene expression under hypoxic conditions and was able to form 
complexes with HIF-1α and -2α (Wollenick et al., 2012). This observation, together with the 
importance of ETV-4 expression in the kidney, the main source of Epo, prompted us to 
investigate the possible involvement of ETV-4 in Epo hypoxic regulation. 
We started by generating stable ETV-4 silenced cell lines by means of lentiviral transduction in 
exREPCs. The shRNA sequence used was remarkably efficient, both at the mRNA and protein 
levels (figure 1D, E and F), and analysis of vimentin (VIM) transcript, a known transcriptional 
target of ETV-4, confirmed functional silencing of the gene (figure 1C). Interestingly, Epo mRNA 
and protein levels were dramatically increased, both in normoxia and hypoxia in ETV-4 
knockdown compared to control cells (figure 1A and B). Hypoxic induction fold of Epo mRNA 
was not significantly different between the two cell lines (data not shown).  
Given the profound effect of ETV-4 knockdown on Epo mRNA and protein, we performed a more 
in-depth analysis of HIF-2, the main regulator of Epo transcription.We measured HIF-1α and -2α 
protein levels in normoxic and hypoxic cells and we could observe a significant and specific 
increase in HIF-2α levels in hypoxic ETV-4 deficient cells compared to control cells (figure 2A). 
Consistently, HIF-2 target gene Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2 (CITED-2) mRNA levels showed a trend of induction in ETV-4 knockdown 
exREPCs, whereas HIF-1 target gene carbonic anhydrase IX (CAIX) levels were similar to 
control cells (figure 2B). Taken together, these data indicate that knockdown of ETV-4 in 
exREPCs results in increased Epo levels both in normoxia and hypoxia and that this effect could 
be mediated by increased HIF-2α levels, at least in hypoxia. Knockdown of HIF-2α would be 
necessary to prove its involvement in Epo regulation by ETV-4. The effect on HIF-2α would 
however not explain the increase in Epo levels observed in normoxic conditions.  
The observations described above are based on a single sequence of shRNA directed against 
ETV-4 mRNA to generate stably silenced cell lines. To rule out shRNA off-target effects (Ramji 
et al., 2013; Fellmann and Lowe, 2014), we decided to knock ETV-4 down by using transient 
siRNA transfection or different shRNAs sequences in order to confirm its regulatory effect on 
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Epo. As shown in figure 3A, the strong increase in Epo mRNA observed in ETV-4 silenced cells 
was unfortunately not reproducible in exREPCs transfected with two different sets of siETV-4, 
despite very good knockdown efficiency. Two of the three siRNAs used showed a trend of 
increased Epo mRNA compared to the control siRNA (siETV-4 #1 and 3), but the effect was 
neither significant nor as dramatic as in the first round of stable knockdown (figure 1A). 
Moreover, a new series of ETV-4 deficient cells was generated with three different shRNAs 
targeting ETV-4, among which an identical sequence used in the first round (shETV-4 #33). 
Again, a slight increase in Epo mRNA could be observed with the most efficient shRNA (shETV-
4 #33), but the trend was not present with the other sequences used (figure 3B). To avoid 
potential unspecific effects due to the shCTR sequence, a shRNA targeting GFP was used in 
this experiment as a control (shGFP). 
Further complications came from the difficulties in measuring ETV-4 at the protein level. 
Different antibodies were tested for immunoblotting and, even if a band was recognized at the 
expected molecular weight (figure 1E), a pattern of multiple bands made it difficult to state which 
one really corresponded to ETV-4 protein. It must be mentioned that ETV-4 protein levels in 
exREPCs appeared to be lower compared to other cell lines, such as HepG2 or PC-3 (figure 
1E). Thus, we decided to test the effect of ETV-4 knockdown on Epo in cell lines with higher 
expression of the gene of interest, such as HepG2. However, stably ETV-4 deficient HepG2 cells 
did not show differences in Epo mRNA levels neither in normoxia nor in hypoxia compared to 
control cells (figure 4).  
In conclusion, the initial, pronounced effect of ETV-4 silencing on Epo mRNA levels observed in 
exREPCs could not be reproduced using independent methods or cell lines. Since the actual 
ETV-4 expression in renal Epo-producing cells in vivo is unknown, at the moment we cannot 
hypothesize an involvement of ETV-4 transcription factor in Epo regulation, despite its ability to 
regulate the oxygen-sensing pathway and interact with HIF-2α, at least in PC-3 cells (Wollenick 
et al., 2012). 
USF-2 
The second candidate factor we selected as a putative Epo regulator consists in the upstream 
stimulatory factor 2 (USF-2). USF-2 and its homolog USF-1, encoded by separate genes, are 
basic helix-loop-helix leucine-zipper transcription factors assembling in homo- or hetero-dimers 
to bind the E-box (CANNTG, where NN can be either GC or CG) core DNA sequence (Sirito et 
al., 1992). Non-canonical E-boxes or pyridine (Py)-rich initiator (Inr) sites can be bound by USFs 
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as well (Pawlus et al., 2012). The two isoforms mainly differ in the N-terminal activation domain, 
thus USF-1 and -2 can establish interactions with different transcriptional partners and have 
different impact on gene transcription. The E-box site can be bound by other transcription 
factors, such as the proto-oncogene c-Myc, well known to be involved in cell proliferation. USFs 
are ubiquitously expressed, albeit with tissue-specific differences, and the most abundant dimer 
in cell lines is usually represented by the USF-1/USF-2 heterodimer (Sirito et al., 1994). Hints on 
the physiological role of USF-2 come from animal experiments: USF-2 knockout mice showed 
clear growth defects after birth, with only 20% of the animals surviving this “critical period”, and 
lower body weight throughout adulthood (Vallet et al., 1997; Sirito et al., 1998). Interestingly, 
USF-2 expression was increased in USF-1-mutant mice (but not vice versa), suggesting that 
USF-2 can compensate for USF-1 loss, and an embryonic lethal phenotype was observed in 
double knockout mice, indicating that USFs are essential during development (Sirito et al., 
1998). Glucose metabolism was also impaired in USF-2-/- mice, which showed decreased 
expression of liver enzymes involved in glucose response (Vallet et al., 1997). The link with 
glucose is additionally suggested by increased USF-1 and -2 expression upon glucose treatment 
in vitro and in vivo (Kahn, 1997; van Deursen et al., 2008). Higher levels of USFs activate in turn 
transcription of genes involved in extracellular matrix deposition and consequent fibrosis. 
Indeed, USF-2 transgenic mice showed worse outcome when diabetic nephropathy was induced 
(Wang et al., 2004; Liu et al., 2007), as well as increased activation of the renin-angiotensin 
system, also contributing to the pathologic phenotype (Shi et al., 2009). In addition, iron overload 
is often observed in USF-2-deficient animals but likely due to disruption of the USF-2 genomic 
locus which is in close proximity to the hepcidin gene, encoding for the major iron-regulatory 
peptide, and resulting in silencing of hepcidin. Erythroid parameters were analyzed only in the 
latter USF-2-/- mouse model mentioned and did not show alterations in adult USF-2 mutant mice 
compared to WT (Nicolas et al., 2001).  
Our hypothesis of USF-2 as an Epo regulator relies on the cross-talk between USF and HIF 
pathways, which has been recently demonstrated in vitro. Recruitment of USFs to hypoxia-
induced gene promoters affected transcription in different cancer cell lines in opposite ways, 
depending on the arrangement of the binding sites. When HREs and E-boxes overlapped, 
competition between USF and HIF dimers occurred, with subsequent inhibition of the HRE-
dependent transcription. On the other hand, when the binding sites were close but not 
overlapping, mutual complementing effects were observed (Hu et al., 2011). Two reports in 
literature investigated the effect of USF-2 on HIF-2α specific target genes, including EPO. 
Knockdown of USF-2 significantly decreased hypoxic induction of several HIF-2, but not HIF-1, 
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target genes in Hep3B and USF-2 binding was detected on promoters and enhancer region of 
EPO and plasminogen activator inhibitor type 1 (PAI1) genes. USF-2 and HIF-2α were found to 
directly interact at the protein level and to recruit general activators of transcription, such as 
p300/CBP (Pawlus et al., 2012). Moreover, signal transducer and activator of transcription 3 
(STAT3C) and USF-2 seem to be involved in HIF-target specificity: their binding to regulatory 
regions of HIF-1 and HIF-2 target genes, respectively, was demonstrated in vitro, as well as their 
ability to directly interact with the specific HIF-α subunit. Knockdown of STAT3C or USF-2 
indeed resulted in impaired hypoxic inducibility of sets of HIF-1 or HIF-2 target genes (Pawlus et 
al., 2013).  Based on these data and considering the fact that EPO is one of the most hypoxia-
sensitive genes and a HIF-2 target, we aimed to study the effect of USF-2 
silencing/overexpression on Epo mRNA and to assess its putative binding on the newly 
discovered 5’-HRE. 
Transient USF-2 knockdown was generated in Hep3B cells by siRNA transfection, in parallel to 
HIF-2α knockdown as a positive control for blunted Epo hypoxic induction (figure 5). Two out of 
three siRNAs used resulted in efficient silencing of USF-2 at the mRNA level and, as expected, 
in reduced Epo transcript levels in hypoxia. CITED-2 mRNA was measured as an alternative 
HIF-2 target gene and displayed lower hypoxic induction in siHIF-2α and siUSF-2 #33 
transfected cells. We concluded that USF-2 silencing was able to decrease Epo hypoxic 
induction, even though this effect was significant only with one of the siRNAs used against USF-
2 mRNA and not as dramatic as in HIF-2α deficient cells or as previously reported (Pawlus et al., 
2012).    
In order to confirm the effect of USF-2 knockdown on Epo induction, we generated stably 
silenced Hep3B cells using two different shRNA sequences targeting USF-2. Figure 6 shows 
that efficient USF-2 knockdown (both at mRNA and protein levels) resulted in decreased amount 
of Epo mRNA upon hypoxic exposure of Hep3B. PAI-1 was used in this case as an alternative 
HIF-2 target gene and its transcript levels were indeed lower in USF-2 knockdown cells 
compared to control cells. It must be mentioned that PAI-1 levels differed a lot between WT and 
shCTR cells, a frequent observation in our hands. 
Since binding of USF-2 on the Epo 3’-HRE has already been demonstrated in Hep3B (Pawlus et 
al., 2012), we performed in silico analysis of putative USF binding sites in the region surrounding 
the novel 5’-HRE using the JASPAR database web server with default settings (Mathelier et al., 
2014) and found a consensus sequence for USF binding overlapping with the HIF binding site 
(HBS, figure 7). We next tested the activity of different Epo reporter constructs (described in 
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chapter 3) in USF-2 deficient cells, along with a PAI-1 promoter controlled vector as positive 
control (figure 8). USF-2 has previously been shown to contribute to PAI-1 hypoxic induction as 
well (Pawlus et al., 2013). In contrast to our expectations PAI-1 driven reporter activity was 
increased and not reduced in two different USF-2 silenced cell lines. Moreover, USF-2 
knockdown seemed to have an effect on Renilla activity as well and, despite testing different 
promoters, increased Renilla counts were observed with all the constructs used (SV40-, CMV- 
and TK- promoter driven Renilla), thus making normalization of the assay not reliable (figure 
8C). As no clear conclusion on the effect of USF-2 knockdown on Epo-reporter constructs could 
be drawn, we decided to switch to an overexpression system. The positive control PAI-1 reporter 
behaved as expected: increased firefly light units were measured when cells were co-transfected 
with USF-2, but not USF-1, overexpressing vector (figure 9). Nevertheless, the effect of USF-1 
and -2 on the 5’-HRE-containing constructs was again not clear: consistently with previous data 
in USF-2 knockdown cells, decreased Renilla counts were observed in the USF-1/2 transfected 
samples compared to the control, thus precluding normalization of the assay. Moreover, we 
could not recapitulate the positive effect of USF-2 overexpression on the Epo promoter/3’-HRE 
reporter construct described by Pawlus et al. (Pawlus et al., 2013). The set of luciferase assays 
performed with USF-2 deficient or overexpressing cells was not sufficient to draw conclusions on 
the putative effect of USF-2 on Epo newly discovered 5’-HRE. Thus, we decided to investigate 
possible binding of USF-2 on the DNA region surrounding the HRE by ChIP. Again, PAI-1 and 
Epo 3’-HRE were used as positive controls and showed specific enrichment for USF-2 binding in 
hypoxia (figure 10), as expected from published data (Semenza and Wang, 1992; Yeo et al., 
2008; Pawlus et al., 2013). However, no binding could be observed on Epo 5’-HRE, indicating 
that the USF-2 dependent Epo mRNA regulation seems to be mediated by the 3’- but not the 5’-
HRE. 
ATF-4 
The activating transcription factor (ATF) family consists of a number of basic-leucine zipper 
transcription factors with broad functions and the ability to bind to a common DNA consensus 
sequence. The ATF binding site is identical to the later discovered cAMP responsive element 
(CRE), characterized by the core sequence 5’-ACGT-3’ and bound by the CRE binding protein 
(CREB), one of the most well-known members of the ATF family (Deutsch et al., 1988; Lin and 
Green, 1989). Of note, ATF binding site can overlap with the HBS (5’-CGTG-3’), suggesting the 
possibility for a cross-talk with the HIF pathway. ATF-4 is a classical stress responsive gene: it is 
up-regulated at the transcriptional and translation level by different stress stimuli, including 
amino acid deprivation, endoplasmic reticulum (ER) stress, unfolded protein response (UPR), 
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oxidative stress and hypoxia. ATF-4 protein can interact with other members of the ATF family to 
form both homo- and hetero-dimers and act as a transcriptional activator or repressor, 
depending on the nature of the recruited co-factors (Ameri and Harris, 2008). ATF-4 is certainly 
known for its role in mediating the cellular response to ER stress: in condition of hypoxia or 
nutrient deprivation, unfolded or misfolded proteins accumulate in the ER and trigger the 
adaptive UPR, found already in yeast and conserved in mammalian cells (Alberts et al., 2002). 
The activation of the PKR-like endoplasmic reticulum kinase/eukaryotic translation initiation 
factor 2α (PERCK/eIF2α) pathway leads to AFT-4 stabilization and transcription of target genes, 
such as vascular endothelial growth factor (VEGF) and CCAAT/enhancer-binding protein 
homologous protein (CHOP), with the aim of ensuring amino acid availability for protein 
biosynthesis and protecting the cell form oxidative/hypoxic stress. When the cell cannot cope 
with the stress situation, UPR will ultimately result in apoptosis (Cullinan and Diehl, 2006).  
Hypoxia can induce ER stress and UPR, thus resulting in increased ATF-4 mRNA and protein 
levels in vitro and in vivo (Blais et al., 2004; Rzymski et al., 2010; Tagliavacca et al., 2012). 
Primary rat fibroblasts have been shown to induce ATF-4 in anoxia (Estes et al., 1995) and ATF-
4 levels were significantly higher in primary human tumours compared to corresponding normal 
tissues (Hiwatashi et al., 2011). More relevant to our aims, ATF-4 was identified as an 
interacting partner of PHD1 and PHD3, with subsequent changes in stability of the protein. In 
particular, PHD1 seemed to increase ATF-4 protein levels, while PHD3 had the opposite effect 
(Köditz et al., 2007; Hiwatashi et al., 2011). An oxygen-dependent degradation domain (ODDD) 
was additionally identified within ATF-4 amino acid sequence and a prolyl hydroxylation 
mechanism was proposed as the link between hypoxia and ATF-4 increased stability, similar to 
regulation of HIF-α subunits by oxygen (Köditz et al., 2007). The transcriptional effect of ATF-4 
has been demonstrated for a few hypoxia-induced genes, including VEGF, CAIX and Epo itself. 
In conditions of hypoxia, activation of the PERCK/ATF-4 arm of the UPR pathway led to 
increased VEGF transcription and angiogenesis in different tumour models (Wang et al., 2012; 
Pereira et al., 2014). Moreover, ATF-4 directly interacted with HIF-1α in hypoxic osteoblasts in 
vitro and prevented its degradation, acting as a broad regulator of the HIF pathway (Zhu et al., 
2013). The classical HIF-1 target gene CAIX can also be regulated by direct binding of ATF-4 on 
its promoter region, at least in vitro, and defects in ER stress response have been shown to 
impair CAIX transcription in hypoxia (van den Beucken et al., 2009). A recent report in literature 
investigated the effect of UPR on Epo transcription in HepG2 cells, both in basal conditions and 
after treatment with cobalt chloride, a hypoxia mimetic. Induction of ER stress led to increased 
ATF-4 levels, subsequent binding of the transcription factor to the Epo 3’-HRE and specific 
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inhibition of Epo transcription (Chiang et al., 2013). In addition to the in vitro data, ATF-4 
knockout mice showed impaired development of the embryonic lens of the eye and severe foetal 
anaemia, persisting as mild anaemia in adult animals (Masuoka and Townes, 2002), suggesting 
again a link with Epo production, probably before birth. We therefore decided to investigate the 
effect of ATF-4 knockdown/overexpression in our Epo-expressing cell models and the possibility 
for ATF-4 to regulate Epo by binding to the 5’-HRE. 
Generation of stably ATF-4 silenced Hep3B turned out to be problematic despite testing different 
shRNA sequences for knockdown efficiency. The highest silencing efficiency we could obtain 
was around 50% at the mRNA level and probably insufficient to detect effects on downstream 
target genes, such as VEGF and CAIX (figure 11). Detection of ATF-4 protein by immunoblotting 
proved to be equally challenging, due to antibody specificity issues. We observed no significant 
differences in Epo mRNA between control and shATF-4 cells but we could not exclude that the 
lack of any apparent regulation was due to inefficient silencing. We next screened for putative 
CREs in the region surrounding the Epo 5’-HRE in order to proceed with reporter assays 
combined with an overexpression approach. We made use of rVista, an online comparative 
genomics tool that aligns genomic DNA sequences of different species (human and mouse in 
this case) and searches for conservation of consensus transcription factor binding sites, 
implementing TRANSFAC database profiles (Loots et al., 2002). Indeed, rVista analysis showed 
a possible ATF-4 binding site shortly downstream of the HRE, with a spatial arrangement similar 
to Epo 3’ enhancer (figure 12, (Chiang et al., 2013)). Based on the in silico data, we 
overexpressed ATF-4 or an empty control vector and evaluated the effect on different Epo 
reporter constructs, as well as on HIF-1 and HIF-2 specific reporters. None of the vectors used 
showed differences in terms of luciferase activity between control and ATF-4 overexpressing 
cells (figure 13). Importantly, CAIX reporter, used as a positive control (van den Beucken et al., 
2009), was also not affected by ATF-4 overexpression. We therefore concluded that no effect of 
ATF-4 on Epo transcription can be observed in Hep3B cells neither in normoxia nor in hypoxia, 
at least under our experimental conditions. 
GATA factors 
As previously mentioned, GATA factors are established regulators of Epo transcription and 
tissue specific expression. The name of these transcription factors is derived from the DNA 
sequence of the binding site and up to now 6 members of the family have been identified 
(GATA-1 to -6) (Shimizu and Yamamoto, 2005). Known as master regulators of haematopoiesis, 
GATAs are zinc finger transcription factors expressed in a variety of tissues, including kidney 
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and liver. In normoxic conditions, GATA-2 and -3 have been shown to repress Epo transcription 
by binding to the GATA box present 30 bp upstream of the Epo transcriptional start site. Upon 
hypoxic exposure, GATA-2 and -3 binding markedly decreased along with dramatic Epo 
induction in vivo (Imagawa et al., 1997). GATA-2 and -3 expression was inversely correlated 
with Epo expression, the opposite of what has been observed for GATA-4, which followed Epo 
expression pattern in the post-natal switch from liver to kidney. Indeed GATA-4 was able to bind 
the same GATA box in the Epo minimal promoter and its knockdown led to impaired Epo 
transcription in hepatoma cell lines (Dame et al., 2004). The GATA binding site within the Epo 
promoter is fundamental to restrict Epo expression to specific cell types in vivo: a single 
nucleotide mutation in the GATA box resulted in constitutive ectopic Epo production by the renal 
distal tubule, the collecting duct and a certain population of epithelial cells in other tissues 
(Obara et al., 2008).  
In order to evaluate putative binding of GATAs to the novel Epo 5’-HRE surrounding region, we 
applied the same approach used for the aforementioned transcription factors and started by 
performing an in silico analysis for predicted GATA boxes with the JASPAR database. As shown 
in figure 14, one such site was predicted in the region of interest; hence we overexpressed 
GATA-2, -3 and -4 together with the different Epo reporter constructs described in chapter 3 
(figure 15). GATA-2 and -3 had an inhibitory effect on the Epo promoter-containing vectors, 
while GATA-4 showed the opposite trend, as expected. Unfortunately, addition of the 5’-HRE did 
not lead to significant changes in luciferase activity compared to the vectors containing the Epo 
promoter alone. As we only used the 100 bp (figure 15) and 300 bp (data not shown) long 
regions surrounding the HRE for this set of experiments, we cannot exclude that the GATA 
factors are able to bind outside of these fragments and regulate Epo transcription through the 5’ 
kidney-inducible element as well.        
DNMT3A 
DNA methyl transferases (DNMTs) are a family of enzymes deputed to methylation at position 5 
of cytosine within the CpG dinucleotide, an epigenetic marker of gene silencing (see 
introduction). Among this family, DNMT3A and 3B are responsible for de novo post-replicative 
DNA methylation but can also participate in maintenance of methylation pattern at 
heterochromatic, transcriptionally inactive regions (Okano et al., 1998). The expression of 
DNMT3A and 3B is high during embryogenesis and in undifferentiated cells and declines with 
development. Nevertheless, DNMT3A remains ubiquitously expressed at detectable levels 
(Jurkowska et al., 2011). DNMTs are essential for embryogenesis, as demonstrated by 
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embryonic or post-natal lethality of mice with inactivation of such genes (Li et al., 1992; Okano et 
al., 1999). Alterations in the genome methylation patter have deleterious consequences on gene 
expression and are thus often implicated in tumour progression: it is not surprising that 
mutations in DNMT3A have been identified in patients with acute myeloid leukemia (Ley et al., 
2010; Yan et al., 2011) and associated to solid tumours (Kim et al., 2013). A recent publication 
by the group of Stephen Lee reported methylation and subsequent silencing of EPAS1, the gene 
encoding for HIF-2α, by DNMT3A in kidney primary cells and cell lines. Moreover, naturally 
occurring defects in DNMT3A were observed in kidney tumours, preventing silencing of HIF-2α 
and thus allowing the malignant cell to proliferate in hypoxic conditions (Lachance et al., 2014). 
We therefore aimed to modulate DNMT3A levels in Hep3B and evaluate a putative effect on 
HIF-2α and Epo expression. 
After checking DNMT3A expression at the mRNA level in our cell model, we transiently knocked 
it down by siRNA transfection (figure 16). We used 3 different siRNAs, all efficiently targeting the 
gene of interest but obtained conflicting reulsts in terms of HIF-2α and Epo transcript levels. In 
particular, increased expression of HIF-2α upon DNMT3A knockdown, as expected from the 
work of Lachance and colleagues (Lachance et al., 2014), could not be recapitulated in our 
hands. 
PAG-1 
Phosphoprotein associated with glycosphingolipid-enriched mircodomains 1 (PAG-1), also 
known as C-terminal kinase (Csk)-binding protein (Cbp), is a transmembrane adapter protein 
broadly expressed in lipid rafts of mammalian cells. The main function of PAG-1 is to inhibit the 
ubiquitous Src pathway by binding to its main regulator, Csk (Brdic̆ka et al., 2000; Kawabuchi et 
al., 2000). Given the pro-proliferative, pro-angiogenic and ultimately transforming effect of Src 
pathway constitutive activation, it is not surprising that PAG-1 expression levels were associated 
with tumour progression due to its ability to regulate Src family kinases (Src, Fyn, Lyn, Yes, Hck, 
Lck, Blk, Fgr, Yrk). Depending on the origin of the tumour, PAG-1 has been proposed as an 
oncogene, like in renal cell carcinoma (Feng et al., 2009), or as a tumour-suppressor gene, like 
in colon cancer and non-small cell lung cancer (Oneyama et al., 2008; Kanou et al., 2011). 
Moreover, PAG-1 was recently identified as a hypoxia-induced gene with moderate but 
consistent induction of mRNA and protein levels in vitro and in vivo (Schörg et al., in 
preparation). Our interest in PAG-1 as a possible Epo regulator arises from studies investigating 
the stabilizing effect of Src kinases on HIF proteins. Src activation has been shown to inhibit 
hydroxylation of the HIF-1α subunit, thus leading to its stabilization even in normoxia in renal 
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carcinoma cell lines (Chan et al., 2002; Lee et al., 2011). The proposed mechanism is based on 
increased reactive oxygen species (ROS) production by Src, decreased vitamin C and 
subsequent PHD activity inhibition (Lee et al., 2011). VEGF transcription can also be 
downstream of Src pathway activation, since Src-deficiency or overexpression of dominant 
negative Src variants impaired VEGF induction in hypoxia (Mukhopadhyay et al., 1995). We 
therefore postulated a similar HIF-stabilizing effect by the PAG-1/Src axis followed by increased 
Epo synthesis and tested the hypothesis in our Epo-expressing cell models. 
We confirmed hypoxic induction of PAG-1 mRNA in Hep3B exposed to different % of oxygen 
and for different time points (figure 17A). However, induction of PAG-1 at the protein level 
seemed to be much less pronounced compared to mRNA in this cell line, at least after 24 h at 
0.2% O2 (figure 17D: representative immunoblot). We efficiently knocked down PAG-1 with two 
different shRNA targeting sequences but could not see any significant changes in Epo mRNA 
levels; HIF-2α deficient cells were used alongside as a control for Epo regulation (figure 17B and 
C). Taken together, these data indicate no effect of PAG-1 silencing on Epo regulation in Hep3B 
cells under the experimental conditions used. 
 
Discussion 
In this study we investigated the role of several factors directly or indirectly involved in the 
PHD/HIF pathway on Epo regulation. Due to the lack of a more appropriate cell model the 
hepatoma cell line Hep3B was used for our studies. These cells are known to strongly induce 
Epo mRNA upon hypoxic exposure (Goldberg et al., 1987) and we could nicely reproduce Epo 
induction in our hands too (see chapter 5). As already mentioned, our main focus is Epo 
regulation in the kidney but culturing of renal Epo-producing cells (REPCs) has been so far 
unsuccessful. Thus, we used a liver-derived cell model, which is likely to have a different 
expression profile compared to kidney cells and does not fully recapitulate what can be observed 
in REPCs in vivo. Indeed, in vivo data from REPCs regarding the expression of the studied 
factors are lacking and would be useful for optimal choice of relevant candidates.  
ETV-4 is expressed in whole mouse kidney in vivo and was recently shown to act as a broad co-
activator of the HIF pathway (Wollenick et al., 2012). Since its interaction with HIF-2α, the main 
Epo regulator, was demonstrated in vitro, we investigated a potential ETV-4 effect on Epo 
transcription. Our experiments in Hep3B cells revealed that ETV-4 has no significant or 
reproducible effect on Epo regulation (figure 3). ETV-4 expression levels in Hep3B are not as 
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high as in other cell lines, such as PC-3 (figure 1E), again suggesting that the cell model used 
could not be optimal to study a putative ETV-4 dependent regulation effect on Epo transcription. 
We evaluated Epo expression in PC-3 and other abundant ETV-4 expressing cell lines but, as 
expected, we could not detect any Epo mRNA product after exposure to hypoxia (data not 
shown), making these cells not suitable to study Epo regulation. On the other hand, HepG2 cells 
showed higher levels of ETV-4 protein (figure 1E) and knockdown of ETV-4 in these cells did not 
result in significant changes in Epo mRNA levels (figure 4). Moreover, we could not show the 
general effect of ETV-4 knockdown on HIF-target genes that was previously observed in PC-3 
cells (Wollenick et al., 2012). Expression levels of broadly hypoxia-inducible genes including 
CAIX, PHD2 and PHD3 were for instance unchanged between control and ETV-4 silenced cells 
(data not shown). ETV-5 is the second most important member of the PEA3 family of 
transcription factors and can compensate in certain cases for ETV-4 loss, as demonstrated by 
single mutant mice generation (Lu et al., 2009). However, ETV-5 expression was not 
significantly increased in ETV-4 knockdown cells, at least at the mRNA level (data not shown). It 
is likely that simultaneous knockdown of both members of the PEA3 family, ETV-4 and -5, is 
necessary to observe any effect on HIF target genes, including Epo. 
USF-2 is also expressed in the kidney in vivo and its effect as a general co-activator of HIF-2 
target genes has been demonstrated in the very same cell model we used, namely Hep3B 
(Pawlus et al., 2013). In particular, binding of USF-2 on Epo regulatory regions (minimal 
promoter and 3’ enhancer) was observed upon hypoxic exposure and the factor was co-
immunoprecipitated with HIF-2α subunit. The goal of this sub-project was to assess possible 
binding of USF-2 on the 5’-HRE surrounding region as well. We first confirmed reduced Epo 
hypoxic induction in USF-2 silenced cells via two independent approaches (transient and stable 
knockdown of the gene, figures 5 and 6), even though the effect was not as dramatic as 
previously shown (Pawlus et al., 2012) and not significant for the other HIF-2 target genes 
tested, CITED-2 and PAI-1. We continued with a series of reporter assays combining 
knockdown and overexpression of USF-2 with different Epo reporter constructs (see chapter 3). 
Unfortunately, luciferase assays gave unclear results due to variation in the activity of the 
normalizing Renilla gene and sometimes due to the controversial results of the control reporter 
vector (PAI-1 promoter driven firefly gene, figures 8 and 9). Finally, we performed ChIP 
experiments with an anti-USF-2 antibody but could not observe any enrichment in USF-2 
occupancy of the 5’-HRE region. The fragment taken in consideration for the reporter and ChIP 
assays is 290 bp long, corresponding to the most conserved region around the 5’-HRE: we 
cannot rule out the possibility that the USF-2 binding site is further away from the HRE. 
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Nevertheless, based on these data the USF-2 dependent Epo regulation seems to be entirely 
mediated by regulatory regions other than the 5’-HRE. 
The interaction of ATF-4 with the PHD/HIF pathway has been demonstrated in vitro and the 
effect of ER-stress response pathways, with subsequent ATF-4 activation, was shown in Hep3B 
to downregulate Epo hypoxic expression (Köditz et al., 2007; Hiwatashi et al., 2011; Chiang et 
al., 2013). The main problems encountered in this part of our study consisted in the low degree 
of knockdown achieved by shRNA transduction and in ATF-4 protein detection issues. Based on 
our results we cannot conclusively state whether silencing of ATF-4 has a significant impact on 
Epo mRNA levels. Luciferase assays showed no effect of ATF-4 overexpression on Epo 
reporters (figure 13); it must be mentioned however that CAIX promoter driven reporter 
construct, used as a control, also did not show the expected results (van den Beucken et al., 
2009), making the interpretation of this set of experiment inconclusive. The above cited reports 
studying ATF-4 and HIF pathway interplay made use of compounds such as tunicamycin and 
thapsigargin to activate UPR and stabilize ATF-4 levels. Hence, another way to investigate ATF-
4 dependent Epo regulation could be to treat Hep3B cells with the same compounds and 
activate a signalling cascade resulting in increased ATF-4 levels.    
The link between the GATA factors and Epo regulation and the essential role of such factors for 
Epo tissue specificity are well established both in vitro and in vivo (Imagawa et al., 1997; Dame 
et al., 2004; Obara et al., 2008). A series of evidences speak for the novel Epo 5’-HRE as a 
region contributing to kidney-specific Epo expression, in a similar way to the well characterized 
3’ liver-inducible element. Animal experiments demonstrated that it is located within the putative 
kidney-inducible element, it contains a functional HRE, endogenous HIF-2α specifically binds to 
the HRE in hypoxic Hep3B cells and the surrounding region is extremely conserved in 
mammalian species (see chapter 3). Thus, we investigated binding of the GATA factors to the 
putative kidney inducible element by overexpressing GATA-2, -3 and -4 in our Epo reporter 
system. As expected, GATA-2 and -3 showed inhibition of reporter activity at different extent, 
with GATA-3 being the most effective factor; on the other hand, GATA-4 displayed an increase 
in luciferase activity. Addition of the 5’-HRE did not lead to significant changes compared to the 
vectors containing Epo minimal promoter and the 3’-HRE (figure 15). Once again, interpretation 
of the results is difficult due to variation in the Renilla reporter gene. Knock down of single GATA 
factors and ChIP experiments are required in order to draw conclusions about the effect and 
binding of the GATAs on the novel regulatory region. Moreover, GATA expression level in 
hepatoma cells is relatively high: an additional strategy consists in repeating the panel of 
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overexpression experiments in cells with low endogenous GATA factor expression, in order to 
avoid any background effect. 
In regards to DNMT3A as a regulator of the HIF pathway, we did not obtain promising results by 
transient knockdown in Hep3B cells (figure 16). Since DNMT3A acts after replication of the cell 
DNA in order to maintain the methylation pattern throughout progeny, a possible explanation 
could be that our time window was too short and did not allow cells to replicate or to have a 
detectable effect on mathylation. A deeper analysis of EPAS1 promoter methylation status, for 
instance via bisulfite treatment followed by DNA sequencing, would be necessary to set up the 
best experimental conditions. 
We could instead conclusively show that silencing of PAG-1 did not influence Epo mRNA levels, 
neither in normoxia nor in hypoxia in hepatoma cells (figure 17). PAG-1 is a negative regulator of 
the Src family of kinases (Brdic̆ka et al., 2000), which has been shown to stabilize HIFs in cancer 
(Chan et al., 2002; Lee et al., 2011). Our lab showed that PAG-1 is a hypoxia-regulated gene in 
a series of cancer cell lines (Schörg et al., in preparation) and we could confirm induction at the 
mRNA level in Hep3B as well. Nevertheless, no significant changes in Epo mRNA levels were 
observed upon PAG-1 knockdown. 
In conclusion, none of the analysed candidate factors showed specific effect on the newly 
discovered Epo 5’-HRE regulatory region under our experimental conditions. More extensive 
ChIP experiments would be required for some of the transcription factors, like USF-2 and the 
GATAs, to draw definitive conclusions on their effect on the 5’-HRE. ETV-4, ATF-4 and PAG-1 
seem less promising candidate to further investigate. Since the in vitro model used is not 
appropriate to study renal Epo regulation, our lab is currently developing a transgenic mouse 
model expressing tamoxifen-inducible Cre recombinase under the control of a large 220 kb Epo 
locus (Epo-Cre) to be crossed with mice carrying floxed genes of interest. In this way, knockout 
of the candidate gene occurs specifically in Epo-producing cells, allowing in vivo investigation of 
the so far in vitro unavailable REPCs. Preliminary results obtained with Epo-Cre mice crossed 
with a Tomato reporter strain (Rosa26-Stop-tdTomato) displayed promising Tomato expression 
in peritubular, fibroblast-like cells in the kidney and co-localization with the interstitial fibroblast 
marker CD-73 , validating targeting of the renal Epo producing cells (unpublished data from Sara 
Santambrogio, Aurelia Lelli and Lisa Crowther) and recapitulating very recent results from the 
Yamamoto group with a non-inducible 180 kb Epo-Cre transgenic model (Yamazaki et al., 
2013). This novel tool will allow in the future dissection of the role of the aforementioned 
candidate factors in Epo regulation in a relevant physiological context. 
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Figure 1 
 
Figure 1 Stable ETV-4 knockdown in exREPCs was generated by means of lentiviral 
transduction. Wild type (WT), control (shCTR) and ETV-4 silenced (shETV-4) cells were 
exposed to 0.2% O2 for the indicated time points and Epo mRNA (A) and protein (B) levels were 
measured by RT-qPCR and ELISA, respectively. Knockdown efficiency was evaluated by 
measuring VIM (C) and ETV-4 (D) mRNA, as well as ETV-4 protein levels (E. representative 
immunoblot, PC-3 cells are known to express high endogenous levels of ETV-4 and were used 
as a positive control; F. quantification of different experiments). Efficiency of the knockdown is 
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shown as % of shCTR cells. All data are expressed as mean ± SEM or mean alone. Statistics: 1-
way ANOVA, Tukey post-test, *p < 0.05.  
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Figure 2 
 
Figure 2 Wild type (WT), control (shCTR) and ETV-4 silenced (shETV-4) cells were exposed to 
0.2% O2 for the indicated time points and HIF-1α and -2α protein (A) levels were measured by 
immunoblotting (quantification of different experiments). HIF-target genes CAIX and CITED-2 
mRNA levels were measured in shCTR and shETV-4 cells by RT-qPCR (B). All data are 
expressed as mean ± SEM or mean alone. Statistics: student’s t-test, * = p < 0.05, ***p < 0.001. 
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Figure 3 
 
Figure 3 Transient (A) and stable (B) ETV-4 knockdown in exREPCs was generated by means 
of siRNA transfection and lentiviral transduction, respectively. Wild type (WT), control 
(siCTR/shGFP) and ETV-4 silenced (si/shETV-4) cells were exposed to 0.2% O2 for 24 h and 
Epo and ETV-4 mRNA levels were measured by RT-qPCR. Efficiency of the knockdown is 
shown as % of siCTR/shGFP cells. All data are expressed as mean ± SEM. 
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Figure 4 
 
Figure 4 Stable ETV-4 knockdown in HepG2 was generated by means of lentiviral transduction. 
Control (shCTR) and ETV-4 silenced (shETV-4 #33 and #35) cells were exposed to 0.2% O2 for 
24 h and Epo and ETV-4 mRNA levels were measured by RT-qPCR. 
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Figure 5 
 
Figure 5 Transient USF-2 knockdown in Hep3B was generated by siRNA transfection. Wild type 
(WT), control (siCTR) and USF-2 silenced (siUSF-2) cells were exposed to 0.2% O2 for 24 h and 
Epo (A), CITED-2 (B), USF-2 (C) and HIF-2α (D) mRNA levels were measured by RT-qPCR. 
Efficiency of the knockdown is shown as % of siCTR cells. All data are expressed as mean ± 
SEM. Statistics: Student’s t-test, *p < 0.05, **p < 0.01.  
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Figure 6 
 
Figure 6 Stable USF-2 knockdown in Hep3B was generated by means of lentiviral transduction. 
Wild type (WT), control (shCTR) and USF-2 silenced (shUSF-2 #34 and #37) cells were 
exposed to 0.2% O2 for 24 h and Epo mRNA (A), PAI-1 (B) and USF-2 (C) levels were 
measured by RT-qPCR. Knockdown efficiency was evaluated at the protein level as well (E. 
representative immunoblot, D. quantification of different experiments). All data are expressed as 
mean ± SEM or mean alone.  
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 Figure 7 
                                                           
                                                             
 Figure 7 Sequence of human genomic DNA surrounding the novel Epo 5’-HRE on the long arm 
of chromosome 7 (UCSC genome browser): the HRE is underlined (CACA repeat + HBS) and 
the putative USF binding site is highlighted in blue. Prediction of USF binding site was performed 
using the JASPAR database with a relative profile score threshold of 80 % 
(http://jaspar.genereg.net/cgibin/jaspar_db. pl?rm=browse&db= core&tax_group=vertebrates).  
 
 
 
 
 
 
 
 
 
>hg19_dna range=chr7:100309066-100309368 
TCAGGCCACATCCTTTCCATCAGCCTGACTGCAAGGCTTCCTTGCCCGGGAGCC 
CCCCAGTAGCCGAGCGGGGAGCCGGCAGGAAGCTGGATGGAGCTGTGTCTCCCT 
GCACGTATGTGCTCCGGGCCTGAGCCCAGCAGAGGTGGTGGCAGGCAGCCTTTC 
CCATCTGGTTTGTTTTGGCAGTTCCCTCCTGCAGCCTATTTGTTTGTTGTTTCT 
ACTCCATGTTTTCTCACTGCTTGCCAGTGGGGCTTCCCTCAGTGGCAGTTCTGC 
AGAAACAGACCTCCACATTGCCACTGAAGGAAG 
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Figure 8 
 
Figure 8 Control (shCTR) and USF-2 silenced (shUSF-2 #34 and #37) Hep3B were co-
transfected with the indicated firefly constructs (see chapter 3) and an SV40-driven Renilla 
construct as transfection control. Results are displayed as R.L.U. (A), firefly counts (B) or Renilla 
counts (C); all data are expressed as mean ± SEM. 
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Figure 9 
 
Figure 9 The indicated firefly constructs (see chapter 3) were co-transfected in Hep3B with an 
empty control or a USF-1/-2 overexpressing vector and an SV40-driven Renilla construct as 
transfection control. Results are displayed as R.L.U. (A), firefly counts (B) or Renilla counts (C); 
all data are expressed as mean ± SEM.  
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Figure 10 
 
Figure 10 ChIP was performed in normoxic or hypoxic (0.2% O2, 24 h) Hep3B cells using 
control (CTR) or USF-2 specific antibodies. (A) The amount of co-precipitated chromatin derived 
from human Epo 5'-HRE, its downstream region and 3'-HRE was determined by qPCR. The 
scheme depicts the different primer regions used for the experiment. (B) PAI-1 promoter was 
used as additional positive control. Data are expressed as mean ± SEM of chromatin input %.  
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Figure 11 
 
Figure 11 Stable ATF-4 knockdown in Hep3B was generated by means of lentiviral 
transduction. Wild type (WT), control (shCTR) and ATF-4 silenced (shATF-4 #76 and #77) cells 
were exposed to 0.2% O2 for 24 h and Epo mRNA (A), VEGF (B), CAIX (C) and ATF-4 (D) 
levels were measured by RT-qPCR. Knockdown efficiency was evaluated at the protein level as 
well using HeLa cells transfected with an ATF-4 overexpressing plasmid (o/e) as positive control 
(E. representative immunoblot). All data are expressed as mean ± SEM. 
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Figure 12 
                              
Figure 12 Sequence of human genomic DNA surrounding the novel Epo 5’-HRE on the long 
arm of chromosome 7 (UCSC genome browser): the HRE is underlined (CACA repeat + HBS) 
and the putative ATF-4 binding site is highlighted in green. Prediction of ATF-4 binding sites was 
performed using the rVista webserver (http://genome.lbl.gov/vista/rvista/submit.shtml) based on 
homology between human and mouse genomic sequences. 
>hg19_dna range=chr7:100309066-100309368 
TCAGGCCACATCCTTTCCATCAGCCTGACTGCAAGGCTTCCTTGCCCGGGAGCCCCCCAG
TAGCCGAGCGGGGAGCCGGCAGGAAGCTGGATGGAGCTGTGTCTCCCTGCACGTATGTGC
TCCGGGCCTGAGCCCAGCAGAGGTGGTGGCAGGCAGCCTTTCCCATCTGGTTTGTTTTGG
CAGTTCCCTCCTGCAGCCTATTTGTTTGTTGTTTCTACTCCATGTTTTCTCACTGCTTGC
CAGTGGGGCTTCCCTCAGTGGCAGTTCTGCAGAAACAGACCTCCACATTGCCACTGAAGG
AAG 
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Figure 13 
 
Figure 13 The indicated firefly constructs (see chapter 3) were co-transfected in Hep3B with an 
empty control or an ATF-4 overexpressing vector and an SV40-driven Renilla construct as 
transfection control. Results are displayed as R.L.U. (A), firefly counts (B) or Renilla counts (C); 
all data are expressed as mean ± SEM.  
Unpublished results: candidate factors involved in Epo regulation 
 
141 
 
Figure 14 
                           
Figure 14 Sequence of human genomic DNA surrounding the novel Epo 5’-HRE on the long 
arm of chromosome 7 (UCSC genome browser): the HRE is underlined (CACA repeat + HBS) 
and the putative GATA factors binding site is highlighted in red. Prediction of GATA factors 
binding site was performed using the JASPAR database with a relative profile score threshold of 
80 % (http://jaspar.genereg.net/cgibin/jaspar_db.pl?rm=browse&db=core&tax_group= 
vertebrates).  
 
>hg19_dna range=chr7:100309066-100309368 
TCAGGCCACATCCTTTCCATCAGCCTGACTGCAAGGCTTCCTTGCCCGGGAGCCCC
CCAGTAGCCGAGCGGGGAGCCGGCAGGAAGCTGGATGGAGCTGTGTCTCCCTGCAC
GTATGTGCTCCGGGCCTGAGCCCAGCAGAGGTGGTGGCAGGCAGCCTTTCCCATCT
GGTTTGTTTTGGCAGTTCCCTCCTGCAGCCTATTTGTTTGTTGTTTCTACTCCATG
TTTTCTCACTGCTTGCCAGTGGGGCTTCCCTCAGTGGCAGTTCTGCAGAAACAGAC
CTCCACATTGCCACTGAAGGAAG 
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Figure 15  
 
Figure 15 The indicated firefly constructs (see chapter 3) were co-transfected in Hep3B with an 
empty control or a GATA-2, -3 or -4 overexpressing vector and an SV40-driven Renilla construct 
as transfection control. Results are displayed as R.L.U. (A), firefly counts (B) or Renilla counts 
(C); all data are expressed as mean ± SEM.  
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Figure 16 
 
Figure 16 Transient DNMT3A knockdown in Hep3B was generated by siRNA transfection. Wild 
type (WT), control (siCTR) and DNMT3A silenced (siDNMT3A) cells were exposed to 0.2% O2 
for 24 h and Epo (A), DNMT3A (B), CAIX (C) and HIF-2α (D) mRNA levels were measured by 
RT-qPCR. All data are expressed as mean alone.  
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Figure 17 
 
Figure 17 PAG-1 expression was measured at the mRNA level by RT-qPCR in exREPCs 
exposed to 21, 1 or 0.2% O2 for the indicated time points (A). Stable PAG-1 knockdown in 
exREPCs was generated by means of lentiviral transduction. Control (shCTR) and PAG-1 
silenced (shPAG-1 #70 and #72) cells were exposed to 0.2% O2 for 24 h and Epo mRNA (B) 
and PAG-1 (C) levels were measured by RT-qPCR. Efficiency of the knockdown is shown as % 
of shCTR and was evaluated at the protein level as well (D. representative immunoblot). All data 
are expressed as mean ± SEM or mean alone. 
 
Unpublished results: candidate factors involved in Epo regulation 
 
145 
 
References 
Alberts B, et al. (2002) Molecular biology of the cell, 4th Edition. New York, Garland Science. 
Ameri K, et al. (2008) Activating transcription factor 4. The International Journal of Biochemistry 
& Cell Biology 40(1): 14-21. 
Balamurugan K, et al. (2009) Onconeuronal cerebellar degeneration-related antigen, Cdr2, is 
strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic 
response. Oncogene 28(37): 3274-3285. 
Blais JD, et al. (2004) Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic 
Stress. Molecular and Cellular Biology 24(17): 7469-7482. 
Brdic̆ka T, et al. (2000) Phosphoprotein associated with glycosphingolipid-enriched 
microdomains (Pag), a novel ubiquitously expressed transmembrane adaptor protein, 
binds the protein tyrosine kinase Csk and is involved in regulation of T cell activation. 
The Journal of Experimental Medicine 191(9): 1591-1604. 
Chan DA, et al. (2002) Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible 
factor-1α. Journal of Biological Chemistry 277(42): 40112-40117. 
Chiang C-K, et al. (2013) Endoplasmic reticulum stress signal impairs erythropoietin production: 
a role for ATF4. American Journal of Physiology - Cell Physiology 304(4): C342-C353. 
Chotteau-Lelievre A, et al. (2003) PEA3 transcription factors are expressed in tissues 
undergoing branching morphogenesis and promote formation of duct-like structures by 
mammary epithelial cells in vitro. Developmental Biology 259(2): 241-257. 
Costantini F (2010) GDNF/Ret signaling and renal branching morphogenesis: from 
mesenchymal signals to epithelial cell behaviors. Organogenesis 6(4): 252-262. 
Cullinan SB, et al. (2006) Coordination of ER and oxidative stress signaling: the PERK/Nrf2 
signaling pathway. The International Journal of Biochemistry & Cell Biology 38(3): 317-
332. 
Dame C, et al. (2004) Hepatic erythropoietin gene regulation by GATA-4. Journal of Biological 
Chemistry 279(4): 2955-2961. 
Deutsch PJ, et al. (1988) Structural determinants for transcriptional activation by cAMP-
responsive DNA elements. Journal of Biological Chemistry 263(34): 18466-18472. 
Eo J, et al. (2011) Complex ovarian defects lead to infertility in Etv5−/− female mice. Molecular 
Human Reproduction 17(9): 568-576. 
Estes SD, et al. (1995) Normal fibroblasts induce the C/EBPβ and ATF-4 bZIP transcription 
factors in response to anoxia. Experimental Cell Research 220(1): 47-54. 
Unpublished results: candidate factors involved in Epo regulation 
   
146 
 
Fellmann C, et al. (2014) Stable RNA interference rules for silencing. Nature Cell Biology 16(1): 
10-18. 
Feng X, et al. (2009) Overexpression of Csk-binding protein contributes to renal cell 
carcinogenesis. Oncogene 28(37): 3320-3331. 
Goldberg MA, et al. (1987) The regulated expression of erythropoietin by two human hepatoma 
cell lines. Proceedings of the National Academy of Sciences of the United States of 
America 84(22): 7972-7976. 
Hiwatashi Y, et al. (2011) PHD1 interacts with ATF4 and negatively regulates its transcriptional 
activity without prolyl hydroxylation. Experimental Cell Research 317(20): 2789-2799. 
Hu J, et al. (2011). Interaction of HIF and USF signaling pathways in human genes flanked by 
hypoxia-response elements and E-box palindromes. Molecular Cancer Research 9(11): 
1520-1536. 
Imagawa S, et al. (1997) Negative regulation of the erythropoietin gene expression by the GATA 
transcription factors. Blood 89(4): 1430-1439. 
Jurkowska RZ, et al. (2011) Structure and function of mammalian DNA methyltransferases. 
ChemBioChem 12(2): 206-222. 
Kahn A (1997) Transcriptional regulation by glucose in the liver. Biochimie 79(2–3): 113-118. 
Kanou T, et al. (2011) The transmembrane adaptor Cbp/PAG1 controls the malignant potential 
of human non–small cell lung cancers that have c-Src upregulation. Molecular Cancer 
Research 9(1): 103-114. 
Kawabuchi M, et al. (2000) Transmembrane phosphoprotein Cbp regulates the activities of Src-
family tyrosine kinases. Nature 404(6781): 999-1003. 
Kim MS, et al. (2013) Mutational analysis of DNMT3A gene in acute leukemias and common 
solid cancers. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 121(2): 
85-94. 
Köditz J, et al. (2007) Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen 
sensor. Blood 110(10): 3610-3617. 
Lachance G, et al. (2014) DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing 
pathway and the cellular response to hypoxia. Proceedings of the National Academy of 
Sciences of the United States of America 111(21): 7783-7788. 
Laing MA, et al. (2000) Male sexual dysfunction in mice bearing targeted mutant alleles of the 
PEA3 ets gene. Molecular and Cellular Biology 20(24): 9337-9345. 
Lee H-Y, et al. (2011) Src activates HIF-1α not through direct phosphorylation of HIF-1α-specific 
prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway. 
Carcinogenesis 32(5): 703-712. 
Unpublished results: candidate factors involved in Epo regulation 
 
147 
 
Ley TJ, et al. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of 
Medicine 363(25): 2424-2433. 
Li E, et al. (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic 
lethality. Cell 69(6): 915-926. 
Lin YS, et al. (1989) Identification and purification of a Saccharomyces cerevisiae protein with 
the DNA binding specificity of mammalian activating transcription factor. Proceedings of 
the National Academy of Sciences of the United States of America 86(1): 109-113. 
Liu S, et al. (2007) Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney 
injury. American Journal of  Physiology - Renal Physiology 293(5): F1727-F1735. 
Loots GG, et al. (2002) rVista for comparative sequence-based discovery of functional 
transcription factor binding sites. Genome Research 12(5): 832-839. 
Lu BC, et al. (2009) Etv4 and Etv5 are required downstream of GDNF and Ret for kidney 
branching morphogenesis. Nature Genetics 41(12): 1295-1302. 
Masuoka HC, et al. (2002) Targeted disruption of the activating transcription factor 4 gene 
results in severe fetal anemia in mice. Blood 99(3): 736-745. 
Mathelier A, et al. (2014) JASPAR 2014: an extensively expanded and updated open-access 
database of transcription factor binding profiles. Nucleic Acids Research 42(D1): D142-
D147. 
Mukhopadhyay D, et al. (1995) Hypoxic induction of human vascular endothelial growth factor 
expression through c-Src activation. Nature 375(6532): 577-581. 
Mukundan H, et al. (2004) 17-[beta] estradiol attenuates hypoxic induction of HIF-1[alpha] and 
erythropoietin in Hep3B cells. Journal of Cardiovascular Pharmacology 44(1): 93-100. 
Nicolas G, et al. (2001) Lack of hepcidin gene expression and severe tissue iron overload in 
upstream stimulatory factor 2 (USF2) knockout mice. Proceedings of the National 
Academy of Sciences of the United States of America 98(15): 8780-8785. 
Obara N, et al. (2008) Repression via the GATA box is essential for tissue-specific erythropoietin 
gene expression. Blood 111(10): 5223-5232. 
Oh S, et al. (2012) ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. 
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1826(1): 1-12. 
Okano M, et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo 
methylation and mammalian development. Cell 99(3): 247-257. 
Okano M, et al. (1998) Cloning and characterization of a family of novel mammalian DNA 
(cytosine-5) methyltransferases. Nature Genetics 19(3): 219-220. 
Oneyama C, et al. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic 
potential of c-src. Molecular Cell 30(4): 426-436. 
Unpublished results: candidate factors involved in Epo regulation 
   
148 
 
Pawlus MR, et al. (2013) STAT3 or USF2 contributes to HIF target gene specificity. PLoS One 
8(8): e72358. 
Pawlus MR, et al. (2012) Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) 
cooperatively activate HIF2 target genes during hypoxia. Molecular and Cellular Biology 
32(22): 4595-4610. 
Pereira ER, et al. (2014) Endoplasmic reticulum (ER) stress and hypoxia response pathways 
interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets 
like vascular endothelial growth factor (VEGF). Journal of Biological Chemistry 289(6): 
3352-3364. 
Ramji K, et al. (2013) Off-target effects of plasmid-transcribed shRNAs on NFκB signaling 
pathway and cell survival of human melanoma cells. Molecular Biology Reports 40(12): 
6977-6986. 
Rzymski T, et al. (2010). Regulation of autophagy by ATF4 in response to severe hypoxia. 
Oncogene 29(31): 4424-4435. 
Semenza GL, et al. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis 
binds to the human erythropoietin gene enhancer at a site required for transcriptional 
activation. Molecular and Cellular Biology 12(12): 5447-5454. 
Shi L, et al. (2009) Activation of renal renin-angiotensin system in upstream stimulatory factor 2 
transgenic mice. American Journal of  Physiology - Renal Physiology 296(2): F257-F265. 
Shimizu R, et al. (2005) Gene expression regulation and domain function of hematopoietic 
GATA factors. Seminars in Cell & Developmental Biology 16(1): 129-136. 
Sirito M, et al. (1998) Overlapping roles and asymmetrical cross-regulation of the USF proteins 
in mice. Proceedings of the National Academy of Sciences of the United States of 
America 95(7): 3758-3763. 
Sirito M, et al. (1994) Ubiquitous expression of the 43- and 44-kDa forms of transcription factor 
USF in mammalian cells. Nucleic Acids Research 22(3): 427-433. 
Sirito M, et al. (1992) Members of the USF family of helix-loop-helix proteins bind DNA as homo- 
as well as heterodimers. Gene Expression 2(3): 231-240. 
Stiehl DP, et al. (2012) Non-canonical HIF-2α function drives autonomous breast cancer cell 
growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene 31(18): 2283-2297. 
Tagliavacca L, et al. (2012) In vivo up-regulation of the unfolded protein response after hypoxia. 
Biochimica et Biophysica Acta (BBA) - General Subjects 1820(7): 900-906. 
Vallet VS, et al. (1997) Glucose-dependent liver gene expression in upstream stimulatory factor 
2 −/− mice. Journal of Biological Chemistry 272(35): 21944-21949. 
Unpublished results: candidate factors involved in Epo regulation 
 
149 
 
van den Beucken T, et al. (2009) Hypoxia-induced expression of carbonic anhydrase 9 Is 
dependent on the unfolded protein response. Journal of Biological Chemistry 284(36): 
24204-24212. 
van Deursen D, et al. (2008) Glucose increases hepatic lipase expression in HepG2 liver cells 
through upregulation of upstream stimulatory factors 1 and 2. Diabetologia 51(11): 2078-
2087. 
Vitari AC, et al. (2011) COP1 is a tumour suppressor that causes degradation of ETS 
transcription factors. Nature 474(7351): 403-406. 
Wang S, et al. (2004) Glucose up-regulates thrombospondin 1 gene transcription and 
transforming growth factor-β activity through antagonism of cGMP-dependent protein 
kinase repression via upstream stimulatory factor 2. Journal of Biological Chemistry 
279(33): 34311-34322. 
Wang Y, et al. (2012) The unfolded protein response induces the angiogenic switch in human 
tumor cells through the PERK/ATF4 pathway. Cancer Research 72(20): 5396-5406. 
Wanner RM, et al. (2000) Epolones induce erythropoietin expression via hypoxia-inducible 
factor-1α activation. Blood 96(4): 1558-1565. 
Wei GH, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. 
EMBO Journal 29(13): 2147-2160. 
Wenger RH, et al. (2009) HIF prolyl-4-hydroxylase interacting proteins: consequences for drug 
targeting. Current Pharmaceutical Design 15(33): 3886-3894. 
Wenger RH, et al. (2010) Regulated oxygen sensing by protein hydroxylation in renal 
erythropoietin-producing cells. American Journal of  Physiology - Renal Physiology 
298(6): F1287-F1296. 
Wollenick K, et al. (2012) Synthetic transactivation screening reveals ETV4 as broad coactivator 
of hypoxia-inducible factor signaling. Nucleic Acids Research 40(5): 1928-1943. 
Yamazaki S, et al. (2013) A mouse model of adult-onset anaemia due to erythropoietin 
deficiency. Nature Communications 4. 
Yan X-J, et al. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase 
gene DNMT3A in acute monocytic leukemia. Nature Genetics 43(4): 309-315. 
Yeo E-J, et al. (2008) Contribution of HIF-1α or HIF-2α to erythropoietin expression: in vivo 
evidence based on chromatin immunoprecipitation. Annals of Hematology 87(1): 11-17. 
Zhu K, et al. (2013) ATF4 promotes bone angiogenesis by increasing vegf expression and 
release in the bone environment. Journal of Bone and Mineral Research 28(9): 1870-
1884. 
Unpublished results: Epo regulatory peptides 
   
150 
 
7. Epo regulatory peptides 
Federica Storti1, Irene Abreu-Rodríguez1, Jerry H. Fuady1, Ian Frew1, Wolf-Georg Forssmann2, 
Roland H. Wenger1 and David Hoogewijs1 
1 Institute of Physiology and Zürich Center for Integrative Human Physiology ZIHP, University of 
Zürich, Zürich, Switzerland 
2 Hannover Medical School and Pharis Biotech GmbH, Hannover, Germany 
 
 
Introduction 
Accumulating evidence suggests the possibility for erythropoietin (Epo) to be regulated by 
peptides and hormones in the blood stream (see introduction, paragraph 1.5). The aim of this 
sub-project was to test in vitro putative Epo regulatory peptides, selected on the basis of 
available literature data and corresponding receptor expression in Hep3B. Tested candidates 
included extracts from hypophysis (bovine pituitary extract, BPE) and the steroid hormones 
aldosterone (ALDO) and β-estradiol (E2). Our approach was additionally complemented by the 
screening of a human haemofiltrate (HF)-derived peptide collection (Schulz-Knappe et al., 1997) 
using hypoxia-inducible factor (HIF)-reporter cell lines in order to identify novel regulators of the 
HIF pathway and, possibly, of Epo production too. Details on the rationale of candidate selection 
and on the chosen strategy are given in the result section. 
 
Materials and methods 
Cell culture, reagents and hormone treatment 
ExREPCs, Hep3B, HepG2, HK-2 and Hek293T were cultured in DMEM (high glucose, Sigma-
Aldrich) supplemented with 10% heat-inactivated foetal calf serum (FCS), 50 IU/ml penicillin and 
50 µg/ml streptomycin (Invitrogen). Hypoxia experiments were carried out at the indicated 
concentration of oxygen and 5% CO2 in a gas-controlled glove box (InvivO2 400, Ruskinn 
Technologies). Dimethyloxaloylglycine (DMOG, Frontier Scientific) was dissolved in dimethyl 
sulfoxide (DMSO) and used at the concentration of 1 mM for 8 h. Deferoxamine (DFX, Sigma-
Aldrich) and cobalt chloride (CoCl2, Sigma-Aldrich) were dissolved in water and used at a 
concentration of 100 μM. For treatment with selected peptides, Hep3B cells were plated at a 
density of 4×105 cells per single well of a 6-well plate. The day after, medium was changed to 
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non-FCS containing medium for 16 h, followed by hormone stimulation and exposure to 21% or 
0.2% of O2 for 24 h (ALDO and E2) or 48 h (BPE). BPE was purchased by Lonza (CC-4009, 
stock concentration: 13 mg/ml) and diluted in FCS-free medium at the indicated concentrations; 
bovine serum albumin (BSA, Sigma-Aldrich) was re-suspended in PBS at 13 mg/ml and diluted 
in FCS-free medium at the indicated concentrations. ALDO (Sigma-Aldrich) was re-suspended in 
ethanol at 100 μM and diluted in FCS-free medium at the indicated concentrations. E2 (Sigma-
Aldrich) was re-suspended in ethanol at 73.4 μM and diluted in FCS-free medium at the 
indicated concentrations. ICI 182,780 (or Fulvestrant, (7α, 17β- [9- [(4, 4, 5, 5, 5 – 
Pentafluoropentyl) sulfinyl] nonyl] estra-1, 3, 5 (10) -triene-3, 17-diol, Sigma-Aldrich) was re-
suspended in ethanol at 33 μM and diluted in FCS-free medium at the indicated concentration. 
RNA extraction and quantitative PCR 
RNA was extracted by using the phenol-chloroform method and cDNA was generated by 
reverse transcription (RT) of 2 µg of total RNA using AffinityScript reverse transcriptase 
(Agilent). Transcript levels were quantified by quantitative (q) PCR using a SybrGreen qPCR 
reagent kit (Sigma) in combination with a MX3000P light cycler (Agilent) or by conventional RT-
PCR (for hV1a and hV2) and the primers listed in table 1. Initial template concentrations were 
calculated by comparison with serial dilutions of a calibrated standard. Ribosomal protein L28 
mRNA levels were used to normalize the data. cDNA from human kidney samples was kindly 
provided by Prof. Olivier Devuyst (University of Zürich, Switzerland). 
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon size 
hV1a CGGCTTCATCTGCTACAACATC CGAGTCCTTCCACATACCCGT 505 bp 
hV2 TGGTCGTCTATGTGCTGTGC GCATAGATCCAGGGGTTGGT 148 bp 
hL28 GCAATTCCTTCCGCTACAAC TGTTCTTGCGGATCATGTGT 198 bp 
hEpo TCACTGTCCCAGACACCAAA CCTCCCCTGTGTACAGCTTC 362 bp 
hPAI-1 ACTGGAAAGGCAACATGACC GAGGAAGGGTCTGTCCATGA 296 bp 
hCAIX GGGTGTCATCTGGACTGTGTT CTTCTGTGCTGCCTTCTCATC 309 bp 
hPGK-1 AACAAGGTTAAAGCCGAGCC TGAGCTGGATCTTGTCTGCA 259 bp 
hGLUT-1 TCACTGTGCTCCTGGTTCTG CCTGTGCTCCTGAGAGATCC 233 bp 
hMR CCAACTTCAGGCTGCTCAGA GCTCCACAGCCTGAGAAACT 290 bp 
hGR GCAGTGGAAGGTAGACAGCA CTCCAACAGTGACACCAGGG 273 bp 
hERβ GTCAGGCATGCGAGTAACAA ATTTTCGTTTCTCCCGAGGG 230 bp 
hPCK AGGCGGCTGAAGAAGTATGA ACGTAGGGTGAATCCGTCAG 299 bp 
hERα AGACATGAGAGCTGCCAACC GCCAGGCACATTCTAGAAGG 299 bp 
Table 1 Primers used for qPCR amplification 
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Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using a high salt extraction buffer 
containing 0.4 M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 x protease inhibitory cocktail (Sigma). 
Protein concentrations were determined by the bicinchoninic acid assay method and up to 80 µg 
of cellular protein was subjected to immunoblot analyses. Membranes were probed with 
antibodies against ERα (sc-542, Santa Cruz Biotechnology) and -actin (Sigma). Signals from 
HRP-coupled secondary antibodies were detected with ECL substrate (all Pierce) using a 
luminescent image analyser (LAS-4000, FUJIFILM). -actin was used as loading control. 
ERα overexpression 
Hep3B cells were plated at a density of 1.5×106 cells per 10 cm dish (for RNA extraction) and 
3.5×106 cells per 15 cm dish (for protein extraction) and transiently transfected after 24 h with 3 
μg of pCMV5-hERα (kindly provided by Prof. Alex Odermatt, University of Basel, Switzerland) or 
pEGFP-C1 (Clontech) as a control, using polyethylenimine (PEI). 24 h post transfection cultures 
were evenly split onto 6-well plates or 10 cm dishes, respectively, and after 8 h medium was 
changed to FCS-free medium for 16 h. Cells were then exposed to the indicated concentration of 
E2 and oxygen for an additional 24 h.  
Reporter cell lines 
For the first screening round (figure 9), exREPCs were plated at a density of 2.5×104 cells per 
single well of a 96-well plate and transiently transfected after 24 h with 5 ng pH3SVL and 0.5 ng 
pRL-SV40 using Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen). For 
the second screening round (figure 11), stable reporter Hep3B were generated by 
electroporation of 50 μg of linearized pH3SVL, pSV2Neo (containing a neomycin resistant 
cassette) and pRL-SV40-hygro (containing a hygromycin resistant cassette) and cultured in 
DMEM supplemented with 10% heat-inactivated FCS, 50 IU/ml penicillin, 50 µg/ml streptomycin 
(Invitrogen), 1 mg/ml G418 (PAA) and 10 μg/ml hygromycin B (Calbiochem). Other reporter cell 
lines (PHD2, Epo 5’-HRE and Epo reporter) were generated by lentiviral (LV) transduction. LV 
expression vectors pDestX1-puro and pDestX1-neo were kindly provided by Prof.  Ian Frew 
(University of Zürich, Switzerland) and used for recombination with entry vectors containing 
firefly and Renilla genes under the control of the regulatory regions depicted in figure 10A and 
12 (all from Invitrogen). Viral particles were produced in Hek293T cells by co-transfection of the 
respective transfer vector (3 μg) with the packaging plasmids pLP1 (4.2 μg), pLP2 (2 μg) and 
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pVSV-G (2.8 μg, all from Invitrogen) using PEI transfection as described before (Stiehl et al., 
2012). Hep3B cells were transduced with lentiviral-pseudotyped particles and cell pools were 
derived by puromycin selection. 
Peptide collection screening and luciferase assay 
A lyophilized peptide collection of 384 fractions, each corresponding to 5 L HF-equivalent, was 
prepared as previously described (Schulz-Knappe et al., 1997). For the first screening round 
(figure 9), each fraction was re-suspended in 200 μl of sterile water and stored at -20°C. 2 μl of 
thawed fractions were added every 2 h to 96-well plates containing reporter Hep3B cells and 
100 μl of FCS-free medium per well, for 8 h (4 total additions) in normoxia and hypoxia. For the 
second screening round (figure 11), each fraction was re-suspended in 40 μl of sterile water 
(STOCK concentration), diluted 1:2 and 1:4 with sterile water and used immediately for 
experiment with the same protocol used for the first screening round. Water alone was used as 
internal control for each experiment. After 8 or 24 h of hypoxia (see protocol scheme, figure 9 
and 10), cells were lysed with 20 μl of passive lysis buffer (PLB) and luciferase activities of 
triplicate wells were determined using the Dual Luciferase Reporter Assay System according to 
the manufacturer’s protocol (Promega). Reporter activities were expressed as relative 
firefly/Renilla luciferase activities. 
 
Results 
BPE  
In vivo experiments suggest a direct link between the pituitary gland, or hypophysis, and renal 
Epo production. Hypoxia in the brain stem of rats results in increased Epo plasma level in a 
hypophysis- and kidney-dependent manner (von Wussow et al., 2005) and the pituitary hormone 
ADH (antidiuretic hormone or arginine vasopressin, AVP) was able to induce Epo when 
administrated to normoxic rats (Engel and Pagel, 1995). The hypophysis is located at the base 
of the brain, just below the hypothalamus, and is divided into an anterior and a posterior part. 
The anterior pituitary gland secretes a number of hormones under the control of hypothalamic 
releasing hormones, while the posterior part belongs to the brain itself since it contains the nerve 
endings of the supraoptic and paraventricular neurons of the hypothalamus. ADH is produced by 
the posterior hypophysis as a consequence of increased blood osmolality or decreased blood 
volume (BV) and is essential for cardiovascular and renal homeostasis. ADH promotes in fact 
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vasoconstriction, in order to increase blood pressure, and water re-absorption by the distal 
nephron, thereby resulting in increased BV (Boron and Boulpaep, 2005). 5 types of ADH 
receptors have been identified so far, all belonging to the family of G-protein coupled receptors 
(GPCRs); the most well-known are the vascular V1 and the renal V2 receptors (Holmes et al., 
2003). Upon ligand binding, V2 receptors mediate fusion of aquaporin-2 (AQP-2)-containing 
vesicles with the apical membrane of principal cells in the collecting duct and increase water 
retention (Boron and Boulpaep, 2005). According to the aforementioned report (Engel and 
Pagel, 1995), ADH administration to rats increased Epo plasma levels via V1a receptor subtype 
without influencing glomerular filtration rate or renal blood flow, suggesting that renal 
vasoconstriction and subsequent hypoxia are not the cause of the observed rise in Epo levels. 
Therefore, we hypothesized a direct effect of ADH on Epo-producing cells.  
In order to test our hypothesis, we evaluated the expression of V1a and V2 receptors in our in 
vitro model, Hep3B cells, alongside with a panel of cell lines and cDNA extracted from human 
kidney and the proximal tubule cell line HK-2 as a positive control. RT-PCR revealed no 
expression of V1a in any of the cell lines tested and low expression of the V2 longer transcript 
variant (figure 1). Given that ADH can bind to both receptors and that the hypophysis-dependent 
effect on Epo could be mediated by other pituitary hormones, we treated Hep3B cells with a 
homogenized extract from bovine pituitary gland (BPE), which most likely contains a 
representation of hypophysis-derived peptides, and measured mRNA levels of HIF-2 and HIF-1 
target genes. HIF-2 specific Epo and PAI-1 (plasminogen activator inhibitor type 1) mRNA levels 
were unchanged between BPE-treated and control cells, as shown in figure 2; HIF-1 target 
genes, such as CAIX (carbonic anhydrase 9), PGK-1 (phosphoglycerate kinase 1) and GLUT-1 
(glucose transporter 1), did not show changes in transcript levels either (figure 3). CAIX mRNA 
levels tended to increase with high doses of BPE, both in normal and reduced oxygen 
conditions, but the effect was not statistically significant (figure 3A). We concluded that Hep3B 
express the V2 receptor, at least on mRNA level, but treatment with BPE does not lead to 
transcriptional changes in the HIF target genes measured under these experimental conditions.  
Steroid hormones 
Steroid hormones (SHs) are produced by the adrenal gland and by the gonads and share the 
same precursor, cholesterol, and the same basic ring structure. SHs can be divided into 5 major 
classes: progestogens, glucocorticoids, mineralocorticoids, androgens and estrogens, exerting a 
wide variety of functions within the human body. Due to their lipophilic nature, SHs can diffuse 
into the cell membrane and bind to their intracellular receptors, which are transcription factors. 
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Upon binding, steroid hormone receptors (SHRs) form homodimers and activate transcription of 
target genes containing the corresponding SH-responsive element in the regulatory regions 
(Alberts et al., 2002). As already discussed in the introduction, most of the data on SH-
dependent Epo regulation involve sexual hormones (Alexanian, 1969; Mukundan et al., 2002; 
Mukundan et al., 2004), but no direct link between SHs and EPO transcriptional regulation has 
been characterized so far.  
We started to study the expression profile of different SHRs in Hep3B cells. Mineralcorticoid 
(MR), glucocorticoid (GR) and estrogen receptor β (ERβ) mRNA was expressed by the Epo-
producing cell model, albeit at low levels (figure 4). We could not detect estrogen receptor α 
(ERα), progesterone receptor (PgR) and androgen receptor (AR) transcripts (data not shown).  
Based on these results, we treated Hep3B cells with different doses of the MR high affinity 
agonist ALDO. ALDO is physiologically produced by the adrenal gland and can bind to GR as 
well with lower affinity. It plays a central role in the renin-angiotensin system, its release being 
increased by angiotensin II, and it acts on principal cells of the collecting duct. ALDO promotes 
sodium and water reabsorption and potassium secretion, thereby increasing BV and blood 
pressure. Since ALDO is a crucial regulator of BV and Epo controls the main cellular component 
of the blood, erythrocytes, we hypothesized a potential role for ALDO in Epo regulation. Figure 5 
displays the results obtained with ALDO treatment of Hep3B: no significant changes could be 
observed in Epo mRNA levels, even though a trend of increased Epo production could be 
measured with the highest (but not physiological) doses of the hormone. CAIX and PCK 
(phosphoenolpyruvate carboxykinase) were used as controls for hypoxic and ALDO exposure, 
respectively. Of note, PCK mRNA was significantly increased only with the highest dose of 
ALDO. 
More data are available concerning the inhibitory effect of estrogens on Epo synthesis that could 
explain the differences in haematocrit (Hct) levels between men and women (see introduction). 
Experiments with Epo reporters in Hep3B showed decreased reporter activity and Epo protein 
levels upon treatment with the ER agonist E2 (Mukundan et al., 2004). Moreover, E2 treatment 
of ER-positive breast cancer cell lines, like MCF-7, resulted in decreased HIF-2α mRNA and 
protein levels, both in normoxic and hypoxic conditions, further suggesting a link between 
estrogen activity and Epo regulation (Jerry H. Fuady, unpublished data). Since Hep3B 
expressed ERβ in our hands, we treated these cells with different doses of E2 and the ER 
antagonist ICI and investigated a potential effect on endogenous Epo mRNA. When considering 
Epo hypoxia/normoxia fold induction, a trend of increased Epo folds could be observed with the 
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lowest E2 concentration and was not present when cells were treated with ICI (figure 6A). 
However, the vehicle control (ethanol alone) gave the strongest reduction in Epo mRNA, 
affecting the interpretation of the whole experiment. The hypoxic control CAIX transcript levels 
resulted to be more stable compared to Epo mRNA levels regardless of E2 or ICI treatment 
(figure 6B). We were not able to recapitulate the MCF-7-based results: HIF-2α mRNA levels 
were not decreased upon treatment of Hep3B with E2 (figure 6C). PgR is known to be a 
transcriptional target of ERs in breast cancer cell lines (Horwitz et al., 1978; Otto, 1995), but no 
PgR mRNA could be detected after estrogen treatment in Hep3B (data not shown): we thus 
lacked a suitable positive control for ER activation. Given the fact that ERα is not expressed in 
Hep3B but could mediate the effect of E2 on Epo as well, we decided to transiently overexpress 
this ER isoform prior to E2 treatment in our cell model. Again, no significant effect on Epo or 
HIF-2α mRNA could be observed after ERα overexpression and treatment with E2 (figure 7A 
and B). Transfection efficiency was relatively low, as demonstrated by GFP expression in the 
control cells (figure 7D); nevertheless ERα could be measured on mRNA and protein level 
specifically in transfected Hep3B cells (figure 7C and D). Collectively, these data suggest no 
clear effect of E2 on EPO or HIF2A transcription in Hep3B cells, at least under our experimental 
conditions. 
Screening of a human HF-derived peptide collection 
Since no Epo regulatory peptide has been identified up to now, we decided to screen a complete 
human HF-derived peptide collection (Schulz-Knappe et al., 1997) for the effect on the HIF 
pathway and, possibly, on Epo expression as well. The collection was prepared by two serial 
chromatographic steps starting from 10,000 L of HF derived from patients with renal failure and 
representing a comprehensive source of blood peptides with a molecular weight lower than   ̴30 
kDa. Subjects affected by end stage renal disease (ESRD) require regular haemofiltration in 
order to eliminate toxic substances without loss of large plasma proteins, immunoglobulin and 
blood cells, a function normally exerted by the kidneys. Moreover, ESRD patients display 
inappropriately low Epo levels, despite the high degree of anaemia (Caro et al., 1979): it is likely 
that Epo regulatory peptides are enriched in HFs from patients with renal failure.  
Briefly, HFs are collected (20-30 L/patient/treatment) and subjected to a first cation-exchange 
chromatography followed by elution with 8 buffers with different pH (from acidic pH 3.6 to basic 
pH 9.0). Each pH pool is subsequently run over a reverse-phase chromatography column and 
48 fractions are retrieved from each pool. The resulting 384 fractions are lyophilized and stored 
at -20°C (Schulz-Knappe et al., 1997; Mark et al., 1999). Once an active fraction is identified, 
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further sub-fractionation steps are required in order to analyse the amino acid sequence by 
mass spectrometry and determine the identity of the peptide. Similar collections have been 
successfully screened for other purposes and endogenous bioactive peptides have been 
identified, such as anti-viral peptides or orphan-receptor ligands (Meder et al., 2003; Fricke et 
al., 2005; Münch et al., 2007; Borst et al., 2013).  
Choosing an appropriate cell model and protocol to perform the screening turned out to be a 
major challenge, since the concentration of the peptides, as well as their half-life and many other 
properties, were unknown in the extremely complex fractions. We thus started by transiently 
transfecting exREPCs with the previously described hypoxia-reporter vector pH3SVL (Wanner et 
al., 2000) together with an SV40-driven Renilla (RL) luciferase (pRL-SV40) as a control for 
transfection efficiency and non-HIF related effects (depicted in figure 8A). In order to choose the 
most optimal stimulus to induce HIF-reporter activity, we exposed exREPCs to hypoxia and to 
different hypoxia-mimetics: 8 h at 0.2% O2 were sufficient to obtain strong and reproducible 
induction of luciferase counts (figure 8C). We therefore performed the screening of the complete 
collection, twice, following the protocol scheme in figure 8B: cells were transiently transfected in 
96-well plates with the reporter constructs, the next day medium was replaced by non-FCS 
containing medium (to avoid potential background effects of the serum) and peptide fractions 
were added every 2 h in normoxia and hypoxia, for a total exposure of 8 h. Results of this first 
screening round are shown in figure 9: the regression analysis of the ratio firefly (FF)/RL in 
hypoxia (figure 9A) indicated poor reproducibility of the two replicates and inhibitory effect of the 
majority of the fractions tested. Nevertheless, some fractions displayed reproducible activity, 
either increasing or decreasing luciferase counts compared to the internal control. We continued 
with the most promising fractions, #04.24 and #06.09 (figure 9B), and tested several sub-
fractions obtained by reverse-phase chromatography from the original fractions. Unfortunately, 
we experienced problems with the transient transfection approach, in terms of luciferase hypoxic 
inducibility and transfection reproducibility (data not shown). In order to circumvent these 
technical complications we decided to change the experimental strategy and repeat the 
screening in stably transfected Hep3B cells.  
The aim of this sub-project was to find peptides that influence the HIF pathway and/or Epo 
production. We thus studied the hypoxia inducibility of different newly generated stable reporter 
cell lines, expressing FF luciferase under the control of the human prolyl-4-hydroxylase domain 
2 (PHD2) promoter (an established HIF target gene (Wollenick et al., 2012)) or of Epo 5’-HRE in 
combination with SV40 promoter (see chapter 3). We compared the new cell models, generated 
by LV transduction of Hep3B, to cells transiently or stably transfected with pH3SVL and pRL-
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SV40 (all the vectors are depicted in figure 10A). We confirmed FF induction of transiently 
transfected Hep3B after 8 h of hypoxia, as in the first screening round; none of the other cell 
models showed increased luciferase counts after 8 h of stimulation. After 24 h of hypoxic 
exposure, all the reporter cell lines displayed induction of FF activity, albeit to a different extent 
(figure 10B). The main problem experienced with the novel PHD2 promoter and Epo 5’-HRE 
constructs was hypoxic induction of the RL gene, which we used to normalize the assay. As 
shown in figure 10A, these two transfer vectors contain the non-hypoxia responsive RL gene 
closely downstream of the hypoxia-induced FF gene. The distance is probably not long enough 
to insulate the two expressing cassettes, thus RL activity pattern follows the FF one, blunting the 
hypoxic induction when the ratio FF/RL is calculated. However, Hep3B stably transfected with 
pH3SVL and pRL-SV40 did show reproducible FF hypoxic induction after 24 h at 0.2% O2, 
stable RL expression and low variability between replicates: we chose this cell model to perform 
the second round of peptide collection screening. We adjusted the screening protocol as shown 
in figure 10C: exposure to hypoxia was increased to 24 h and peptide fractions were added 
every 2 h for the last 8 h of hypoxia. Moreover, 3 different fraction concentrations were added to 
the cells, in order to check for potential dose-dependent effects. Indeed, the new protocol and 
cell model gave more reproducible results, as demonstrated by the regression analysis of the 
fold induction hypoxia/normoxia in figure 11A. Fractions were more broadly distributed between 
“activatory” and “inhibitory” and we selected 8 total fractions based on the extent of the effect, 
degree of reproducibility and dose-dependency. In addition, neighbouring fractions were 
preferentially chosen since the same peptide can be sequentially eluted during chromatography 
(data concerning selected fractions are shown in figure 11B). We are currently confirming these 
results by treating the samples with the aspecific protease subtilisin or with heat inactivation: 
these treatments will validate if the effect observed is dependent on the peptide component of 
the fractions. Based on the results obtained in the confirmation phase, selected fractions will be 
subjected to sub-fractionation steps in order to identify the HIF regulating peptides.   
 
Discussion 
A number of experimental observations in human and animals suggest that EPO transcription 
could be regulated by circulating peptides, albeit no humoral factor has been demonstrated so 
far to act directly on Epo-producing cells. In the first part of this project, we selected and tested 
in vitro a series of candidate peptides for which a link with Epo production has been indicated. 
Based on our results, we concluded that none of the candidates had a significant effect on Epo 
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synthesis in Hep3B cells under our experimental conditions. This could be explained by the fact 
that renal Epo-producing cells (REPCs), the main source of Epo in adults, are most likely 
differentially sensitive to stimulation with the humoral factors of interest compared to Hep3B. We 
evaluated expression of the receptor mRNA in our liver-derived cell model before treating the 
cells with the corresponding stimulus, but expression levels as well as activation status could 
differ between Hep3B and REPCs. Immunohistochemistry or immunofluorescence analysis of 
renal receptor expression in vivo are required in order to choose the most promising candidates 
to treat animals with before checking Epo levels in normoxia and hypoxia. Another possible 
approach consists in overexpressing in vitro the receptor of interest prior to treatment with the 
hormone. We carried out this strategy by overexpressing ERα in Hep3B (figure 7) but the 
transfection efficiency was probably too low to see an effect on endogenous transcription, as 
demonstrated by the GFP control. Concerning the effect of E2 on HIF-2α mRNA, it is possible 
that Hep3B do not express the right set of receptors/signalling machine to respond to estrogen 
treatment like MCF-7, a breast cancer-derived cell line which express ERα, ERβ and PgR at 
considerable levels and show estrogen-dependent growth (Levenson and Jordan, 1997). 
Generation of stable receptor-overexpressing cell lines and optimization of hormone treatment 
would be necessary to draw conclusions on the effect of the tested candidates on EPO 
transcription.   
Since treatment of Hep3B with specific putative Epo-regulators gave inconclusive results, we 
decided to complement our investigation with a different approach: we sought HIF-regulating 
factors in a comprehensive patient HF-derived peptide collection. This strategy has the 
advantage to be a priori, thus allowing identification of unknown peptides as well, and to use 
endogenous material from human subjects affected by ESRD, thereby increasing the probability 
to find Epo-regulating peptides. Epo response to anaemia is in fact impaired in these patients 
(see general introduction and results) and production of such Epo regulators is likely to be 
increased. Despite difficulties encountered with selection of a suitable protocol and 
reproducibility of the initial screening rounds, stably transfected cell models gave reliable results 
and some fractions did show an interesting “activatory” or “inhibitory” activity in our HIF-reporter 
assay (figure 11). Confirmation of the effect and further sub-fractionation steps are required in 
order to identify single peptides responsible for the effect. It must not be forgotten that the 
composition of each peptide fraction is extremely complex and sub-fractionation could lead to 
increased activity, because of dilution of inhibitory factors present in the same fraction, as much 
as loss of the activity, because of the necessity of more factors to act simultaneously. 
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Unfortunately, the outcome is not predictable at this level of complexity and test of different sub-
fraction sets is ongoing.  
A parallel approach we are using to achieve the aim of finding novel Epo-regulatory hormones is 
represented by the generation of Epo-reporter cell lines. As described in chapter 3, we 
characterized a previously unknown HRE located upstream of the EPO gene. The first Epo 5’-
HRE containing construct we generated (figure 10A) showed hypoxic inducibility but contained a 
strong and artificial viral promoter, the SV40 promoter. Therefore, we built a new construct 
containing Epo 5’-HRE, the endogenous minimal promoter and the 3’-HRE of the gene, depicted 
in figure 12. This construct should contain the most relevant EPO locus regulatory elements, 
thus being the most optimal Epo-reporter up to date. Generation of stable cell lines via LV 
infection using this construct and a TK (thymidine kinase) promoter-driven RL as non-hypoxia 
inducible control is ongoing and will be used for confirmation of fractions selected from the 
screening in HIF reporter cells, as well as for future screening rounds. 
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Figure 1 
 
Figure 1 Expression levels of ADH receptors V1a and V2 assessed by RT-PCR using cDNA 
from different human cell lines. Samples of human kidney and HK-2 cells cDNA were used as 
positive control. The PCR for V2 receptor results in 2 bands, corresponding to 2 known transcript 
variants of the gene, one of 215 bp long and one of 148 bp in length. Quality of cDNA was 
checked by evaluating L28 transcript levels (data not shown). 
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Figure 2 
 
Figure 2 Hep3B cells were treated with different concentrations of BPE or BSA control, for 48 h 
in normoxia or hypoxia (0.2% O2). Epo (A) and PAI-1 (B) mRNA levels were measured by RT-
qPCR. All data are expressed as mean ± SEM. 
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Figure 3 
 
Figure 3 Hep3B cells were treated with different concentrations of BPE or BSA control, for 48 h 
in normoxia or hypoxia (0.2% O2). CAIX (A), PGK-1 (B) and GLUT-1 (C) mRNA levels were 
measured by RT-qPCR. All data are expressed as mean ± SEM. 
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Figure 4 
 
Figure 4 MR (A), GR (B) and ERβ (C) mRNA levels were measured in normoxic and hypoxic 
Hep3B by RT-qPCR. All data are expressed as mean ± SEM. 
 
Figure 5 
 
Figure 5 Hep3B cells were treated with different concentrations of ALDO (vehicle control: 
0.014% ethanol, corresponding to the amount used for the highest concentration of ALDO), for 
24 h in normoxia or hypoxia (0.2% O2). Epo (A), CAIX (B) and PCK (C) mRNA levels were 
measured by RT-qPCR. All data are expressed as mean ± SEM. Statistics: t-test, *p < 0.05, 
compared to vehicle control in hypoxia. 
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Figure 6 
 
Figure 6 Hep3B cells were treated with different concentrations of E2 and ICI (vehicle control: 
0.02% ethanol, corresponding to the amount used for the highest concentration of E2), for 24 h 
in normoxia or hypoxia (0.2% O2). In the combined treatment, 10 μM ICI and 10 nM E2 were 
used. Epo (A), CAIX (B) and HIF-2α (C) mRNA levels were measured by RT-qPCR. All data are 
expressed as mean alone. 
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Figure 7 
 
Figure 7 Hep3B cells were transfected with a GFP- or an ERα-overexpressing vector and 
treated with 10 nM E2 (vehicle control: 0.02% ethanol), for 24 h in normoxia or hypoxia (0.2% 
O2). Epo (A), HIF-2α (B) and ERα (C) mRNA levels were measured by RT-qPCR. ERα 
overexpression was evaluated by immunoblotting as well (D, left panel). GFP-transfected cells 
were used to check efficiency of transfection with a fluorescent microscope (D, right panel). All 
data are expressed as mean alone. 
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Figure 8 
 
Figure 8 ExREPCs were transiently transfected with pH3SVL and pRL-SV40 (depicted in A) and 
exposed to normoxia, hypoxia or hypoxia mimetics for 8 h; results of the luciferase assay are 
displayed as R.L.U. (C). All data are expressed as mean ± SEM. B. schematic representation of 
the screening protocol.  
 
Figure 9 
 
Figure 9 A. Regression analysis of the ratio FF/RL in hypoxia normalized on internal control 
(CTR): each dot represents one of the 384 peptide fractions in the two screening repetitions; the 
most “activatory” and “inhibitory” fractions are highlighted in green and red, respectively. Axes 
origin represents the CTR. B. Results of the luciferase assay from selected fractions #04.24 and 
#06.09 are displayed as R.L.U. All data are expressed as mean alone. 
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Figure 10 
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Figure 10 Hep3B were transiently or stably transfected or transduced with pH3SVL, pRL-SV40, 
PHD2 promoter or Epo 5’-HRE reporter vectors (depicted in A) and exposed to hypoxia for 8 or 
24 h; results of the luciferase assay are displayed as R.L.U. (B). All data are expressed as mean 
± SEM. C. schematic representation of the screening protocol.  
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Figure 11 
 
Figure 11 A. Regression analysis of the fold hypoxia/normoxia calculated on ratio FF/RL and 
normalized on internal control (CTR): each dot represents one of the 384 peptide fractions in the 
two screening repetitions (STOCK concentration); the selected “activatory” and “inhibitory” 
fractions are highlighted in green and red, respectively. Axes origin represents the CTR. B. and 
C. Results of the luciferase assay from the most “activatory” and “inhibitory” fractions, 
respectively, at different concentrations are displayed as fold induction hypoxia/normoxia. 
Fractions marked in red were selected for further confirmation and sub-fractionation. Data are 
expressed as mean alone. 
 
Figure 12 
 
Figure 12 Schematic representation of the novel Epo-reporter and TK-RL vectors. The two 
constructs were cloned into the transfer vectors pDestX1-puromycin and pDestX1-neomycin, 
allowing generation of LV particles. 
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8. CRISPR/Cas-mediated genome editing to dissect the role of endogenous distal 
and proximal hypoxia response elements in regulating oxygen-dependent Epo 
expression 
Federica Storti1, Lisa Crowther1, Patrick Spielmann1, Roland H. Wenger1 and David Hoogewijs1 
1 Institute of Physiology and Zürich Center for Integrative Human Physiology ZIHP, University of 
Zürich, Zürich, Switzerland 
 
Introduction 
Erythropoietin (Epo) is the key hormone promoting red blood cell production in response to 
hypoxia and anemia. While the kidney is the primary site of adult Epo synthesis, the liver is the 
main source during development. Hypoxia-inducible Epo transcription is controlled by distinct 
regulatory sequences in liver and kidney. These regulatory regions flank the Epo coding 
sequence on both sides, the long-sought for kidney-inducible element (KIE) located far upstream 
in the 5′-region and the well-established liver-inducible element in the 3′-region. We recently 
characterized a novel hypoxia-response element (HRE) located upstream of the erythropoietin 
(EPO) gene, named Epo 5’-HRE and likely representing the hitherto unidentified KIE (Storti et 
al., 2014). We could show that the functional 5’-HRE is specifically induced by hypoxia-inducible 
factor (HIF)-2α using reporter gene assays and that endogenous HIF-2α protein binding on the 
HRE is enriched in hypoxic Hep3B cells. We propose that the Epo 5’-HRE represents the 
hypoxia-inducible regulatory element necessary for renal inducibility of the gene. The enhancer 
is indeed located within the so called KIE, as defined by transgenic animal experiments, and the 
arrangement of the HIF binding site (HBS) and CACA repeat resembles the one of the 3’-HRE, 
the established Epo liver-inducible element (Köchling et al., 1998; Suzuki et al., 2011). HIF-2 
specificity of Epo induction further supports our hypothesis (see introduction, section 1.3). In 
order to assess the contribution of the novel 5’-HRE in endogenous EPO transcription, we aimed 
to mutate this element in the genomic context of Hep3B, the same established Epo-producing 
cell line used for functional characterization of the HRE (see chapter 3). Our approach consists 
in specifically targeting the HBS using a novel genome targeting technique: the cluster regularly 
interspace short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) technology. 
Targeted genome editing, i.e. modification of the endogenous genomic DNA (gDNA) sequence 
at precise, predetermined loci, has been extensively used in biomedical research to study the 
function of genes, regulatory elements, disease-causing mutations and polymorphisms (Kim and 
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Kim, 2014). The classic approach, used for instance to generate knock-out and knock-in 
animals, consists in recombination of the genomic locus of interest with a homologous cassette, 
resulting in interruption of the gene or replacement with the desired mutation. Homologous 
recombination strategies in mouse embryonic stem cells or other mammalian cells allowed in the 
past decades generation of sophisticated animal and cell models, including conditional knock-
out/knock-in with help  of enzymes like Cre and FLP recombinases (reviewed by (Capecchi, 
2005)). Nevertheless, classic genome editing remains complex and time-consuming. Nowadays 
more efficient strategies based on the use of site-specific nucleases, enzymes that cleave 
double strand (ds)DNA at the desired position, are broadly used to target gDNA loci in 
mammalian cells and include zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and CRISPR/Cas technology. These techniques mainly differ in the way by 
which precise genome targeting is achieved: TALENs and ZFNs are based on modular proteins 
designed to bind specific DNA sequences, while the CRISPR/Cas system relies on 
complementary RNA-DNA hybridization to guide the nuclease at the desired site in the genome.  
ZFNs are recombinant proteins consisting of a FokI restriction enzyme nuclease domain at the 
C-terminus and a series of zinc-finger DNA-binding domains at the N-terminus, each recognizing 
a 3 bp DNA sequence. Target specificity is achieved by generating recombinant, modular zing-
finger proteins (Gupta et al., 2012; Bhakta et al., 2013). Not all the combinations of DNA-binding 
motives, however, lead to efficient cleavage: it has been calculated that a single functional ZFN 
pair can be obtained on average every  ̴100-bp DNA sequence (Kim et al., 2009). A similar 
modular approach is valid for TALENs, where the FokI nuclease domain is fused to DNA binding 
motives derived from the plant pathogenic bacterium Xanthomonas. Each domain recognizes a 
specific nucleotide, thus allowing generation of modular proteins able to recognize virtually any 
DNA sequence (Moscou and Bogdanove, 2009; Deng et al., 2012). The only requirement seems 
to be the presence of a thymine at the 5’ end of the target sequence, although contradictory data 
on the stringency of this requirement can be found in literature (Kim and Kim, 2014). Since the 
FokI cleavage domain needs dimerization to generate double strand breaks (DSBs), both 
TALENs and ZFNs are used in pairs, simultaneously increasing target sequence length and 
specificity. Two monomers are designed to bind adjacent half-sites that are separated by a 5-7 
bp spacer for ZFNs and a 12-14 bp spacer for TALENs (Bitinaite et al., 1998). Cells are then 
transfected with two plasmids, each overexpressing one of the specific nucleases, and single 
cell-derived colonies are screened for efficient genome editing. Compared to ZFNs, the TALEN 
technology shows improved targeting efficiency, decreased cytotoxicity and decreased off-target 
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effects but still requires the design of two recombinant proteins and a target sequence size of 
approximately 30-40 bp to reach efficient and specific genome editing (see table 1). 
The novel CRISPR/Cas system uses RNA-guided engineered nucleases (RGENs) and is 
derived from bacterial and archaea adaptive immune system. In early 2013, four research teams 
reported engineering of the bacterial system in order to target mammalian cell genome and in 
the past two years a rapidly increasing number of publications have exploited the CRISPR/Cas 
system to generate desired mutations in human cells, mice, rats, zebrafish, bacteria, Drosophila, 
yeast and nematodes (Pennisi, 2013). This technology uses guiding (g)-RNAs that are 
complementary to the desired gDNA locus to guide the Cas9 endonuclease, capable of 
generating DSBs at the position of interest. The most used system so far is called type II and is 
derived from Streptococcus pyrogens. In the natural pathway, the CRISPR operon in the 
bacterial genome contains all the genes necessary for functionality of the system, including 
different Cas genes and a long pre-CRISPR (pre-cr)-RNA. gRNAs are generated from 
processing of the long non-coding pre-crRNA, which consists of short palindromic repeats 
interspaced by variable sequences, the proto-spacers. The latter represent the adaptive part of 
the defence mechanism since they are complementary to exogenous DNA potentially derived 
from phages or other pathogens. An auxiliary trans-activating crRNA (tracrRNA), transcribed 
from the same operon, helps the processing of long precursors by RNase III into discrete units 
containing a 20 nucleotide (nt) gRNA and a partial direct repeat, generally forming a hairpin 
structure and interacting with Cas9. In the type II CRISPR system the target sequence, 
complementary to the gRNA, must immediately precede a 5’-NGG-3’ proto-spacer adjacent 
motif (PAM, where N can be any nt). The PAM sequence is probably used for selection of proto-
spacers in invading nucleic acid to be included in the CRISPR operon. It is in fact required, 
together with the gRNA, for specific binding of Cas9 to target DNA, resulting in cleavage of the 
sequence (Makarova et al., 2011). An overview of the endogenous type II CRISPR/Cas system 
is depicted in figure 1.  
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Table 1 Comparison between the available nuclease-based genome editing technologies (Kim 
and Kim, 2014). 
For in vitro and in vivo genome editing purposes, the crRNA and tracrRNA have been combined 
into a single guiding (sg)-RNA containing the sequence complementary to the 20 nt target of 
interest, followed in the genomic sequence by the PAM. The sgRNA-expressing vector is co-
transfected with a codon-optimized Cas9 expressing vector and single colonies are screened for 
targeting of the desired locus. It has been calculated that 5’-NGG-3’ sequences are found in the 
human genome every 8-12 bp, thus making this system less versatile compared to TALENs but 
much easier to design (Ran et al., 2013). Moreover, ZFNs and TALENs cut randomly within the 
spacer sequence between the two adjacent half sites, whereas Cas9 cleaves exactly between 
the 17th and 18th position in the target sequence (3 bp upstream of the PAM) (Jinek et al., 2012).  
For all the genome editing techniques described, repair of the DSBs can follow the same two 
major DNA-repair pathways: the error-prone non-homologous end joining (NHEJ) or the high 
fidelity homology-directed repair (HDR, figure 2). NHEJ generates random mutation in the form 
of small insertion/deletion around the cleaved site and can result in frame-shift or premature 
stop-codon formation in coding regions. When a single or double strand DNA template is 
provided, HDR mediate homologous recombination of the DSB, allowing insertion of the exact 
desired sequence. However, HDR is usually less frequent than NHEJ and active only in dividing 
cells (Saleh-Gohari and Helleday, 2004; Chen et al., 2011). 
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One of the advantages of RGENs compared to ZFNs and TALENs is the possibility of efficient 
and simultaneous targeting of different genomic loci, therefore generating cells or animals with 
multiple gene mutations. Despite generation of rats with double mutations by zygote injection of 
two ZFN pairs and corresponding HDR dsDNA templates was recently reported (Brown et al., 
2013), the complex and time-consuming design and production of ZFNs and double-stranded 
donor vectors limit the application of this method. The CRISPR/Cas technology has instead 
been used for one-step generation of mice with up to 5 simultaneous genome modifications 
(Wang et al., 2013; Yang et al., 2013; Zhou et al., 2014) and a vector containing multiple 
sgRNAs together with Cas9 was successfully used to target multiple loci in human cells with a 
single transfection (Sakuma et al., 2014). On the other hand, frequency of off-targets seems to 
be higher with RGENs compared to the other site-directed nucleases. Cas9 can tolerate 
mismatches between the gRNA and the DNA target sequence, especially in the 5’ region of the 
RNA (opposite to the PAM), thus cutting homologous DNA loci as well (Fu et al., 2013; Lin et al., 
2014). Other reports in literature show contradictory data and describe substantially low 
frequency of off-targets for the CRISPR/Cas system in mammalian cells (Cho et al., 2014; Veres 
et al., 2014). Based on genome-wide analysis of Cas9 binding in mouse embryonic stem cells, it 
is likely that Cas9 has many off-target binding sites but actually cleaves only a small fraction of 
them (Wu et al., 2014). New strategies to decrease the possibility of off-targets include 
generation of informatics tools for improved design of gRNA sequences, optimization of extent 
and duration of Cas9 expression and use of paired Cas9 nickases instead of nucleases. Nickase 
enzymes are known to have low off-target activity and generate single strand breaks (SSBs) in 
the DNA locus: if the two SSBs are close enough, the NHEJ machine will repair the damage, 
thus resulting in the same effect of a DSB (Cho et al., 2014; Shen et al., 2014). 
Given the high success rate of the CRISPR/Cas technique in mammalian culture and the easy 
design of specific sgRNA sequences, we decided to exploit the advantages of this novel system 
in order to separately mutate endogenous Epo 5’- and 3’-HRE in Hep3B to assess the relative 
contribution of these mutations on hypoxia-inducible EPO transcription. 
 
Materials and methods 
Cell culture  
Hep3B, HepG2 and Hek293T were cultured in DMEM (high glucose, Sigma-Aldrich-Aldrich) 
supplemented with 10% heat-inactivated foetal calf serum (FCS), 50 IU/ml penicillin and 50 
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µg/ml streptomycin (Invitrogen). Hypoxia experiments were carried out at the indicated 
concentration of oxygen and 5% CO2 in a gas-controlled glove box (InvivO2 400, Ruskinn 
Technologies). 
Generation of stably Epo 5’- or 3’-HRE targeted Hep3B by CRISRP/Cas-mediated genome 
editing 
Cells were plated at a density of 1.5x106 cells per 10 cm dish and transfected with pRGEN-
Cas9-HA-CMV, pRGEN-U6-sgRNA for Epo 5’- or 3’-HRE targeting, a 100 bp long single strand 
(ss)-DNA oligo as a template for HDR and a linearized puromycin resistance vector (3 μg of total 
DNA) using polyethylenimine (PEI) transfection. pRGEN vectors were all purchased from 
ToolGen and ssDNA oligos from Microsynth (see figure 3 for sgRNA and partial ssDNA oligo 
sequences). Control cells were transfected with pEGFP-C1 (Clontech) and a linearized 
puromycin resistance vector (3 μg of total DNA). 72 h post-transfection, medium was changed to 
1.5 μg/ml (Hep3B) or 1 μg/ml (HepG2) puromycin-containing medium for an additional 72 h, until 
all the wt control cells died. After two weeks of recovery, cells were sub-cloned by limited dilution 
in 96-well plates or 10 cm dishes and single cell-derived colonies were picked and grown for 
further experiments.  
gDNA extraction and detection of targeted loci 
Approximately 1x106 cells were harvested, washed 2x with phosphate-buffered saline (PBS) and 
re-suspended in 600 μl of 200 mM NaCl, 50 mM Tris/HCl (pH 8.00), 10 mM EDTA and 1% 
sodium dodecyl sulphate (SDS) lysis buffer. Proteinase K (15 μl, Thermo Scientific) was added 
and lysates were incubated at 65°C overnight. On the next day, 200 μl of water-saturated NaCl 
was added, followed by precipitation at 15 krpm for 30 minutes at 4°C. Supernatants (750 μl) 
were transferred to a new tube and DNA was precipitated with 450 μl of isopropanol at 15 krpm 
for 30 minutes at 4°C. DNA pellet were washed with 70% ethanol, air-dried and re-suspended in 
50 μl of Tris/EDTA (TE) buffer. 
500 ng of gDNA were used as template for PCR amplification of the loci of interest using the 
primers and annealing temperatures listed in table 2. Primer pairs (2) contain XhoI restriction 
sites (in bold) for cloning into pBlueScriptII SK (+) and sequencing (see below). PCR products 
were evenly split for overnight digestion with TaiI or PstI (Thermo Scientific) at 65/37°C and 
loaded on a 2.1% agarose gel. 
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Name Forward primer (5’-3’) Reverse primer (5’-3’) 
Amplicon size 
(Tai//PstI 
restriction) 
5’-HRE 
(1) 
CCACATCCTTTCCATCAGCCT GGAACTGCCAAAACAAACCAGAT 
505 bp 
(108/73 bp) 
5’-HRE 
(2) 
CCCCCTCGAGTCAGTGGCAATGTGGAG CCCCCTCGAGCTGCGGACATTTCTATCA 
148 bp 
(195/133 bp) 
3’-HRE 
(1) 
TGGCAAGCTGTGACTTCTCC GCCCTGGGCAGGGTTG 
198 bp 
(301/132 bp) 
3’-HRE 
(2) 
CCCCCTCGAGTGGCAAGCTGTGACTTCT CCCCCTCGAGCCCTGGGCAGGGTTG 
362 bp 
(304/140 bp) 
Table 2 Primers used for gDNA amplification 
gDNA loci sequencing 
500 ng of gDNA from selected colonies were used as template for PCR amplification of the loci 
of interest using XhoI restriction site-containing primers (table 2). After overnight digestion with 
XhoI, PCR products were cloned into pBlueScriptII SK (+) vector and sequenced with a M13 
primer.  
RNA extraction and quantitative PCR 
RNA was extracted by using the phenol-chloroform method and cDNA was generated by 
reverse transcription (RT) of 2 µg of total RNA using AffinityScript reverse transcriptase 
(Agilent). Transcript levels were quantified by quantitative (q) PCR using a SybrGreen qPCR 
reagent kit (Sigma-Aldrich) in combination with a MX3000P light cycler (Agilent) and the primers 
listed in table 3. Initial template concentrations were calculated by comparison with serial 
dilutions of a calibrated standard. Ribosomal protein L28 mRNA levels were used to normalize 
the data.  
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon size 
hL28 GCAATTCCTTCCGCTACAAC TGTTCTTGCGGATCATGTGT 198 bp 
hEpo TCACTGTCCCAGACACCAAA CCTCCCCTGTGTACAGCTTC 362 bp 
hCITED-2 GGAGCAGAAATCGCAAAAAC GACCCATGAACTGGGAGTTG 334 bp 
hCAIX GGGTGTCATCTGGACTGTGTT CTTCTGTGCTGCCTTCTCATC 309 bp 
hPGK-1 AACAAGGTTAAAGCCGAGCC TGAGCTGGATCTTGTCTGCA 259 bp 
Table 3 Primers used for qPCR amplification 
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Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using a high salt extraction buffer 
containing 0.4 M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1 x protease inhibitory cocktail (Sigma-
Aldrich). Protein concentrations were determined by the bicinchoninic acid assay method and 40 
µg of cellular protein was subjected to immunoblot analyses. Membranes were probed with 
antibodies against HIF-1α (clone 54/HIF-1α, BD Transduction Laboratories), HIF-2α (PAB12124, 
Abnova) and -actin (Sigma-Aldrich). Signals from HRP-coupled secondary antibodies were 
detected with ECL substrate (all Pierce) using a luminescent image analyser (LAS-4000, 
FUJIFILM). -actin was used as loading control for combined cytoplasmic and nuclear extracts. 
 
Results 
In order to achieve efficient targeting of the Epo 5’- and 3’-HRE in Hep3B, we first optimized 
several transfection conditions, including amount of cells, amount of DNA, transfection reagent 
and puromycin concentration. gDNA was extracted from transfected pools of cells before and 
after puromycin selection and efficiency of the targeting was assessed by restriction analysis of 
the loci of interest, following the scheme depicted in figure 3. The PCR amplicon from wt gDNA 
is completely digested by TaiI, whereas efficient HRE targeting destroys the TaiI restriction site, 
resulting in the presence of an undigested band on the gel. Moreover, when the DSB is repaired 
via HDR, using a 100 bp ssDNA oligo as a template, a PstI restriction site is introduced. This 
strategy easily allows identification of targeted as well as homology recombined alleles. As 
expected, puromycin selection greatly increased the amount of HRE-mutated amplicons, often 
not detectable before selection (figure 4). HDR is known to occur less frequently compared to 
NHEJ (Saleh-Gohari and Helleday, 2004): consistently, we seldom observed PstI-digested 
bands in the transfected pools. After selecting the most efficiently targeted pools, we continued 
with single cell cloning in order to obtain clonal populations of Hep3B carrying the same mutated 
alleles. 
Screening of several single cell-derived Hep3B clones revealed that targeting efficiency of the 3’-
HRE genomic locus was higher compared to the 5’-HRE one. In order to increase targeting 
efficiency for the Epo 5’-HRE locus, we transfected the cells twice with the same CRISPR/Cas 
set of vectors, resulting in slightly higher number of partially targeted colonies (figure 5). 
Nevertheless, no colony carrying only mutated alleles could be obtained with this approach. A 
Unpublished results: CRISPR/Cas-mediated genome editing of endogenous Epo 5’ and 3’-HREs 
 
181 
 
number of factors can explain the difference between 5’- and 3’-HRE targeting, including 
different efficiency of the gRNAs in driving the Cas9 on the target sequence and/or chromatin 
accessibility of the genomic region. Indeed, it was recently shown that the presence of DNase I 
hypersensitivity sites (DHS) is the strongest predictor of Cas9 binding in a genome-wide analysis 
performed in mammalian cells (Wu et al., 2014). The HBS contains a CG dinucleotide that can 
be methylated (Yin and Blanchard, 2000) and CpG methylation was shown by the same study to 
represent a negative determinant of Cas9 binding as well, even though contradictory results 
have been reported (Hsu et al., 2013; Wu et al., 2014). To further investigate the possible 
reason for less efficient targeting of the Epo 5’- compared to 3’-HRE locus, we sequenced the 
PCR product from both genomic loci in wt cells and compared it to the reference sequence 
obtained from the UCSC Genome Browser which was used to design the gRNAs. No differences 
to the UCSC reference sequence could be detected for the 5’- and 3’-HRE PCR products from 
gDNA derived of wt Hep3B, HepG2 and Hek293T (data not shown). These results exclude 
impaired hybridization of the gRNA to the target sequence as the reason for lower efficiency of 
5’-HRE targeting. As an additional approach to mutate the endogenous 5’-HRE in Epo-
expressing cells, we transfected the same set of targeting vectors in HepG2. Figures 5 and 6 
show higher success rate in this cell line, with 4 100% mutated clones and several partially 
mutated ones. Characterization of the 5’-HRE mutated HepG2 clones is ongoing. 
In contrast to targeting the 5’-HRE, Hep3B clones with successful CRISPR-Cas-mediated 
mutation of the 3’-HRE were obtained. Two independent clones were characterized by 
comparing Epo mRNA levels between these clones and wt cells, the pool of cells transfected 
with the CRISPR/Cas vectors after puromycin selection and one partially targeted (+/-) clone, 
which underwent the same single cell cloning procedure as the positive ones. Figure 6B shows 
measurement of Epo mRNA in normoxic and hypoxic conditions: Epo hypoxic induction was 
completely abrogated in the two positive, mutated clones (genotype was confirmed in figure 7A). 
Interestingly, the pool and the partially targeted clone, showing the same genotype, displayed 
reduced Epo mRNA levels compared to wt cells upon hypoxia, suggesting a dose-dependency 
of functional HREs and Epo induction. In order to ensure functionality of the HIF pathway, we 
evaluated the behaviour of the HIF-2 target gene Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 (CITED-2), as well as the HIF-1 target genes carbonic 
anhydrase IX (CAIX) and phosphoglycerate kinase 1 (PGK-1) (figure 7B and C). Consistent with 
preserved endogenous HIF- -
genes displayed comparable hypoxic induction in all tested cell lines. Sequencing of the 3’-HRE 
PCR amplicons derived from gDNA of the mutated clones revealed the presence of two 
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differentially targeted alleles in each clone (figure 7E). Clone (1) displayed repair of the DSB via 
NHEJ by insertion of two nucleotides on each allele, while clone (2) displayed one HDR-
mediated repaired allele and one small deletion of the locus (13 nucleotides). 
In summary, we could show that mutation of the 3’-HRE is sufficient to abrogate Epo hypoxic 
induction in Hep3B cells. Our results do not provide definitive conclusions on the contribution of 
the 5’-HRE in regulating oxygen-dependent Epo expression in Hep3B cells as no clone 
displaying stable and complete editing of the locus could be obtained so far. However, we were 
able to mutate this locus in HepG2 cells, an alternative Epo-expressing cell line: evaluation of 
the effect of the 5’-HRE disruption on endogenous Epo mRNA hypoxic levels is ongoing. 
 
Discussion 
After characterizing the newly discovered Epo 5’-HRE in vitro (Storti et al., 2014), we aimed to 
mutate the locus in the context of endogenous genomic DNA in Epo-producing cell lines and 
evaluate the effect on Epo mRNA induction in hypoxia. We additionally applied the same 
genome editing approach to the established Epo 3’-HRE, in order to assess the contribution of 
both loci in regulating oxygen-dependent EPO gene transcription. In the present study we 
implemented a novel technique, the CRISPR/Cas technology, which exploits an RNA sequence 
complementary to the locus of interest to guide the DNA-cleaving enzyme (Cas9) at the desired 
position. DSB will result in NHEJ or HDR, if a homologous template is provided, and thus in 
mutation of the gDNA (see introduction). In our hands, NHEJ was more frequent compared to 
HDR for both tested loci, consistent with observations by others (Saleh-Gohari and Helleday, 
2004). Alternative approaches to improve the efficiency of HDR could be to increase the amount 
of donor template (ssDNA oligonucleotide in our case) or to switch to a dsDNA donor template, 
i.e. a plasmid containing the homologous region of interest. In the latter case, longer homology 
arm are required compared to ssDNA (Findlay et al., 2014): increased size of double strand 
homology arms positively correlated with HDR efficiency in vitro (Li et al., 2014). 
Genome editing of the Epo 3’-HRE in Hep3B cells was successful and initial screenings resulted 
in two independent colonies carrying mutated alleles for this locus. In vivo experiments 
previously showed that the 3’ enhancer is necessary and sufficient to drive hepatic Epo 
expression: transgenic mice with mutated HBS within the 3’-HRE displayed absent Epo 
expression in hepatocytes after embryonic day 14.5 and during adulthood under anaemic 
conditions. Nevertheless, the enhancer is dispensable during early embryonic stages and renal 
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expression in adult mice: Epo levels in the kidney were in fact comparable to wt after birth, 
suggesting that distinct hypoxia-regulated elements are responsible for EPO transcription in liver 
and kidney (Suzuki et al., 2011). In the two mutated clones hypoxic Epo mRNA induction was 
completely abrogated, despite normal functionality of the HIF pathway, supporting the 
importance of the 3’-HRE in our liver-derived cell model (figure 7).  
Unfortunately, we experienced difficulties in targeting the Epo 5’-HRE in Hep3B cells. Editing 
efficiency seemed to be lower compared to the 3’, as many more colonies had to be screened in 
order to find at least partially positive clones. The presence of a higher number of alleles could 
explain why we were not able to easily get a 100% 5’-HRE mutated clone. We indeed do not 
exactly know how many alleles for the EPO locus are present in the genome of Hep3B and the 
number is likely to be higher than 2, given the tumoral origin of these cells (Strachan and Read, 
1999; Alberts et al., 2002; Kim et al., 2013). A few reports in literature studied the karyotype of 
Hep3B, defined as hypotriploid, without highlighting specific abnormalities on the long arm of 
chromosome 7 where EPO is located (Gray et al., 2000; Wong et al., 2000). The genome of 
cancer cell lines is however unstable and it is possible that additional modification of the 
karyotype occurred in culture, despite the fact that at least one report showed stability of Hep3B 
karyotype after repeated passages in culture (Gray et al., 2000). Our preliminary data on 
karyotyping of a non Epo-expressing batch of Hep3B revealed an extremely complex copy 
number situation, with a modal chromosome number of 122 and the presence of 4 to 7 copies of 
chromosome 7 per analysed metaphase (personal communication from Adriano Guetg, 
University Hospital Zürich, Zürich, Switzerland). The full procedure of transfection and 
puromycin-dependent selection, followed by sub-cloning and analysis of genome editing 
efficiency and Epo levels can take for Hep3B up to three months, during which cells are kept in 
culture and subjected to relatively high stress. Therefore, it is not easy to prevent aging of the 
cells and subsequent genome instability while performing this technique. An alternative 
explanation for poor yield of 5’-HRE targeting could be the cell model used for these studies. As 
a matter of fact, according to our hypothesis the 5’-HRE represents the hypoxia-inducible 
contribution to renal Epo expression. It must not be forgotten that the cell model we used is 
derived from human hepatoma and the KIE could be kept in a “closed” chromatin conformation, 
limiting the access of the CRISPR/Cas machinery to the DNA. Another epigenetic modification 
that was shown to inhibit modification of gDNA is CpG methylation (Wu et al., 2014), which can 
also be found within HBSs (see introduction, (Wenger et al., 1998)).  
Since our main goal is to assess the potential role of Epo 5’-HRE, rather than the established 3’-
HRE, an alternative approach is needed in order to get stably targeted Hep3B cells. Other gRNA 
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sequences complementary the 5’-HRE locus are currently being tested for efficient editing. 
Unfortunately, no alternative PAM sequences can be used to have DNA cleavage directly into 
the HBS but generating DSB in close proximity of the binding site can lead to deletion of bigger 
pieces of DNA as well, resulting in disruption of the locus of interest. In order to increase 
transfection efficiency and to make the entire procedure technically easier, lentiviral transfer 
vectors are now available containing the sgRNA, the Cas9 gene and the puromycin resistance 
cassette in one single construct and can be used to generate lentiviral particles for cell 
transduction. Pre-treatment of cells with hypoxia (0.2% O2, for 24 h) might help making the locus 
more accessible for the sgRNA/Cas9 complex, since we have previously observed enrichment 
of HIF-2α binding under these conditions, possibly indicating “opening” of the chromatin 
structure (Storti et al., 2014). Repeated transfection cycles with the 5’-HRE targeting vectors 
would also represent an option, as well as obviously increasing the number of screened 
colonies. It is fundamental to ascertain that clones are derived from single cells, in order to have 
a homogenous population of cells with stable genomic background. This can be achieved by 
increasing the dilution factor and ensuring the cells are well separated when seeded, for 
instance by passing them through a syringe needle. These aforementioned options are part of 
ongoing approaches. Furthermore, we transfected with the 5’-HRE targeting vectors another 
Epo-expressing cell line, HepG2, also derived from hepatocellular carcinoma. Targeting 
efficiency seems to be higher in these cells (figure 5), possibly due to higher transfectability of 
HepG2 compared to Hep3B, at least in our hands (data not shown). Indeed, 4 clones displaying 
disruption of the Epo 5’-HRE could be obtained (figure 6) and are being currently investigated for 
Epo hypoxic induction. Targeting of the 3’-HRE in the same cells is necessary in order to 
evaluate the contribution of single hypoxia-driven elements on Epo mRNA levels and is indeed 
ongoing.  
Additional future plans include the generation of double 5’- and 3’-HRE mutant cells, because a 
putative effect of the 5’-HRE on Epo expression could be visible only in the context of mutated 
3’-HRE. Moreover, we are performing chromatin immunoprecipitation as well to evaluate the 
effect of mutating the 3’-HRE on potential HIF and USF-2 binding (see chapters 3 and 6). An 
interesting development of this sub-project would be to mutate the CACA repeat, both in the 5’- 
or 3’-HRE. While it is known that this element is necessary for functionality of both 5’- and 3’-
HREs (Semenza and Wang, 1992; Storti et al., 2014), it has never been mutated in the 
endogenous context. A cell line engineered for the CACA repeat could also be a useful tool to 
identify the potential protein binding to this region. 
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In summary, site-directed mutagenesis of the Epo 3’-HRE showed that this element is necessary 
and sufficient for Epo hypoxic induction in Hep3B cells, while the actual contribution of the 5’-
HRE remains elusive. This does not exclude the importance of the 5’-HRE as the hypoxia-
regulated element within the KIE because the cell model used is liver-derived and not kidney-
derived. Ideally, mutation of the 5’-HRE in vivo in renal Epo-producing cells is necessary to draw 
conclusions on the role of the novel HRE in Epo transcription. Our findings demonstrate that the 
CRISPR/Cas-mediated approach represents a tool to functionally validate hypoxia response 
elements in mammalian cell lines and opens new possibilities of exploring regulatory element 
function, including for instance the cryptic CACA repeat.  
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Figure 1 
 
Figure 1 Schematic overview of endogenous type II CRISPR/Cas system: the CRISPR locus is 
transcribed and processed to produce crRNAs (or gRNAs) that guide effector nucleases to 
locate and cleave nucleic acids complementary to the spacer. First, tracrRNAs hybridize to 
repeat regions of the pre-crRNA. Second, endogenous RNase III cleaves the hybridized crRNA-
tracrRNA, and a second event removes the 5′ end of the spacer, generating mature crRNAs that 
remain associated with the tracrRNA and Cas9. The complex cleaves complementary proto-
spacers only if a PAM sequence is present (adapted from (Mali et al., 2013)). 
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Figure 2 
 
Figure 2 Schematic representation of the two major DNA repair pathways, valid for ZFNs and 
TALENs as well. DSB: DNA double strand break, NHEJ: non-homologous end joining, HDR: 
homology-directed repair (Ran et al., 2013). 
 
Figure 3 
 
Figure 3 Scheme depicting the strategy used for CRISPR/Cas-mediated targeting of Epo 5’- and 
3’-HRE loci. A. Wild type (wt) human gDNA sequence from the UCSC Genome Browser 
database; the HRE (HBS + CACA repeat) is highlighted in bold, the gRNA sequence is 
underlined and the PAM sequence is marked in italic. The sequences of ssDNA oligos used for 
HDR are indicated below the wt sequence and the exact position of the predicted Cas9 cleavage 
site is shown by the arrow. The ssDNA oligos are 100 bp long and contain the desired mutation 
approximately in the middle. B. Restriction analysis of the wt and HDR-mutated Epo 5’- and 3’-
HRE loci: the wt sequence contains a TaiI restriction site while the homology recombined one 
contains a PstI restriction site. 
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Figure 4 
 
Figure 4 PCR and restriction analysis for Epo 5’- (A) and 3’-HRE (B) loci on gDNA from wt cells 
or pools of cells transfected with 5’- or 3’-HRE targeting CRISPR/Cas constructs or a GFP-
expressing control (named 5’-HRE, 3’-HRE or GFP, respectively). Cells were harvested before (-
) or after (+) 72 h of puromycin selection. Two experiments are shown (I and II). PCR was 
performed using 5’-HRE primer pair (1) and 3’-HRE primer pair (1), see table 2. Percentage of 
NHEJ was calculated by quantification of band intensity and the following formula: 
, where  is the intensity of the mutated, undigested band normalized on the 
length in bp,  and  are the intensities of the wt, digested bands normalized on the length in bp. 
wt n.d. = wt gDNA, not digested. 
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Figure 5 
 
Figure 5 Single cell-derived Hep3B or HepG2 colonies were screened via restriction analysis 
(figure 3) and the % of wt (-), partially (+/-) or completely (+) mutated colonies was calculated. 5’-
HRE 1x/2x = cells transfected once or twice, respectively, with the Epo 5’-HRE CRISPR/Cas 
targeting vectors. 3’-HRE = cells transfected once with the Epo 3’-HRE CRISPR/Cas targeting 
vectors. The number of corresponding screened colonies is indicated below.  
 
Figure 6 
 
Figure 6 PCR and restriction analysis for Epo 5’-HRE locus on gDNA from wt cells or colonies 
derived from sub-cloning of HepG2 transfected with the corresponding CRISPR/Cas vectors. 
PCR was performed using primer pair (2), see table 2. 
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Figure 7 
 
Figure 7 A. PCR and restriction analysis for Epo 3’-HRE locus on gDNA from wt cells or 
colonies derived from sub-cloning of Hep3B transfected with the corresponding CRISPR/Cas 
vectors. PCR was performed using primer pair (1), see table 2. The indicated cell lines were 
exposed to 0.2% O2 for 24 h and HIF-2 target genes Epo and CITED-2 (B), as well as HIF-1 
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target genes CAIX and PGK-1 (C) mRNA levels were measured by RT-
additionally evaluated by immunoblot analysis (D). E. Sequence of Epo 3’-HRE in gDNA from wt 
Hep3B and the two positive (mutated) clones. Pool = mixed population of cells transfected with 
CRISPR/Cas vectors; +/- and + (1 and 2) = partially and totally mutated single cell-derived 
colonies. 
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9. Conclusions and future perspectives 
Oxygen is a fundamental molecule for the life of all aerobic organisms and oxygen sensing 
through the prolyl-4-hydroxylase domain/hypoxia-inducible factor (PHD/HIF) pathway is 
necessary in order to maintain tissue oxygen partial pressure (pO2) at values that are compatible 
with life (Alberts et al., 2002; Semenza, 2014). One of the most well-known oxygen-dependent 
genes is erythropoietin (EPO), the main regulator of red blood cell homeostasis and thus of O2 
uptake, transport and availability in higher vertebrates (Wenger and Kurtz, 2011). Despite the 
history of Epo discovery and characterization starts at the end of the 19th century (Viault, 1890), 
the precise molecular mechanism of transcriptional regulation of the EPO gene in the main 
producing organ, the kidney, remains elusive. The aim of the thesis was to investigate 
modulation of oxygen-regulated Epo expression by employing the available in vitro cell models. 
In particular, we investigated Epo regulation on three levels:  
I. By functionally characterizing a novel hypoxia-response element (HRE) located upstream 
of the EPO gene, within the so-called kidney-inducible element (KIE), and by evaluating 
the role of a variety of candidate factors on oxygen-dependent Epo regulation 
II. By studying the effect of newly identified mutations in the Egl9 homolog 1 (EGLN1) gene, 
encoding for PHD2, associated with secondary congenital erythrocytosis 
III. By screening a series of humoral factors and a collection of human blood peptides in 
order to identify novel HIF, and possibly Epo, regulators 
Role of a novel distal HRE and evaluation of different candidate factors in Epo hypoxic induction 
Comprehensive in silico analysis confirmed the presence of a previously uncharacterized HRE 
upstream of the EPO gene (Epo 5’-HRE), inside the distal region conferring kidney-specificity of 
Epo expression (KIE), as defined by animal experiments (Köchling et al., 1998; Fandrey, 2004). 
The presence of a CACA repeat close to the HIF binding site (HBS) resembles the structure of 
the known Epo 3’-HRE, within the established liver-inducible element (Suzuki et al., 2011; 
Semenza, 2013). Reporter assays in different cell lines showed hypoxia-inducibility of the 5’-
HRE and separate mutation of the HBS or CACA repeat completely abolished the effect of 
hypoxia, indicating functionality of the HRE within the KIE. Moreover, overexpression of the two 
HIF-α subunits showed HIF-2 responsiveness of the 5’-HRE and chromatin immunoprecipitation 
(ChIP) experiments revealed enrichment of HIF-2α binding in hypoxic Hep3B cells, consistently 
with HIF-2 specificity of Epo expression (chapter 3, (Storti et al., 2014)). Taken together, these 
data indicate that the 5’-HRE could be the putative hypoxia-regulated element necessary for 
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renal Epo expression. Indeed, when the 3’-HRE was mutated in transgenic animals, hypoxia-
inducible expression of the transgene was lost in the liver but not in the kidney (Suzuki et al., 
2011), implying the presence of a different HRE inside the EPO locus. 
In the context of the newly characterized HRE, we evaluated a series of candidate factors, 
mainly transcription factors, for their role in Epo hypoxic regulation. We chose to knockdown 
and/or overexpress these genes and combined this approach with the Epo reporter constructs 
containing the 5’- and/or the 3’-HRE. None of the factors tested resulted in significant 
contribution to Epo expression, except for the upstream stimulatory factor 2 (USF-2). USF-2 
knockdown led to decreased Epo mRNA levels in hypoxic Hep3B cells, consistent with a 
previous report (Pawlus et al., 2012), but we could detect binding of USF-2 only on the Epo 3’- 
and not 5’-HRE (chapter 6). 
In order to study the contribution of the 5’-HRE to endogenous EPO transcription, we exploited 
the novel  cluster regularly interspace short palindromic repeat (CRISPR)/CRISPR-associated 
protein (Cas) technology for genome editing in Epo-expressing Hep3B. Alongside the 5’-HRE, 
we mutated the 3’-HRE too, both as a control and to dissect the role of the single HREs in Epo 
hypoxic induction. In our hands, the CRISPR/Cas technique was very efficient in Hep3B cells for 
the 3’-HRE locus and we could obtain two clones carrying stably HBS-mutated alleles. Exposure 
of the 3’-HRE targeted cells to hypoxia revealed complete abrogation of Epo mRNA induction, 
despite preserved functionality of the HIF pathway (see chapter 8), suggesting that the 
downstream enhancer is necessary and sufficient for Epo expression in Hep3B cells. Targeting 
of the 5’-HRE in Hep3B cells was more difficult to achieve and up to now we could not obtain a 
100% mutated clone. Many reasons can underlie the difficulties encountered with this locus, in 
particular polymorphisms in the genomic DNA sequence, chromatin accessibility and epigenetic 
modifications (Wu et al., 2014). As mentioned in chapter 8, different guiding RNA (gRNA) 
sequences are currently being tested for higher editing efficiency of the 5’-HRE locus. Moreover, 
this locus could be kept in a closer chromatin status compared to the 3’-HRE in liver-derived cell 
lines. ChIP experiments showed indeed binding of both HIF-1α and -2α to the 3’-HRE, while only 
HIF-2α binding was enriched in our hands on the 5’-HRE (chapter 3): this could indicate more 
stringent HIF isoform specificity of the upstream element or closer chromatin structure compared 
to the downstream one. However, DNaseI hypersensitivity assay and methylation analysis of the 
HBS are needed in order to conclude that chromatin accessibility is the reason for less efficient 
targeting of Epo 5’-HRE. Also, the presence of more than two alleles containing the EPO locus 
could be a reason for decreased targeting efficiency and the remaining wt allele can be used for 
homology-directed repair of the mutated ones, resulting in loss of the desired targeting (Wu et 
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al., 2013). In addition, Hep3B cells do not form easily single-cell derived colonies, a condition 
that is necessary in order to isolate clonal population of cells carrying the same mutation. 
Generation of mutated Epo 5’-HRE clones is thus still ongoing and we cannot draw conclusions 
at the moment about the contribution of the 5’-HRE to endogenous EPO transcription in Hep3B 
cells. However, we were able to mutate this element in an alternative Epo-producing cell line, 
HepG2: characterization of the 5’-HRE targeted clones is at the moment ongoing. In summary, 
CRISPR/Cas-mediated genome editing is an efficient and relatively easy technique but success 
in endogenous genomic DNA stable modification depends on the locus of interest, as well as on 
the chosen cell model. A number of variations and applications of CRISPR/Cas system have 
been successfully tested in the last few months, confirming the high degree of flexibility of this 
novel technology and making it appealing for different experimental purposes (Chen et al., 2013; 
Fennell et al., 2014; Hsu et al., 2014; Li et al., 2014). To the best of our knowledge, this study is 
the first to implement the CRISPR/Cas methodology to assess the ability of an HRE in oxygen-
dependent transcriptional regulation.  
Generating Hep3B carrying stable mutations of the 5’- and/or 3’-HREs opens the possibility for 
many future perspectives, starting from chromatin immunoprecipitation experiments in order to 
confirm lack of binding of HIF and additional known or candidate transcription factors binding, 
including hepatic nuclear factor 4 α (HNF-4α), the GATA factors and USF-2 (ongoing). 
Furthermore, the 3 dimensional chromatin structure of the EPO locus can be explored by 
performing chromosome conformation capture (3C) assays, a relatively new technique that 
allows visualization of looping between distant DNA segments, usually promoter and enhancer 
regions (de Wit and de Laat, 2012; Duan et al., 2012). In this context, genome-edited cells could 
be used to assess the role of HIFs and other transcription factors in looping of the Epo locus, 
which was already proposed to occur between the minimal promoter and the 3’ enhancer in 
hypoxic Hep3B cells (Huang et al., 1997; Stockmann and Fandrey, 2006). Interestingly, a recent 
study by our group investigating the molecular mechanism of oxygen-dependent expression of 
the transmembrane adaptor protein PAG1 (phosphoprotein associated with glycosphingolipid-
enriched mircodomains 1) by a 82 kb upstream HRE confirmed HIF-independent pre-formed 
chromatin looping (Schörg et al., in preparation). Finally, as mentioned in chapter 8 for the 
CACA repeat, other binding sites/DNA elements can be mutated via CRISPR/Cas in order to 
further investigate the molecular basis of EPO gene regulation.   
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Novel EGLN1 mutations causing secondary congenital erythrocytosis 
Five different mutations in the EGLN1 gene were identified in patients suffering from secondary 
erythrocytosis in an attempt to link genotype and phenotype of the subjects (Ladroue et al., 
2012). Importantly, three of them have not been described so far (P200Q, D254H and R398X). 
Functional characterization of the resulting mutant PHD2 proteins in terms of HIF hydroxylation, 
stabilization and transcriptional activity led to classification of the mutations into 2 groups:  
1. Mutations with weak effect on PHD2 protein activity (P200Q and R371H) 
2. Mutations with deleterious impact on PHD2 protein activity, often associated with 
increased risk of developing tumours such as paraganglioma/pheochromocytoma 
(R398X, H374R and D254H) 
The most interesting mutation from a molecular point of view belongs to the first group (P200Q): 
no strong difference could be detected between wt and mutant PHD2 in terms of effect on the 
HIF pathway, despite the patient carrying this mutation displayed the highest Epo plasma levels 
of the cohort (90 mU/ml compared to a normal range of 5-25 mU/ml). We therefore decided to 
further investigate in this direction but repetition of the HIF transcriptional and stability assay in a 
more physiological Epo-producing cell model showed no differential behaviour between wt and 
mutant PHD2. All the reporter assays performed within this sub-project require overexpression 
of the PHDs, thus leading to a very artificial situation. PHD2 knockdown or CRISPR/Cas-
mediated deficiency and reconstitution of the wt or mutated form up to normal expression levels 
would be the optimal approach to assess the actual role of the P200Q mutation on functionality 
of the protein. Other possible explanations include an effect of the mutation on interaction of 
PHD2 with an unknown factor, particularly crucial for Epo expression. Co-immunoprecipitation 
experiments would be useful to rule out this possibility or to identify novel Epo-regulatory factors. 
We cannot at the moment exclude the possibility that the P200Q mutation is not causing the 
disease, as only the EGLN1 gene from patients’ genomic DNA was sequenced in the study. 
Indeed, future research efforts aim to study the full exome or genome these erythrocytosis 
patients (Petousi et al., 2014).   
Putative Epo-regulating humoral factors 
Since data in literature suggest the existence of humoral factors, such as hormones and 
peptides, regulating Epo expression in the kidney (see introduction), we selected a number of 
candidates based on the available evidences and tested them in normoxic and hypoxic Epo-
expressing Hep3B. Addition of bovine pituitary extract or steroid hormones (aldosterone and 
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estrogen, see chapter 7) did not lead to measurable effects on Epo mRNA levels. Consequently, 
we decided to screen a priori a collection of peptides derived from human haemofiltrates (HFs) 
of patients suffering from renal failure (Schulz-Knappe et al., 1997). These patients display 
dysregulated Epo expression, thus screening a representation of the peptides present in their 
blood increases the chance to find Epo regulatory peptides. To this aim, we generated stable 
HIF-reporter Hep3B cells and optimized a protocol for peptide addition and exposure of the cells 
to hypoxia. The rationale of the screening is to identify fractions containing bioactive peptides, 
further sub-fractionate them and test them again in the same assay until the amino acid 
sequence of a single peptide can be determined (Münch et al., 2007; Borst et al., 2013). We 
performed the screening twice and found fractions reproducibly displaying an “activatory” or 
“inhibitory” effect in our HIF reporter assay. We are now at the confirmation step, where we 
evaluate if the effect is reproducible and truly dependent on the peptide component of the 
fraction. According to the results of the confirmation phase, we will select the most promising 
fractions for further steps of sub-fractionation. Given that many HIF regulatory peptides are 
already known (Wenger et al., 2005) whereas no Epo regulatory peptide has been described so 
far, we generated novel stable Epo-reporter Hep3B cells, based on the Epo 5’ HRE finding in 
this thesis, by transduction of the lentiviral constructs depicted in chapter 7, figure 12 (starting 
from the reporter plasmids used in chapter 3). Testing of these cell lines is currently ongoing 
and, in case of promising results, they will be used further for stimulation with the fractions 
selected from the complete screening performed in HIF-reporter cells or for new screening 
rounds.  
Another research line we would like to follow is the inhibitory effect of estrogen on HIF-2α mRNA 
and protein levels, previously observed in breast cancer cell lines (Jerry H. Fuady, unpublished 
data). The effect seems to be mediated by both estrogen receptor α and β (ERα and β) which 
are poorly or not expressed by our Epo-producing cell models (see chapter 7): generation of 
stably ERα/β overexpressing Hep3B cells represents an option to investigate estrogen effect on 
HIF-2 and Epo levels. 
Final remarks 
As a general comment, it must not be forgotten that the cell model used for the aforementioned 
experiments is derived from human hepatoma and probably recapitulates the situation of Epo 
regulation in the liver. To understand the actual contribution of the Epo 5’-HRE in regulating 
oxygen-dependento Epo expression and answer many other questions regarding renal Epo 
regulation, a kidney-derived in vitro model is required. Numerous previous attempts to generate 
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renal Epo-producing cells (REPCs) growing in cell culture conditions failed and our group is 
currently working on a mouse model carrying the tamoxifen-inducible Cre recombinase gene 
under the control of a 220 kb Epo gene locus (Epo-Cre). This tool will allow specific targeting of 
REPCs in vivo and can be used for isolation of REPCs in culture. Crossing between Epo-Cre 
and a ubiquitous Tomato reporter mouse already showed promising results and fluorescence-
activated cell sorting (FACS) could be used to isolate Tomato-positive REPCs. Another idea is to 
cross the Epo-Cre strain with the so-called Terminator mouse, an animal model in which the 
murine Rosa26 locus was engineered by introducing the diphtheria toxin receptor flanked by 
loxP sites (Guo et al., 2013). In this way, correctly recombined cells (in this case, REPCs) do not 
express the receptor and survive in culture with diphtheria toxin-containing medium, an elegant 
approach to enrich in vitro the cell type of interest.    
Besides the interest from a physiological point of view, studying the molecular mechanisms 
regulating Epo production has clinical applications in patients affected by erythrocytosis, 
anaemia or chronic kidney disease (CKD). Especially for the cases in which Epo levels are sub-
optimal, the expensive therapy with recombinant human Epo (rhEpo) could be replaced with oral 
drugs, combining higher compliance of the patient, reduced costs and side effects (Haase, 
2013). As mentioned in the introduction, a number of such compounds, mainly PHD inhibitors, 
are currently under clinical investigation (Wang et al., 2012; Hong et al., 2013; Flamme et al., 
2014). In this scenario, unraveling the molecular basis of EPO gene regulation and the 
characteristics of REPCs can help for instance to find more specific ways to stimulate 
endogenous Epo production in the damaged kidney of CKD patients.  
In summary, the results of this thesis contribute to the understanding of EPO gene regulation by 
characterizing a novel hypoxia-regulated DNA element, by functionally linking different mutations 
in the gene encoding for PHD2 to secondary congenital erythrocytosis and by evaluating a 
series of humoral factors for their effect on Epo expression. Whereas the discovery and 
characterization of a distal 5’-HRE likely representing the long sought-for kidney inducible 
element regulating Epo expression forms a major achievement in this work, many questions still 
remain to be answered and the approaches described above will help in the near future to shed 
light on the complex regulation of the most hypoxia-sensitive gene, erythropoietin. 
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